

Subject Index

- 1,25-(OH)₂D₃ I-15:9
 - 1- α -hydroxylase I-5:7, I-15:9
 - 1- α -hydroxyvitamin D II-14:10
 - 11- β -hydroxylase deficiency I-23:7
 - 11- β -hydroxysteroid dehydrogenase I-23:8, I-23:9
 - ¹²⁵I-iothalamate I-1:39
 - 17- α -hydroxylase deficiency I-23:7
 - 17-ketosteroids I-23:7
 - 18 β -hydroxylase I-20:7
 - 18 OH-cortisol I-20:7
 - 18 oxo-cortisol I-20:7
 - 18-hydroxycorticosterone levels I-23:4
 - 18-hydroxycortisol I-2:25, I-23:6
 - 18-oxocortisol urine I-2:25
 - 2,3-diphosphoglycerate I-5:24
 - 2,8-dihydroxyadenine I-15:3
 - 21-deoxyaldosterone I-23:6
 - 24-hour ambulatory blood pressure I-20:4
 - 24-hour urine collection I-15:22
 - 5-hydroxytryptophan receptors I-21:5
 - 5-flucytosine III-6:14
 - 8-methoxypsoralen II-1d:33
 - 9 α -fludrocortisone I-3:47

 - α -adrenergic blocking II-13:27
 - α -adrenergic effect I-3:35
 - α -intercalated cells I-2:8
 - α -ketoglutarate I-3:11
 - α -OH ketoadipate II-13:12

 - AAMI II-1a:19, II-4:31
 - AAMI Standards For Hemodialysis Water Quality II-1a:28
 - ABO compatibility II-1d:16
 - abortion I-9:25
 - abruptio placentae I-9:4
 - abscess I-1:30, I-12:11, III-6:14
 - brain a. III-6:14, 15
 - gas a. I-12:11
 - intrarenal or perinephric a.es I-12:10
 - liver a. II-5:3
 - renal parenchymal a.es I-12:17
 - spinal epidural a. II-2:10
 - absorption I-19:4
 - absorptive hypercalciuria I-15:8
 - acarbose I-19:8
 - access
 - recirculation II-6:8
 - thrombosis II-7:14
 - ACE see angiotensin converting enzyme
 - Acebutolol I-19:8, I-25:21
 - acetaminophen I-10:12, I-19:8, II-13:19
 - a. overdose II-13:1
 - acetate II-1a:3, II-6:9
 - concentrate a. II-4:26
 - dialysis a. II-4:4
 - acetazolamide I-3:42, I-5:20, I-19:8
 - acetoexamide I-19:8
 - acetone I-3:30
 - acetonuria I-15:21
 - acetyl-CoA I-3:35
 - acetylcholine release II-1d:27
 - acetylsalicylic acid (Aspirin) I-19:8
 - achromobacter II-1a:23
 - acid
 - a. balance I-3:2
 - acetic a. I-1:1, II-1a:21
 - acetoacetic a. I-15:27, I-19:8
 - a. concentrate II-4:26
 - a. load I-3:16
 - acid-base
 - a.-b. disturbances II-4:20
 - a.-b. homeostasis II-8:7
 - a.-b. disturbance, mixed I-2:39
 - acid-citrate dextrose II-1d:13
 - acidemia I-3:27
 - acidosis I-15:11, I-17:17, II-1b:2
 - mixed respiratory alkalosis-metabolic a. II-13:18
 - chronic metabolic a. I-3:12
 - chronic respiratory a. I-3:48
 - D-lactic a. I-3:43
 - high anion gap a. II-13:8
 - high anion gap metabolic a. II-13:17
 - hyperchloremic metabolic a. I-3:21, I-7:9
 - intracellular a. I-3:43
 - L-lactic a. I-3:24
 - lactic a. I-23:10, II-5:2
 - metabolic a. I-3:5, 19, I-5:27, I-18:3, II-4:26, II-5:2
 - renal a. I-3:44
 - renal tubular a. I-3:7, I-15:11, I-17:28
 - tissue a. I-3:28
 - type A L-lactic a. I-3:37
 - type B L-lactic a. I-3:38
 - type II renal tubular a. I-11:17
 - type IV renal tubular a. I-7:9
- Acinetobacter II-1a:23
- acquired immunoglobulin deficiencies III-6:4
- acquired multicystic disease I-18:6
- acquired renal cystic disease I-16:7
- acrivastine I-19:8
- acrocyanosis I-17:7
- acrolein I-17:31
- acromegaly I-5:23, I-23:16
- activator protein-1 I-24:12
- active pumps I-4:1
- active transport I-5:3
- activity limitation II-10:2
- acute beriberi I-3:39
- acute fatty liver of pregnancy I-9:27
- acute relapsing MS II-1d:28
- acute renal failure (ARF) II-1a:14
 - complications of ARF I-17:20
 - intrarenal structural ARF I-17:1
 - pigment-induced ARF I-17:8
 - postrenal obstructive ARF I-17:1
 - postrenal ARF I-17:2
 - prerenal functional ARF I-17:1
 - prerenal ARF I-17:2
- acute urate I-1:10
- acyclovir I-19:8, III-6:8
- adaptive responses I-17:12
- Addison's disease I-2:29, I-4:16

Subject Index

- adducin I-20:7
adenocarcinoma I-1:44
adenoma I-5:10
– adrenal a. I-2:23, I-23:4, I-24:5
– nephrogenic a. I-1:44
– parathyroid a. I-5:7
– renal cortical a. I-16:7
adenosine I-17:12, I-19:8
adenosine triphosphate I-3:1
adenovirus I-12:17, III-6:7, 12
adenylate cyclase I-5:5, 20
adhesion I-8:4
– a. receptors II-1a:12
adrenal
– a. adenoma I-2:23, I-23:4, I-24:5
– a. cortex I-20:10
– a. destruction with tuberculosis, bilateral I-2:29
– a. hemorrhage I-2:29
– a. hyperplasia, bilateral I-2:23, I-23:4, I-24:5
– a. hyperplasia, unilateral I-23:4
– a. infarction I-2:29
– a. insufficiency, chronic primary I-2:29
– a. medulla I-23:10
– a. replacement I-2:29
– a. vein blood sampling I-24:5
– a. vein sampling I-2:23
– a. venous aldosterone measurements I-23:4
adrenalectomy
– bilateral a. I-24:5
– laparoscopic a. I-24:5
– unilateral a. I-2:25
adrenergic uptake inhibiting II-13:27
adsorption II-1a:5
adsorptive pinocytosis I-17:27
adult respiratory distress syndrome (ARDS) I-12:11
advanced glycosylation end products I-7:3
adverse drug reactions I-19:5
aerobactin iron sequestration system I-12:7
aerobic exercise tolerance I-20:17
aeromonas II-1a:23
afferent
– a. nerve I-21:9
– a. phase III-1:1
– a. pulmonary reflexes I-3:50
afterload II-1c:14
afterload-reducing agents I-3:38
agenesis I-1:36
air
– a. contrast cystography I-1:42
– a. embolism II-4:20, 21, 23
– a. hunger I-3:30
alanine I-15:15
alanine amino-transferase I-8:31
albumin I-4:4, II-1d:15
albuminuria I-7:6
albuterol I-19:8
alcaligenes II-1a:23
alcohol I-11:5, I-20:2
– a. dehydrogenase I-3:39
– a. withdrawal II-4:20
alcuronium I-19:8
aldosterone I-23:2
– a. competitive inhibitor spironolactone I-2:19
– a. synthase I-20:7, I-23:6
aldosteronism
– glucocorticoid remediable a. I-2:24, I-20:7, I-24:5
– idiopathic a. I-24:5
– primary a. I-20:4, I-24:5
alendronate I-5:16, I-8:10, I-21:6
alfacalcidol I-21:6
alfentanil I-19:8
aliphatic II-6:2
alizapride I-23:19
alkalemia I-9:3, II-1d:14
alkali I-3:27
alkaline diuresis II-13:1
alkaline pH I-2:7
alkalosis I-5:20
– acute respiratory a. I-5:8
– chronic respiratory a. I-3:50, I-12:20
– selective Cl⁻-depletion a. I-2:35
– hypokalemic a. I-24:3
– metabolic a. I-1:3, 5, 35, I-4:16, II-4:26
– mixed respiratory a.-metabolic acidosis II-13:18
– rebound metabolic a. I-3:27
– respiratory a. I-3:35, 41, I-5:25, II-13:18
alkaptonuria I-1:2
alkylating
– a. agents I-23:20
– a. therapy I-8:17
allergic reactions, acute II-4:13
allergy I-19:1
– latex a. I-1:23
alloantigens III-1:1
allograft II-1d:25, III-1:1
– a. survival III-2:13
– sensitization to future a. II-7:5
alloimmunity III-1:1
allopurinol I-10:18, I-15:28, I-17:33, I-19:8, II-13:15
allotransplantation III-4:3
alpha blockers I-20:17
alpha-fetoprotein (AFP) I-11:14
alpha-interferon I-8:28
alpha-mercaptopropionylglycine I-15:27
Alport syndrome I-11:9
Alport's disease I-20:8
alprazolam I-19:8
alteplase I-19:8
alternate pathway II-1a:11
altretamine I-19:8
aluminum
– a. encephalopathy II-4:20, 21
– a. overload II-7:4
– a. toxicity I-18:8, II-4:21
– a.-containing phosphate binders II-7:4
alveolar capillary membrane I-3:49
alveolar ventilation I-3:48
– fixed a.v. I-2:40, I-3:49
alveolar-arterial (A-a) I-3:49
– A-a oxygen gradient II-5:45
Amadori products II-6:2
amantadine I-19:8
ambulatory blood pressure monitoring II-9:6
amenorrhea I-2:19, II-1d:24
amenorrheagonadism, hypoprimary I-23:7
American Society of Apheresis II-1d:2
amezinium II-4:7
amikacin I-19:8
amiloride I-4:8, I-15:26, I-19:8, I-20:7, I-24:5, I-25:19
– a.-sensitive epithelial sodium channel I-20:7
amines II-6:2
amino acids II-1b:10
– non-essential a.a. I-17:18
– sulfur-containing a.a. I-15:20
aminoglycosides I-12:10, I-17:27, II-9:14
aminoguanidine I-7:12, II-13:20
aminophenols I-1:42
amiodarone I-19:8, II-13:22
amitriptyline I-19:8
amlodipine I-19:8, I-20:19

- ammonium (NH_4^+) I-3:3, I-4:15
 – NH_4^+ production I-3:15
 amoxapine I-19:8
 amoxicillin I-19:8
 amphetamine I-20:4, I-23:12,
 II-13:3
 amphotericin I-19:8, II-5:19
 – a. B I-2:27, I-12:16, I-17:28,
 III-6:14
 – a. B colloidal dispersion I-19:8
 – B lipid complex I-19:8
 ampicillin I-12:5, I-19:8, III-6:6
 amputation II-5:67
 amrinone I-19:8
 amylase I-8:15, II-13:10
 amyloid I-8:22
 amyloid fibrils II-1a:16
 amyloidosis I-1:23, I-8:2, 22
 – β 2-microglobulin a. II-8:2
 – dialysis-related a. II-1a:16,
 II-5:41
 AN69 II-4:15
 ANA I-8:3
 anabolism I-2:4
 anaerobic glycolysis I-3:4
 anaphylactoid reactions II-1a:14,
 II-13:22
 anaphylatoxins II-1a:5, 11
 anarotide I-17:16
 anastomosis III-3:5
 ANCA I-8:3
 androgen I-23:7, II-7:3
 anemia I-21:5, II-7:1
 – autoimmune hemolytic a.
 II-1d:30
 – erythropoietin-resistant
 microcytic a. II-4:21
 – microangiopathic hemolytic a.
 I-8:5, III-2:16
 – normochromic a. I-6:49
 – pernicious a. I-2:4
 – sickle cell a. II-1d:30
 – sideropenic a. I-6:47
 – transfusion-dependent a. II-7:3
 – uremic a. II-7:5
 anephric patients II-7:3
 anergy III-1:6
 anesthesia I-24:2
 aneurysm I-8:19
 – a., aortic and coronary I-11:5
 – a. formation I-24:3
 – false a. I-1:38
 aneurysmal dilations I-22:4
 anger II-14:12
 angitis, leukocytoclastic I-8:13
 angina I-22:3, II-9:8
 angiofibroma I-11:8
 angiokeratoma I-11:16
 angiomyolipoma-hamartoma
 I-16:8
 angiomyolipomas I-1:29, 33,
 I-11:8
 angioplasty I-1:38, I-22:4
 – percutaneous transluminal a.
 I-1:38, I-22:8, I-25:23
 – percutaneous transluminal
 balloon catheter a. II-2:21
 angiotensin-converting enzyme
 (ACE) I-6:38, I-20:7, II-7:5
 – ACE fetopathy I-13:22
 – ACE gene I-24:13
 – ACE inhibitor I-18:10
 angiotensin I-18:10, I-20:10
 angiotensinogen I-20:7, 10, I-25:6
 aniline dye I-1:33
 anion I-3:2
 – a. exchanger I-3:8
 – a. gap I-3:9
 anionic charge barrier I-7:6
 anisotropic crystals I-1:4
 anistreplase I-19:8
 ankylosing spondylitis I-8:22
 anorectics I-20:4
 anorexia I-18:3
 anoxia/ischemia II-4:20
 antacids I-5:30, I-19:3
 antagonists II-2:19
 – AT-1 receptor a. I-13:22
 – b-adrenergic a. II-4:22
 – endothelin receptor a. III-7:2
 – olic acid a. I-9:16
 antecubital vein II-1d:12
 antegrade pyelography III-3:14
 anterior hypothalamus I-4:5
 anti-AchR II-1d:27
 anti-CD25 III-4:8
 anti-DNAase I-1:22
 anti-factor Xa Institute Choay
 Units II-1a:32
 anti-GBM antibody disease
 I-11:14
 anti-HCV I-8:29
 anti-IL-2R III-4:8
 anti-peripheral nerve-myelin
 antibody II-1d:25
 anti-Scl-70 I-8:21
 anti-Tac III-4:8
 anti-thymocyte globulin III-4:12
 antibiotics I-9:15
 antibodies I-8:12, I-11:12
 – anti-acetylcholine receptor a.
 II-1d:27
 – anticytokine a. I-8:12
 – antilymphocyte a. III-4:6
 – antiphospholipid a. I-1:22
 – anti-apo (a) a. II-1d:31
 – anti-C5 a. I-8:12
 – anti-DNA a. I-8:9
 – anti-HLA class I a. III-5:5
 – anti-HLA class II a. III-5:5
 – anti-immunoglobulin a. I-6:42
 antibody synthesis II-1d:24
 antibody-dependent cell-mediated
 cytotoxicity or ADCC III-1:10
 anticardiolipin antibody I-9:22
 anticentromere autoantibodies
 I-8:21
 anticholinergic agents I-12:13,
 II-13:27
 anticoagulants II-4:22
 antigen mismatch III-8:6
 antigen presenting cells III-1:3
 antigenemia III-6:9
 antigens (HLA) III-1:1
 antihistamines II-4:22
 antihyaluronidase I-1:22
 antihypertensive treatment
 I-20:15
 antimicrobial sensitivity testing
 I-12:8
 antineoplastic I-17:31
 antiphospholipid syndrome
 I-10:24, II-1d:24
 antiplatelet agents II-1d:21
 antiporters I-4:7
 antiseptic II-1b:12
 antistreptokinase I-1:22
 antithrombin III II-5:59
 – a. III protein C I-6:10
 antitubular basement membrane
 disease I-10:2
 anuria I-17:6
 anxiety I-2:2, I-4:15, II-10:8,
 II-14:12
 anxiety disorders III-2:20
 aortic
 – a. arch I-20:9
 – a. bifurcation I-9:13, I-20:5
 – a. coarctation I-25:11
 – a. dissection I-20:15, I-24:3
 – a. grafting I-22:10
 – a. regurgitation I-11:5
 – a. root dilatation I-11:5
 – a. syndrome, middle I-25:12

Subject Index

- a.-femoral revascularization II-5:67
- aortitis III-6:14
- aortoarteritis I-25:12
- aortorenal endarterectomy I-22:9
- APACHE II or III II-1c:19
- apatite I-15:2
- apical membrane I-2:5, I-5:20
- apoptosis III-1:6
- apparent mineralocorticoid excess I-20:7
- apparent volume of distribution II-13:6
- appendicitis II-5:11
- apprehension II-4:27
- apraxia II-4:21
- aquaporin-1 water channels I-4:1
- aquaporin-2 water channels I-4:5
- arachnidonic acid II-5:35
- arginine I-5:4
- arginine hydrochloride II-13:3
- arginine vasopressin I-3:31, I-20:10
- arginine-lysine-aspartate peptides I-17:34
- arrhythmias I-2:1, II-4:8, II-5:32, II-1d:14
- arsenic I-17:30
- arterial
 - a. angiography I-22:7
 - a. perforation I-22:9
 - a. rupture I-1:38
 - a. spasm I-22:9
- arteries
 - arcuate a. I-1:37
 - carotid a. II-2:7
 - cervical a. I-11:5
 - interlobar a. I-1:37
 - intimal expansion in a. I-8:20
 - uterine spiral a. I-9:5
- arteriography I-16:4, II-2:14
- arteriolar hyalinosis I-7:4, I-21:7
- arteriolar narrowing I-20:5
- arterioles I-8:12
- arteriosclerosis I-8:4, I-22:1, III-4:21
- arteritis
 - coronary a. I-8:28
 - aortoa. I-25:12
 - central retinal a. I-8:28
 - necrotizing a. III-5:6, 11
 - peria. nodosa I-1:23
 - polya. nodosa I-8:19
 - Takayasu A. I-8:19, I-24:3
- arteriovenous (AV)
 - AV shunting I-17:21
 - AV fistulas II-2:1
 - AV grafts II-2:1
- arthralgia I-17:7, III-2:15
- arthritis I-1:22, I-8:19
- Asahi II-1d:11
- ascites I-4:1, I-9:5, I-11:5, I-17:21
 - a. standard, chylous II-5:3
 - post-transplant a. II-5:62
 - urinary a. III-3:12
- ascorbic acid I-1:2, I-6:5, I-15:13
- Ashkenazi Jews II-5:56
- Ask-Upmark kidney I-13:1, I-25:11
- ASO I-1:22
- aspergillosis III-6:14
- Aspergillus III-6:4, 14
- aspiration II-4:21
 - a. cytology I-16:4
 - suprapubic a. I-1:1
- aspirin I-9:28, II-1a:32, II-2:19, II-7:14, II-13:16, III-5:14
- assays III-6:9
- Association for Advancement of Medical Instrumentation see AAMI
- astemizole I-19:8
- asthenia I-17:21
- asthma I-20:4, III-2:22
- astrocytoma I-11:8
- asymmetrical dimethylarginine I-21:4
- asymptomatic bacteriuria I-12:1
- Asymptomatic Carotid Atherosclerosis Study (ACAS) III-2:21
- AT-1 receptor I-20:18
- atenolol I-19:8, I-20:17, I-25:21
- ATGAM III-4:7
- atherectomy device II-2:22
- atheroembolic
 - a. disease I-21:10
 - a. emboli I-8:3
 - a. renovascular disease I-1:6
- atherogenesis II-2:4
- atheroma III-5:28
- atherosclerosis I-1:37, I-22:3, II-5:2
- atherosclerotic regression II-1d:31
- Atovaquone I-19:8, III-6:17
- ATP/PI ratio I-1:36
- atracurium I-19:8, III-3:3
- atrial fibrillation I-24:13
- atrial gallop rhythm I-24:13
- atrial
 - a. natriuretic factors I-20:11
 - a. natriuretic peptide (ANP) I-20:11
- atrioventricular
 - a. block I-11:16, II-13:22
 - a. conduction defects, I-24:9
- atrophy
 - disuse a. II-10:2
 - glomerular a. III-4:21
 - ischemic optic a. II-5:2
 - segmental renal a. I-13:1
 - tubular a. I-8:8, 14
- atropine II-13:23
- auditory event-related potentials II-7:13
- auranofin I-19:8
- Australian Management Committee study I-20:15
- autoantibodies I-1:21
- autoimmune
 - a. adrenalitis I-2:29
 - a. diseases I-1:23
 - a. hemolytic anemia II-1d:30
- autologous or synthetic conduits I-22:10
- automated peritoneal dialysis II-1b:21, II-14:7
- automated reprocessing II-1a:18
- automobile antifreeze I-3:41
- autonomic
 - a. dysfunction I-18:11, I-20:4, II-1d:27
 - a. hyperreflexia I-23:16
 - a. insufficiency II-5:2
 - a. neuropathy II-4:3, II-5:2
- autosomal dominant
 - a.d. disorders I-2:26, 27
 - a.d. hypocalcemia I-5:3
 - a.d. polycystic kidney diseases I-20:4, I-21:9
- autosomal recessive
 - a.r. disorders I-2:26
 - a.r. polycystic kidney disease I-11:8
- autotransplantation I-25:23
- axillary freckling I-20:8
- azathioprine I-8:7, I-19:8, II-1d:20, 27, III-4:3
- azithromycin I-19:8, III-6:5
- azlocillin I-19:8
- azoles I-12:16
- aztreonam I-19:8
- azuophil granule protein I-1:20

- B-cell clonal proliferation II-1d:24
 β 2 microglobulinuria I-11:17
 β 2-microglobulin II-1a:4
 β 2M amyloidogenesis II-1a:16
 B7 III-1:6
 Babinski sign, positive II-13:27
 backdiffusion II-1a:9
 backfiltration II-1a:9
 backflow I-14:6
 – pyelorenal b. I-13:22
 backtransport II-1a:9
 backwashing II-4:31
 bacteremia I-11:3, I-12:4, II-9:13
 bacteria II-4:32
 bacterial adherence I-12:3
 bacterial overgrowth I-15:14
 bacteriuria I-12:1
 Balkan I-16:12
 ball thrombus II-2:12
 balloon dilatation I-24:3
 band keratopathy I-5:13
 Banff classification I-1:46, III-5:10
 barbiturate II-4:22, II-13:17, III-2:20
 barium I-1:31
 barium poisoning I-2:2
 baroreceptor I-20:2
 baroreceptor sensitivity II-4:3
 – b. sensitivity slope II-4:3
 baroreflexes II-4:3
 Bartter's syndrome I-20:10, I-2:16, 21, I-23:8
 base balance I-3:2
 basolateral membrane I-2:5, I-4:6, I-4:7, I-5:18
 basophils II-4:16
 B cells I-8:27
 behavioral disturbances II-14:12
 benazepril I-19:8, I-20:18
 benzodiazepines I-9:8, II-4:22
 bepridil I-19:8
 Berger disease I-6:35
 berylliosis I-5:12
 beta agonists I-23:12
 beta blocker I-20:16
 betamethasone I-19:8, I-19:10
 betaxolol I-19:10
 bezafibrate I-19:10
 bicarbonate I-17:24
 – b. buffer system I-3:19
 – b. dialysis II-4:4
 – b. loss II-1c:16
 – b.-based dialysate II-6:9
 – serum b. I-9:3
 bicarbonaturia I-2:14, I-3:42, I-15:20
 bicuspid aortic valve I-24:3
 biguanides I-3:30
 bile salts I-15:14
 bilirubin I-1:2, I-9:4
 bioavailability I-19:3
 biocompatibility II-1a:3
 biocompatible II-1a:13
 – b. membranes II-1a:13
 biopsy, open I-1:49
 biotransformation I-19:4
 bismuth I-17:30
 bisoprolol I-19:10
 bisphosphonates I-5:15
 bladder
 – areflexic b. I-1:44
 – atonic b. III-3:7
 – b. anastomotic III-8:11
 – b. and/or perineal trauma I-1:24
 – b. calculi I-1:44
 – b. carcinoma I-1:6
 – b. dehiscence III-3:6
 – b. diverticuli I-1:42
 – b. dynamics III-3:7
 – b. irrigation I-12:16
 – b. malignancy I-11:23
 – b. neck I-11:22
 – b. outlet obstruction I-1:43, I-14:11
 – b. stones I-15:2
 – exstrophy of the b. I-11:23
 – neurogenic b. I-1:24, 25, 43, I-12:7
 – radiograph of the b. I-15:21
 blastomycosis I-12:17
 bleeding I-5:15, I-17:20
 – b. tendency II-4:17
 – b. time I-18:9, II-7:13
 – gastrointestinal b. I-1:14
 – gingival b. II-4:18
 – intracapsular b. III-3:7
 bleomycin I-19:10
 blindness I-3:40, I-9:5
 bloating II-5:3
 blood
 – b. aluminum concentration II-4:21
 – b. cell, "fragile" white I-2:11
 – b. cell rigidity and fragility, red II-4:17
 – b. coagulation factors II-4:18
 – b. compartment II-1b:2
 – b. compartment volume II-1a:2
 – b. count, complete I-20:5
 – b. culture I-11:3
 – b. cultures I-12:8
 – b. flow, changes in II-6:10
 – b. flow, constant II-1a:4
 – b. flow, low II-1c:9
 – b. flow, myocardial I-24:7
 – b. flow rate II-1d:12
 – b. flow, renal I-20:12
 – b. inlet and outlet II-1a:2
 – b. leak detectors II-1c:7
 – b. lines II-4:21
 – b. loss II-7:4
 – b. loss, acute II-7:5
 – b. or fibrin clots II-1b:25
 – b. pressure, black persons I-20:1
 – b. pressure load I-20:4
 – b. pressure, mean arterial I-7:10
 – b. pressure monitoring, oscillometric I-24:7
 – b. pump II-2:25
 – b. sampling, central venous I-23:15
 – b. side resistance II-1a:8
 – b. sugar, fasting I-20:5
 – b. thiocyanate levels I-24:8
 – b. urea nitrogen (BUN) I-9:1
 – BUN to serum creatinine ratio I-17:9
 – b. vessels, medial hyperplasia of the I-22:1
 – b. viscosity I-7:13, II-7:13
 – b.-membrane interactions II-1a:1
 blue toe syndrome I-10:26
 blurred vision II-13:22, II-14:6
 BM25 II-1c:7
 BN 52021 III-5:8
 body mass index I-20:2
 body surface area II-1b:15
 bone I-11:9, I-15:9, III-6:15
 – cancellous b. II-8:2
 – cortical or compact b. II-8:2
 – b. densitometry scanning I-8:10
 – lamellar b. II-8:3
 – b. pain II-14:9
 – subperiosteal b. resorption I-5:11
 – woven b. II-8:3
 bone disease
 – adynamic b.d. II-8:2, II-14:10
 – aluminum-related b.d. II-8:2
 – β 2-microglobulin-amyloid b.d. II-1a:13
 – hypoplastic b.d. II-4:21
 – low-turnover b.d. II-8:17
 – metabolic b.d. III-7:7
 bone lesion
 – high-turnover b.l. II-14:9

Subject Index

- low turnover b.l. II-14:9
- lytic b.l. I-10:18
- bone marrow
 - b.m. cells II-8:5
 - b.m. cultures III-6:16
 - b.m. suppression I-5:15
 - b.m. transplant I-12:17
 - b.m. transplantation I-17:32
 - b.m. transplantation, autologous I-8:25
- bone remodeling II-14:9
- bone remodeling units II-8:5
- bone structural units II-8:3
- bone turnover II-8:7
- bony erosion I-8:15
- bopindolol I-19:10
- boric acid II-13:1
- Bosniak classification I-16:6
- Bouin's solution, alcoholic I-1:49
- bowel
 - b. incarceration II-1b:25
 - b. infarction II-5:11
 - b. perforation I-8:15
 - b. sounds, decreased I-3:30
 - b. wall I-8:15
 - inflammatory b. disease I-10:21, I-14:3
 - selective b. decontamination III-6:3
 - short b. syndrome I-10:21
 - small b. II-5:11
 - small b. hernia II-5:11
 - whole b. irrigation II-13:1
- Bowman's space I-13:7
- brachytherapy II-2:19
- bradycardia II-4:3, 14, 30
- bradykinin I-20:10, II-1a:12, II-4:15
- brain abscess III-6:14, 15
- brain cells I-4:14
- brain perfusion I-25:23
- brain water II-4:25
- brain-to-plasma urea ratio II-4:25
- bretylum I-19:10, II-13:25
- bromocriptine I-19:10
- bromocriptine mesylate I-23:20
- bromothymol blue I-1:3
- brompheniramine I-19:10
- bronchial carcinoma III-7:9
- bronchial hypersecretion II-4:14
- bronchiolitis obliterans I-8:15
- bronchitis I-11:11
- bronchogenic I-8:27
- bronchospasm II-4:14, II-13:22
- bruit I-20:5, II-2:15, III-5:28
- brush border membrane I-5:18
- brush cytology I-1:42
- brushite I-15:3
- bubble trap II-1c:10
- budesonide I-19:10
- buffer II-1b:9, II-4:2
- buffy coat II-1d:33
- bulb pyelogram I-1:42
- bumetanide I-19:10
 - bumetanide-sensitive $\text{Na}^+ - \text{K}^+ - 2\text{Cl}^-$ co-transporter I-2:22
- BUN see blood urea nitrogen I-9:1
- bupropion I-19:10
- burn-out by dialysis, parental II-14:12
- burn victim I-4:18
- burst-forming units-erythroid II-7:2
- buspirone I-19:10, I-23:22
- busulfan I-19:10
- butorphanol I-19:10
- button-hole method II-2:18
- bypass
 - aortorenal b. I-22:10
 - cardiopulmonary b. II-13:25
 - coronary artery b. grafting I-24:2
 - heart-lung b. II-1a:13
 - hepatorenal or splenorenal b.es I-22:10
 - iliorenal b. I-22:10
 - jejunoileal b. I-15:14
 - supraceliac aorto-renal b.es I-22:10
- C(3b)nBb II-1a:11
- C-cell hyperplasia I-23:12
- C-reactive protein (CRP) I-8:9, I-13:25, II-5:21
- C0 II-6:20
- C1q I-6:31
- C1q binding assay I-1:23
- C3 nephritic factor I-6:33
- C3 nephritogenic factor (C3NeF) I-1:21
- C3b II-1a:11
- C3bBb II-1a:11
- C5a II-1a:11
- cyclosporine A arteriopathy III-4:21
- cachexia I-2:11, II-1a:32
- cadaveric kidney/renal transplant I-7:7, III-2:1
- cadmium I-10:20, I-23:20
- cafe au lait spots I-11:8, I-20:8
- caffeine I-10:12, I-23:17, II-4:7
- calbindin I-5:3
- calcareous stones I-15:2
- calcification I-11:8
 - central c. I-16:11
 - conduction system c.s II-4:8
 - extraskelatal c. II-5:2, II-14:9
 - metastatic c. I-5:13, I-17:33
 - metastatic pulmonary c. II-5:2
 - parenchymal c. I-1:24
 - soft tissue c. I-18:6
 - vascular c. II-5:2
- calcinosis, tumoral I-5:23
- calciphylaxis II-5:3, II-5:57
- calcitonin I-5:15, I-8:10, I-20:8, calcitriol I-5:2, I-15:27, I-18:6
- calcium I-20:2
 - c. absorption, intestinal I-15:8
 - c. chloride II-1a:30
 - c. citrate I-15:28
 - c., dialysate II-1a:33
 - c. excretion, urinary I-20:16
 - c. nephrolithiasis, hypomagnesiuric I-15:15
 - c. gluconate I-2:10
 - c., ionized I-5:2
 - c., nadroparin II-1a:32
 - c. nephropathy I-5:13
 - c. oxalate I-11:3, I-15:2
 - c. oxalate crystals II-13:12
 - c. oxalate precipitation I-17:6
 - c. phosphate I-15:3, I-15:5
 - c. pump I-5:4
 - c. supplementation I-9:7
- calcium channel
 - L-type c.c. I-20:19
 - T-type c.c. I-20:19
- calcium channel blockers I-18:10, I-20:19
 - dihydropyridine c.c.b. I-18:10, I-22:10
 - T-type c.c.b. I-24:2
- calcium-dependent protein phosphatases (calcineurin) III-1:5
- calcium-phosphorus product II-8:21
- calculi I-15:1
- calmodulin I-21:3
- caloric requirements I-17:18
- calorie I-18:2, I-20:4
- calpain I-9:28
- calyceal deformities I-13:6
- calyceale III-3:10
- cAMP II-6:2
- cancer I-8:1

- c. of the lip III-7:9
 - c. risk II-5:60
 - candida albicans II-5:13
 - candida UTI I-12:15
 - candidiasis III-6:13
 - candoxatril I-20:21
 - CANUSA II-1b:18
 - capacity
 - adsorptive c. II-13:4
 - decreased cognitive c. II-10:8
 - diluting c. I-1:17
 - functional residual c. II-5:45
 - inspiratory c. II-5:45
 - minimal bactericidal c. II-5:21
 - salt-excreting c. I-20:12
 - total iron binding c. II-7:5
 - capillary I-4:4, I-8:12
 - alveolar c. membrane I-3:49
 - c. hydrostatic pressure II-4:2
 - c. leakiness I-17:23
 - c. permeability I-20:11
 - c. sclerosis I-10:13
 - c. thrombosis I-8:20
 - c. wedge pressures I-24:7
 - pulmonary c. wedge pressure I-3:37, I-9:5, I-24:13
 - capreomycin I-19:10
 - capsular
 - c. drop lesion I-7:4
 - c. tear II-5:2
 - captopril I-19:10, I-20:5, I-22:6, I-25:22
 - c. renography I-1:30, I-22:7
 - c. test I-20:10, I-22:6
 - carb-bicarb I-3:26
 - carbamazepine I-11:16, I-19:10, II-4:22
 - carbamylation of proteins II-6:3
 - carbenoxolone I-2:7, I-23:9
 - carbidopa I-19:10
 - carbohydrate
 - c. meal I-2:27
 - c. metabolism I-3:4, I-18:3
 - carbon
 - c. dioxide II-4:10
 - c. filters II-1a:26, II-4:31
 - c. filtration II-1a:25
 - c. monoxide uptake I-6:47
 - granular activated c. II-1a:27
 - carbonic anhydrase inhibitor I-3:46
 - carboplatin I-17:30, I-19:10
 - carcinogenic II-1a:25
 - carcinoids I-23:14
 - carcinoma I-8:27, I-23:4
 - c. of uterus III-2:18
 - cardiac
 - c. catheterization I-17:7
 - c. function I-18:10
 - c. irritability II-4:30
 - c. ischemia II-7:12
 - c. output I-20:8, I-22:2, II-4:2, II-13:25
 - c. tamponade II-4:9
 - c. toxicity I-2:10
 - c. valve disease I-11:5
 - cardiogenic shock II-13:25
 - cardiolipin I-1:22
 - cardiomegaly I-23:16, II-13:12
 - cardiomyopathy I-18:10, II-9:8
 - dilated c. I-23:10
 - cardiopulmonary
 - c. receptors II-4:4
 - c. recirculation II-6:8
 - cardiovascular
 - c. disease I-20:1
 - c. function I-18:1
 - c. morbidity I-24:2
 - c. mortality I-24:2
 - c. system I-18:9
 - cardioversion II-13:23
 - caries I-5:9
 - carmustine I-19:10
 - carotene deficiency II-5:43
 - carotid sinus I-20:9
 - carpal tunnel syndrome I-23:16, II-4:32, II-5:2
 - carpopedal spasm II-1d:14
 - carteolol I-19:10
 - cartilage I-9:16
 - carvedilol I-19:10, I-20:17
 - cast I-17:8
 - acellular c. I-1:7
 - c. nephropathy I-8:22, I-10:16
 - catabolism I-2:4
 - cataracts I-5:9
 - catecholamine I-2:2, I-20:12, 20, I-24:4, I-25:13, II-4:22
 - cathepsin G I-1:20
 - catheter II-3:1
 - c. cuff II-3:15
 - c. erosion II-5:11
 - c. exit site II-5:1
 - c. malfunction II-1b:24
 - c. malposition II-2:11
 - c. migration II-3:4, II-14:8
 - c. obstruction II-3:14
 - c. tunnel II-3:4
 - c. venogram II-2:12
 - center c.s II-3:5
 - central venous c.s II-2:4
 - Cruz c.s II-3:5
 - delayed exteriorization of c.s II-3:15
 - double lumen venous c.s II-1c:9
 - Foley c. I-1:43, I-12:12
 - indwelling c.s I-12:12
 - kinking of the c.'s intramural segment II-1b:25
 - midline c. implantations II-1b:24
 - percutaneous transluminal balloon c. angioplasty II-2:21
 - peritoneal c.s II-1b:10
 - permanent c. II-1b:10
 - pigtail c. I-1:37
 - pressure transducer c.s I-1:43
 - pulmonary arterial c. III-3:2
 - rigid peritoneal c. II-1b:10
 - silastic central c.s II-2:1
 - single and dual-lumen venous c.s II-14:5
 - Tenckhoff c. II-1b:10, II-3:4
 - Tenckhoff single and double cuff c.s II-5:9
 - Tesio c.s II-2:5
- catheter-related complications II-1b:24
- catheter/adaptor junction II-3:14
- catheterization I-1:1, I-14:11
 - cardiac c. I-17:7
 - chronic c. I-12:13
 - intermittent c. I-12:13
 - right heart c. I-17:14
- catheterography II-1b:25
- cation I-3:12
- cation transport I-21:8
- cation-exchange resin I-2:30
- C_{Av} II-6:20
- cavitary lesions I-8:15
- CD40 III-1:6
- CD45 (leukocyte common antigen) III-1:7
- CD46 (membrane cofactor protein) III-9:11
- CD55 III-9:11
- CD59 (homologous restriction factor) III-9:11
- cefaclor I-19:10
- cefadroxil I-19:10
- cefalexin I-9:15
- cefamandole I-9:15, I-19:10
- cefazolin I-9:15, I-19:10
- cefepime I-19:10, III-6:5
- cefixime I-19:10
- cefmenoxime I-19:10
- cefmetazole I-19:10
- ceftazadime III-6:5

Subject Index

- cefonicid I-19:10
- cefoperozone I-9:15, I-19:10
- ceforanide I-19:10
- cefotaxime I-19:10
- cefotetan I-9:15, I-19:10
- cefoxitin I-19:10
- cefpodoxime I-19:10
- cefprozil I-19:10
- ceftazidime I-19:10, II-1d:20
- ceftibutin I-19:10
- ceftizoxime I-19:10
- ceftriaxone I-19:10, III-6:6, II-1d:20
- cefuroxime axetil I-19:12
- cefuroxime sodium I-19:12
- celiac sprue I-15:14
- celiprolol I-19:12, I-20:17
- cell
 - activation-induced c. death III-1:12
 - c. lysis III-3:8
 - c. membrane antigens I-6:42
 - c. membranes I-4:1
 - c.-mediated immunity II-7:13, II-1d:4
 - dendritic c.s III-1:4
 - principal c.s I-2:5
- cellular
 - c. casts I-1:7
 - activation of c. components II-1a:12
- cellulose II-1a:3
 - c.-based fibers II-1a:2
 - c.-diacetate II-1d:11
 - DEAE c. II-1d:32
 - substituted c. II-1a:3
- cellulosic membrane hollow fibers II-1a:2
 - cellulosynthetic membrane hollow fibers II-1a:3
- Center for Disease Control II-1a:14
- central nervous system (CNS) I-11:7, I-18:10, I-20:11
 - CNS infarctions I-8:28
 - CNS vasculitis I-8:16
- central respiratory centers I-3:348
- central respiratory stimulation I-3:41
- central retinal arteritis I-8:28
- central tolerance III-1:13
- central vein I-2:9
- central venous
 - c.v. access II-1d:12
 - c.v. blood sampling I-23:15
 - c.v. catheters II-2:4
 - c.v. pressure III-3:2
 - c.v. pressure monitoring I-17:21
 - c.v. vessels I-4:7
- centrifugal
 - c. plasma separation II-1d:9
 - c. ultrafiltration II-13:23
- centrifugation
 - continuous c. II-1d:9
 - intermittent c. II-1d:9
- cephalexin I-19:12, II-5:27, II-13:15
- cephaloridine I-17:29
- cephalosporins I-9:15, I-17:29
 - first-generation c. I-12:5
- cephalothin I-19:12
- cephapirin I-19:12
- cephradine I-19:12
- cerebellar ataxia I-11:9
- cerebellum I-24:11
- cerebral
 - acute c. edema II-14:6
 - c. edema II-4:27
 - c. function II-7:12
 - c. swelling II-4:25
 - c. vascular disease II-5:2
 - c. vasculitis I-6:42
 - middle c. artery I-11:5
- cerebrospinal fluid I-11:5
- cerebrovascular
 - c. accident II-9:9
 - c. disease II-9:9
 - ischemic c. I-11:16
- cervix I-11:22
- cetirizine I-19:12
- charcoal
 - c. filters II-4:31
 - activated c. II-13:1
 - multiple doses of activated c. II-13:1
- chelating agents I-15:27
- chelation I-19:3
- chelation therapy III-6:15
- chemical irritation I-12:18
- chemoadsorption onto dextran sulfate II-1d:31
- chemotactic activity I-5:24
- chemotherapeutic agents III-2:15
- chemotherapy II-1d:23
- chest roentgenogram I-20:5
- chewing tobacco I-2:7, I-20:4
- chicken III-6:8
- chills II-13:22
- Chlamydia III-6:3
- Chlamydia trachomatis I-12:15
- chloral hydrate I-19:12
- chlorambucil I-6:16, I-19:12
- chloramine II-1a:25, II-4:28, 31, II-7:4
- chloramphenicol I-19:12
- chlorazepate I-19:12
- chlordiazepoxide I-19:12
- chlorhexidine II-14:8
- chloride I-20:7
- chlorinated compounds II-3:13
- chlorine II-1a:25, II-4:31
- chloroacetaldehyde I-17:31
- chloroamphenicol II-5:19
- chloroform II-4:31
- chloroquine I-19:12
- chloroquine phosphate II-4:13
- chlorpheniramine I-19:12
- chlorpromazine I-19:12
- chlorpropamide I-4:23, I-19:12
- chlorthalidone I-19:12, I-25:19
- chlorvynol II-13:6
- cholelithiasis I-23:12, III-2:19
- cholesterol I-20:1
 - c. crystal embolism syndrome I-10:26
 - c. emboli I-17:7
 - c. embolic disease I-13:8
 - c. embolism syndrome I-10:23
 - c.-containing lipoproteins II-1d:7
 - HDL c. I-7:12
 - LDL c. I-7:12, I-20:5
 - lecithin-c. acyltransferase I-6:8
- cholestiramine I-15:28, I-19:12, II-13:23
- cholinesterase inhibitor II-13:29
- chondrocalcinosis I-5:13
- choreoathetosis II-13:27
- chromaffin I-23:10, I-25:23
- chromatography/radioimmunoassay, liquid II-13:23
- chromium I-10:20, I-17:30
- chromogenic limulus test II-4:32
- chronic
 - c. fasting I-3:16
 - c. obstructive pulmonary disease (COPD) III-6:1
 - c. primary adrenal insufficiency I-2:29
 - c. progressive MS II-1d:29
 - c. renal allograft failure syndrome III-4:16
 - c. renal disease I-21:1

- c. renal failure I-5:21
- c. renal insufficiency I-13:19, I-18:1
- Churg-Strauss syndrome I-8:3
- Churg-Strauss vasculitis I-1:23
- Chvostek I-5:31
- cibenzoline I-19:12
- cidofovir I-19:12
- cigarette smoking I-20:1
- cilastin I-17:29, I-19:12
- cilazapril I-19:12
- cimetidine I-19:12, II-4:22, II-13:15
- cinoxacin I-19:12
- ciprofloxacin I-12:5, I-19:12, II-5:23, II-13:15, III-6:5
- circulation
 - enterohepatic c. II-13:22
 - extracorporeal c. volume II-1a:2
 - portal c. I-19:3
- cirrhosis I-8:2,31
- cirrhotic glomerulosclerosis I-8:31
- cisapride I-19:12, II-5:32
- cisplatin I-17:30, I-19:12
- citrate I-3:5, I-5:8, I-10:22, I-15:6
 - c. anticoagulation II-1a:30
 - c. excretion I-3:15
 - c. lyase I-15:11
 - low urinary c. I-11:3
 - rate of excretion of c. I-3:15
- citraturia I-3:15
- citric acid I-15:10, II-1d:13
- citrus fruits I-15:20
- Cl-shunt disorder I-2:7
- cladribine I-19:12
- clarithromycin I-19:12
- claudication I-22:3
- clavulanic acid I-19:12
- clean-catch/midstream-voided I-1:1
- clearance II-1a:4, II-6:10
 - c. studies II-1a:20
 - continuous equivalent of intermittent c. II-6:11
 - continuous equivalent of renal c. II-6:24
 - convective solute c.s II-1a:10
 - creatinine c. II-1b:15
 - delivered c. II-6:6, 11
 - dialyzer c. II-6:10
 - dialyzer urea c. II-6:28
 - integrated c. II-6:11
 - mean patient c. II-6:15
 - native kidney c. II-6:20
 - normalized weekly c.s II-1b:15
 - patient c. II-6:15
 - peritoneal solute c.s II-1b:7
 - plasma c. I-17:27
 - prescribed c. II-6:6, 11
 - renal c. I-1:11
 - residual c. II-1b:16, II-6:17
 - small solute c. II-6:6
 - sulfate c. II-5:49
 - urea c. II-6:6
- cleft clitoris I-11:23
- clindamycin I-19:12, III-6:17
- clodronate I-19:12
- clofazamine I-19:12
- clofibrate I-19:12
- clomipramine I-19:12
- clonazepam I-19:12
- clonidine I-9:11, I-19:12, I-20:20, I-24:2, 9, I-25:21
 - suppression test I-23:13
- clonus II-13:27
- Clostridium welchii I-9:26
- clotrimazole II-5:19, III-6:13
- clotted fibers II-1a:3
- clotting factors I-9:4
- clotting time, activated II-1d:13
- co-transporters I-4:7
- CO₂ angiography I-1:38
- CO₂ injection and digital subtraction angiography I-22:7
- CO₂ production I-3:48
- CO₂ removal I-3:48
- coagulase-negative Staphylococcus I-9:15
- coagulation
 - c. factor inhibitors II-1d:30
 - c. system I-18:9
 - disseminated intravascular c. I-9:4, I-12:10, III-6:8
 - intravascular c. I-9:4
- coarctation of the aorta I-24:3
- coaxial cylinder configuration II-2:6
- Cobe 2997 II-1d:9
- cocaine I-23:12, I-24:9
- cocaine packets II-13:1
- coccidioidomycosis III-6:1
- coccidiomycosis I-5:12
- Cockcroft and Gault equation I-19:2
- codeine I-10:12, I-19:12
- cognitive dysfunction II-5:2
- cognitive function II-7:12, III-2:20
- COL4A3 I-11:13
- COL4A4 I-11:13
- COL4A5 I-11:13
- COL4A6 I-11:13
- colchicine I-8:24, I-10:19, I-19:12
- cold agglutinins II-1d:30
- cold ischemia III-3:3
- cold pressor test II-4:3
- colestipol I-19:12
- colic I-8:19
- coliform bacilli I-12:2
- collagen II-8:5
- collagen vascular disease I-1:23, II-1d:30
- collateral vessels II-2:28
- colloid I-17:21
 - c. osmosis II-1b:2
 - c. osmotic pressure I-4:4
 - c. starches II-1d:17
- colloidal II-1d:15
- colonic
 - c. lesions II-7:5
 - c. motility I-2:34
 - c. mucosa I-2:34
 - c. polyps II-5:56
- colony-forming units-erythroid II-7:2
- colorimetric indicator I-1:3
- coma I-9:27, II-4:24
- comorbid conditions II-9:1, 3, 5, 7, 9, 11, 13, 15, 17
- compensatory growth I-13:9
- compensatory hypertrophy I-13:14, III-4:23
- compensatory hyperventilation II-4:10
- complement activation II-4:11, 14 II-1a:3
- complement cascade II-1a:11
- complement-activated leukocytes II-1a:16
- compliance III-2:22, III-5:20
- complicated cystic I-16:4
- compound muscle action potential II-1d:26
- compressive bandages II-4:7
- computed tomography I-20:5
- concentrating ability I-1:17
- concentration gradient II-1b:3
- concentration, time-averaged II-6:25
- condom drainage I-12:13
- confluent fibrosis III-4:26
- confusion II-4:24, 29, II-10:8
- congenital
 - c. anomalies I-9:10, 19
 - c. hepatic fibrosis I-11:8

Subject Index

- c. megalocytes I-11:22
- c. nephrotic syndrome I-11:14
- c. nephrotic syndrome of Finnish type I-11:14
- c. obstruction I-1:36
- c. vesicoureteral reflux I-12:7
- c. vesicoureteric junction abnormality I-11:22
- Congo red I-1:50, I-8:30
- conjugated estrogens I-17:20
- Conn syndrome I-24:5, I-25:13
- consciousness
 - level of c. I-3:32
 - loss of c. II-4:14
- constant (Fc) portion of IgG III-1:10
- constipation I-13:6, I-23:10, II-1b:25
- contact pathway activation II-1a:12
- contact/hypersensitivity dermatitis II-5:3
- contamination II-4:29, II-1a:19
- continuous
 - c. ambulatory peritoneal dialysis (CAPD) II-1b:1
 - c. arteriovenous hemodiafiltration II-1c:6
 - c. arteriovenous hemodialysis II-1c:6
 - c. arteriovenous hemofiltration II-1c:2
 - c. centrifugation II-1d:9
 - c. cyclic peritoneal dialysis II-1b:1
 - c. equivalent of intermittent clearance II-6:11
 - c. equivalent of renal clearance II-6:24
 - c. high-flux dialysis II-1c:7
 - c. quality improvement II-12:7
 - c. renal replacement therapy II-1c:6
 - c. veno-venous hemodialysis II-1a:6, II-1c:7
 - c. veno-venous hemofiltration II-1c:6
- contraceptive agents
 - c.a., estrogen-containing oral I-13:21
 - c.a., progesterone-only I-13:21
- contraceptives, oral I-20:4, I-24:4, II-13:15, III-2:15
- contrast media I-1:23
- contrast peritonography II-5:44
- convection II-1a:5
- convective
 - c. losses II-6:17
 - c. solute clearances II-1a:10
 - c. transport II-1a:5
- Coomassie blue method I-1:15
- copper I-5:6, II-4:28, II-7:4
- core and surface antibody III-6:2
- corneal deposits I-11:16
- coronary
 - c. accidents I-11:16
 - c. arteritis I-8:28
 - c. artery disease I-18:1
- cortical
 - c. collecting duct I-2:4, I-4:8
 - c. striations I-5:11
 - c. tubers I-11:8
- corticomedullary junction I-11:9
- corticosteroids I-8:7
- corticotropin-releasing hormone I-23:21
- cortisol I-2:6, I-20:7, I-23:2
 - c. level I-24:4
 - c.-aldosterone hybrid compounds I-2:25
 - c.-induced mineralocorticoid excess I-23:8
 - syndrome of c. resistance I-23:7
 - urinary free c. level I-24:4
- cortisone I-2:6, I-19:12, I-23:2
- Corynebacterium III-6:5
- cost-effectiveness II-10:5
- costovertebral angles I-12:8
- cotrimoxazole I-8:18
- counter current flow II-1a:6
- counter-regulatory hormones I-3:29
- counting (Fuchs-Rosenthal) chamber I-1:4
- Cox II inhibitors, selective I-17:26
- Coxsackie I-8:2
- crack vials II-13:1
- cramps II-4:6
- cranberry juice I-12:2
- creatinine clearance II-1b:15
- creatinine level I-18:8
- crescent formation II-1d:25
- crests I-6:45
 - fibrous c. I-8:4
- CREST syndrome I-8:21
- Crohn's disease I-1:20, I-15:14
- cromakalim I-20:21
- crossed ectopia I-11:21
- crush injury I-2:4
- crush syndrome I-17:22
- Cruz catheters II-3:5
- cryofiltration II-1d:1, 22, 32
- cryogel II-1d:33
- cryoglobulinemia I-8:2, 29
 - mixed c. III-2:15
 - Type II mixed c. I-8:30
- cryoglobulinemic vasculitis I-8:30
- cryoglobulins I-1:22, I-8:29
- cryoprecipitate I-17:20
- cryptococcal antigen test III-6:14
- cryptococcosis III-6:14
- Cryptococcus I-12:17
- Cryptococcus neoformans III-6:14
- crystal aggregation I-15:4
- crystalloid osmotic pressure II-1b:2
- cuff width I-20:3
- cuffs II-1b:10
- cuprophane membranes I-17:20, II-1a:11, II-4:10
- Cushing disease I-24:3
- Cushing response I-23:16
- Cushing's Syndrome I-20:5, I-24:3, I-25:13
- cutaneous
 - c. function I-18:1
 - c. necrotizing vasculitis II-1a:19
 - c. T-cell lymphoma II-1d:33
 - c. testing II-4:14
- cyanate II-6:3
- cyanide I-9:13, I-24:8
- cyanide-nitroprusside test I-15:21
- cyanosis I-25:15
- cyclic AMP I-2:2
- cyclic GMP phosphodiesterase I-6:9
- cyclophosphamide I-6:16, I-8:7, I-17:31, I-19:12, I-24:5, III-5:16
 - pulse c. II-1d:24
- cycloserine I-19:12
- cyclosporine I-2:7, I-8:11, I-19:12, II-1d:20
- cyclosporine A I-21:6, III-4:15
- cyclosporine-induced hyperkalemia I-2:32
- cyclosporine nephrotoxicity I-1:30
- cyproheptadine II-4:22
- cyst I-11:2
 - c. puncture I-16:4
 - simple c. I-16:3
- cysteamine I-10:19
- cysteine protease I-9:28
- cystine I-1:10
- cystine stones I-15:3

- cystinuria I-15:3
 cystitis
 – acute hemorrhagic c. I-12:17
 – cholec. II-5:11
 – hemorrhagic c. I-6:50, III-6:12
 cystography I-1:42
 cystometrogram I-1:43
 cystoscopy I-1:42
 cystotomy III-3:6
 cystourethrography I-1:42
 cysts I-1:28
 cytarabine I-19:12
 cytochrome CYP2E1 (P450 2E1)
 II-13:20
 cytochrome P450 enzymes III-6:18
 cytokines I-5:6, II-4:32, III-1:2
 cytomegalovirus (CMV) I-12:17
 – CMV hyperimmune globulin
 III-2:9
 – CMV retinitis III-6:4
 cytopheresis II-1d:1
 cytoplasmic receptor I-2:6
 cytotoxic agents I-6:16
 – c. T lymphocytes III-1:8
 – c. T lymphocyte antigen-4
 III-1:11
 cytotoxin alpha hemolysin I-12:7
 D-lactate I-3:10
 dacarbazine I-24:5
 dacron II-3:2, II-5:24
 dacron velour II-1b:10
 danazol I-23:18, II-1d:29
 dapsone I-19:14
 darvon II-13:17
 daunorubicin I-19:14
 daytime ambulatory peritoneal
 dialysis II-1b:13
 deafness I-6:6
 death II-13:17
 decay accelerating factor III-9:22
 decongestants I-20:4
 deferoxamine I-19:14, II-8:28,
 III-6:15
 deformability II-4:17
 deglymidodrine II-4:7
 dehydrogenase
 – 11 β -hydroxysteroid d. I-2:6,
 I-23:2, 8
 – 11 β -OH steroid d. I-20:8, I-24:6
 – β -hydroxybutyrate d. I-3:36
 – β -OH-steroid d. I-20:4
 – D-2-hydroxy acid d. I-3:44
 – D-glyceric d. I-15:15
 deionization II-1a:26
 delavirdine I-19:14
 delayed graft function (DGF)
 III-5:1
 delayed-type hypersensitivity
 I-10:1, III-1:9
 deletion III-1:13
 delirium II-4:24
 delivered clearance II-6:6, 11
 delta waves II-4:25
 dementia II-4:21
 dendritic cells III-1:4
 dense deposits disease I-6:31
 density I-16:4
 dental aplasia I-5:9
 Denys-Drash syndrome I-11:15
 deoxycorticosterone I-23:6, 7
 deoxycorticosterone acetate
 I-14:10
 deoxycortisol I-23:6
 deoxyspergualin III-9:17
 deposition II-14:8
 depletion
 – acute lymphocyte d. III-4:3
 – cholinesterase d. II-1d:16
 – phosphate d. I-5:13
 – platelet d. II-13:8
 depression I-20:20, II-5:2, II-10:8,
 II-14:12, III-2:20
 dermatitis I-8:10, I-15:27
 – contact/hypersensitivity d. II-5:3
 desalination I-4:5
 desipramine I-19:14
 desmopressin II-4:19
 detrusor I-1:43
 detrusor sphincter dyssynergia
 I-1:43
 developmental studies I-9:11
 dexamethasone I-2:25, I-19:14
 dexamethasone suppression I-23:5
 dexamethasone-suppressible
 hyperaldosteronism I-23:6
 dextrans II-1b:10, II-4:7
 dextrose II-1b:8
 Di George syndrome I-5:22
 Diabetes Control and Complica-
 tions Trials (DCCT) III-8:3
 diabetes insipidus I-1:17
 – nephrogenic d. insipidus
 II-13:13
 diabetes mellitus (DM) I-18:1, 4,
 I-20:4
 – streptozotocin-induced DM
 I-7:13
 diabetic neuropathy I-7:9, II-5:2
 diacetate II-1a:3
 dialysate
 – bloody d. II-1b:24
 – countercurrent d. flow II-1c:6
 – d. analysis II-6:18
 – d. buffer II-1a:32
 – d. calcium II-1a:33
 – d. channeling II-1a:2
 – d. composition II-1a:32
 – d. cooling II-4:5
 – d. flow II-6:10
 – d. flow distribution II-1a:2
 – d. leakage II-1b:24, II-3:14
 – d. temperature II-4:22
 – d. to plasma ratios II-1b:6
 – d.-induced immune defects
 II-5:64
 – d./plasma creatinine II-5:4
 – d./plasma equilibration II-1c:8
 – fluoride-contaminated d. II-4:28
 – hypotonic d. II-7:4
 – low d. flow areas II-1a:2
 – overheated d. II-7:4
 dialyzer clearance (KD) II-6:10
 – KD, effective (delivered) II-6:14
 – KD, minimum effective II-6:15
 dialyzer
 – d. clotting II-4:24
 – d. header volume II-1a:20
 – d. reuse II-1a:17
 – d. rupture II-4:24
 – d. urea clearance II-6:28
 – dry pack d. II-1a:19
 – high-flux d. II-1a:8
 – hollow fiber d. II-1a:1, II-4:14,
 II-6:11
 – low-flux d. II-1a:8
 – parallel plate and coil d. II-4:14
 dialysis II-6:1
 – automated peritoneal d.
 II-1b:21, II-14:7
 – bicarbonate d. II-4:4
 – continuous high-flux d. II-1c:7
 – continuous cyclic peritoneal d.
 II-1b:1
 – continuous ambulatory peritone-
 al d. I-21:4, II-1b:1
 – daytime ambulatory peritoneal
 d. II-1b:13
 – d. acetate II-4:4
 – burn-out by d., parental II-14:12
 – d. dementia II-4:21, II-8:22
 – d. disequilibrium II-4:24
 – d. disequilibrium syndrome
 II-4:20, II-14:6
 – d. encephalopathy II-4:21
 – d. exchange II-3:7
 – d. membrane I-17:19

Subject Index

- d. morbidity and mortality study II-7:10
- d. pericarditis II-4:9
- d. schedule II-6:22, 24
- d. tubing II-1a:2
- d. without anticoagulation II-1a:30
- d.-associated seizures II-4:20
- d.-induced hypercalcemia II-4:29
- d.-related pain syndrome II-5:11
- dose of d. II-6:6
- heparin-free d. II-1a:30
- high-flux d. II-1a:1
- inadequate d. II-1b:15
- initial peritoneal d. regimen II-1b:20
- intensity of d. II-6:16
- intensive d. I-17:19
- intermittent peritoneal d. II-1b:13
- intestinal d. II-13:1
- log mean urea concentration during d. II-6:20
- modulated d. II-4:6
- nocturnal intermittent peritoneal d. II-1b:7
- optimum d. dose II-6:9
- peritoneal d. (PD)
- chronic PD II-1b:20
- semipermeable d. membrane II-6:2
- d. therapy, duration of II-1a:18
- tidal peritoneal d. II-1b:14
- vein-to-vein d. II-6:8
- withdrawal of d. II-11:1
- diapact CRRT II-1c:7
- diaphragm I-5:24, I-23:10, II-1b:3
- diaphragm/spermicide I-12:11
- diaphragmatic defect II-1b:25
- diarrhea I-3:7, I-19:4, I-20:20
 - chronic d. I-15:11
- diarrheal fluid I-3:20
- diastolic I-20:3
- diastolic heart failure I-24:1
- diatrizoate meglumine I-1:11, II-1b:24
- diatrizoic or iohalamic acid I-1:23
- diazepam I-19:14, II-13:29
- diazoxide I-9:12, I-19:14, I-24:9, I-25:23
- diclofenac I-19:14
- dicloxacillin I-19:14
- didanosine I-19:14
- diet, protein-restricted I-18:2
- dietary fat intake I-25:7
- dietary protein intake II-1b:18
- diethylaminoethyl (DEAE) II-1a:4
 - DEAE cellulose II-1d:32
- diethylenetriamine pentaacetic acid I-1:39
- diffuse leiomyomatosis I-11:11
- diffuse mesangial sclerosis I-11:14
- diffusion I-3:49, II-1a:5, II-6:12
- diffusion gradient II-1a:1
- diflucan II-5:19
- diflunisal I-19:14
- digital subtraction arteriography I-1:37
- digitalis II-4:8
 - altered color perception of d. toxicity II-13:22
- digitoxin I-19:14
- digoxin I-19:14, II-1d:20
 - fluorescence polarization immunoassay for d. II-13:23
 - d.-like substance immunoreactivity II-13:23
 - d.-specific antibody fragments (Fab fragments) II-13:1, 23
- dihydropyridine calcium channel blockers I-22:10
- dihydropyridine-sensitive Ca²⁺ channel I-2:28
- dihydropyridinesencies I-20:19
- dihydroxytachysterol II-14:10
- dilantin III-2:20
- dilatation
 - aortic root d. I-11:5
 - balloon d. I-24:3
 - ureteral d. I-9:1
 - inappropriate peripheral venod. II-4:3
- dilated collecting system (International Grades) I-13:8
- dilators II-1b:10
- dilevalol I-19:14
- diltiazem I-19:14, I-20:19
- dimethyl-sulfoxide I-17:33
- diphenhydramine I-19:14
- diphenylhydantoin I-5:8, I-11:16, II-4:22
- diphtheria III-6:2
- dipivalyladrenaline hydrochloride I-23:19
- dipping I-20:4
- dipstick testing I-1:1
- dipyramidole I-7:13
- dipyridamole I-9:28, I-19:14, II-2:19, II-7:14
- dirithromycin I-19:14
- disequilibrium
 - dialysis d. II-4:24
 - dialysis d. syndrome II-4:20, II-14:6
 - flow-dependent d. II-6:9
 - solute d. II-6:8, 14
- disinfection II-1a:20, 26
 - heat d. II-1a:21
- disopyramide I-19:14
- dissecting aortic aneurysm I-24:7
- dissection I-1:38, I-22:9
- distal convoluted tubule I-4:5
- distal nephron I-4:5
- distribution volume I-19:2
- disulfiram I-23:20, 21
- disuse atrophy II-10:2
- diuresis
 - alkaline d. II-13:1
 - forced d. II-13:1
 - osmotic d. I-2:4
 - postobstructive d. I-14:1
- diuretic abuse I-2:22, I-20:10, I-23:8
- diuretics I-20:16
 - loop d. I-20:16
 - potassium-sparing d. I-25:19
 - thiazide d. I-20:7
- divalproex sodium II-13:19
- diverticulum I-11:5, II-5:56
- diverticulitis II-5:11, III-3:4
- dizziness I-20:23, I-25:15
- DM see diabetes mellitus
- DNA topoisomerase I I-8:21
- dobutamine I-19:14
- dobutamine stress echocardiography II-9:7, III-2:21
- Döhle bodies I-11:11
- Donnan effect I-4:4
- doppler sonography I-1:25, I-17:10, II-1c:18
- dorsal rhizotomy I-21:3
- dose I-3:27
- dose denominator II-6:6
- dose interval I-19:6
- dose reduction I-19:6
- dosimetry I-17:28
- “double-D” configuration II-2:6
- doxacurium I-19:14
- doxazosin I-19:14, I-20:17, I-25:21
- doxepin I-19:14

- doxorubicin I-19:14
doxycycline I-19:14
drain II-1b:21
drain line II-3:4
drainage bag I-12:12
drug
– anticonvulsant d. II-4:20
– antiplatelet d. II-2:19
– Immunosuppressive d. I-17:32
– lipid-soluble d. II-13:3
– lipids I-17:18
– nonsteroidal anti-inflammatory d. I-20:4
– plasma d. levels II-13:18
drug absorption I-19:3
drug dosing I-19:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29
drug levels I-17:28
drug overdose II-13:1f
drug withdrawal II-4:20
dual-energy X-ray absorptiometry III-7:8
Duboscq-Brazil I-1:49
ducts of Bellini I-13:1
duodenitis II-7:4
– erosive d. II-5:56
duodenum I-5:3
dwell time II-1b:1
dye load I-22:7
dynamic CT I-1:31
dynamic pressure measurements II-2:26
dyphylline I-19:14
dysarthria II-4:29
dysgeusia I-6:49
dyslipidemia I-7:12
dysphagia I-11:11
dysplasia III-7:9
– fibromuscular d. I-22:3, I-25:11
– fibrous muscular d. I-1:37
dyspnea II-4:9, 14
dysproteinemias I-8:2, I-8:22
dysproteinurias I-8:1
dysrhythmias I-23:17
dysuria I-11:3, I-12:1, I-13:6

Eaton-Lambert Syndrome II-1d:27
Ebola virus III-9:3
echymoses I-8:14, II-4:18, III-6:14
echocardiography I-20:5
– dobutamine stress e. II-9:7, III-2:21
– transesophageal e. I-24:7

echogenicity I-1:28
ecto-ATP diphosphorylase (ecto-ATPDase) III-9:6
ectopia kidney I-11:21
eczema I-5:9
edema I-4:1, I-11:14, I-20:19
– abdominal wall and genital e. II-1b:25
– acute cerebral e. II-14:6
– angio- II-13:22
– cerebral e. II-4:27
– facial e. II-4:14
– non-cardiogenic pulmonary e. II-13:17
– papille. I-20:5, I-24:7, II-7:14, II-1d:29
– pulmonary e. I-9:26, I-20:4, II-4:23, II-5:2, II-1c:15
EDRF II-7:13
effective circulating volume I-4:15
effective respiratory ‘equipment’ I-3:49
effective vascular compartment I-4:15
efferent arteriolar resistance I-13:10
efferent arteriole I-7:3
efficiency II-1a:8
ejaculatory ducts I-11:22
ejection fraction II-9:8
elastase I-1:20
elastic recoil I-22:9
elbow brachial-cephalic fistula II-2:15
elderly, isolated systolic hypertension in the I-24:1
electrical gradient I-3:1
electrical pacing II-13:23
electrocardiogram I-20:5
electrochemical gradient I-5:5
electrogenic exit I-2:3
electrogenic reabsorption I-2:14
electrolyte I-20:4, 15
electrolyte homeostasis II-1b:8
electrolyte-free water I-4:1, I-4:12
electromyography I-1:43, II-4:12, II-9:12
electroneutral entry I-2:2
electroneutrality I-4:7
electrophoresis I-1:16, I-10:18
elimination constant II-6:10
embolic renal disease I-1:38
embolism I-10:23
embolization I-1:38, I-22:9

emergency plasmapheresis II-1d:4
emergency therapy I-2:8
emphysema III-2:22
emphysematous pyelitis I-12:11
employment II-10:1
empty bed contact time II-1a:27
enalapril I-19:14, I-25:22
enalkiren I-20:21
encephalitis II-4:20, III-6:8
encephalopathy I-5:24, I-24:7
– aluminum e. II-4:21
– dialysis e. II-4:21
– hypertensive e. I-20:5
– metabolic e. I-5:24
– uremic e. I-18:11, II-4:20
– Wernicke’s e. II-13:1
end cap compartments II-1a:1
end-organ damage I-23:7, I-24:6
endothelium I-20:11
end-stage renal disease (ESRD) I-18:1, 7, I-21:1
end-to-end anastomoses III-3:5
end-to-side III-3:5
endocarditis II-2:10, II-9:13, III-6:14
– infective e. I-8:3, 34
– subacute bacterial e. I-1:23
endocrine function I-18:1
endocrine systems I-18:5
endocrinopathy II-1d:28
endogenous bradykinin release II-1d:19
endogenous pyrogens II-4:32
endometriosis II-1b:25
endopeptidase activity I-5:26
endopeptidase inhibitors I-24:2
endophthalmitis III-6:14
endoplasmic reticulum I-23:2
endoscopy II-5:56
endoscopy of the upper urinary tract I-1:44
endosteal erosion I-5:11
endostreptosin I-6:42
endothelial trauma III-5:4
endothelial-derived relaxant factor I-17:11
endothelialitis III-5:10
endothelin I-20:11, I-21:4, II-7:13
endothelin receptor III-7:2
endotoxin II-4:32
enemas I-5:30
enflurane III-3:3
enoxaparine III-5:9

Subject Index

- enteral feedings II-5:68
- enteric anastomotic III-8:11
- enterobacter I-12:4
- enterobacteriaceae I-12:11
- enterococcus I-12:4, II-5:13
- enterohepatic circulation II-13:22
- entrapment of the seventh nerve I-8:15
- environment I-7:2
- enzyme P-450 I-2:25
- enzyme-linked immunosorbent assay (ELISA) I-1:16, II-4:14
- enzymuria I-17:27
- eosin I-1:50
- eosinophilia I-2:30, I-10:6
- eosinophils I-1:6
- epidemiologic I-20:2, II-9:1
- epidermal growth I-21:4
- epidermal growth factor I-17:14
- epididymal cystadenoma I-23:12
- epidural regional anesthesia III-3:3
- epinephrine I-23:19
- epiphyseal II-8:5
- epiplopepy II-3:16
- epirubicin I-19:14
- epispatias I-11:23
- epistaxis I-25:15
- epitaxial growth I-15:4
- epithelial cancers I-8:26
- epithelial Na⁺ channel (ENaC) I-2:5
- EPO see erythropoietin
- Epstein Barr Virus I-8:2, III-6:2, III-6:8
- equilibrated Kt/V II-6:15
- equilibration
 - d./plasma e. II-1c:8
 - extra- to intravascular e. II-1d:5
- erbastine I-19:14
- erosive azotemic arthropathy II-5:2
- erythrocyte II-7:2
- erythrocyte membrane transport I-25:6
- erythrocyte sedimentation rate I-8:9, I-13:25
- erythrocytosis I-10:24, I-23:17, II-7:5
- erythromycin I-8:33, I-19:14, II-13:15, III-6:5
- erythropoiesis II-7:1
- erythropoietin II-7:1
- Escherichia coli I-9:15, I-15:16
- esmolol I-19:14, I-24:9
- esophageal rupture II-5:3
- esophagitis II-5:3, II-5:56
- esophagus I-11:11
- estazolam I-19:14
- esterases I-1:4
- estimated plasma volume II-1d:7
- estrogen I-9:1, I-23:18
- ethacrynic acid I-19:14
- ethambutol I-19:14, III-6:17
- ethchlorvynol I-19:14
- ethics II-11:2
- ethionamide I-19:14
- ethosuximide I-19:14, II-4:22
- ethylene diaminetetraacetic acid I-1:39, I-5:8
- ethylene glycol I-3:4, I-15:15
- ethylene oxide II-4:14
- etidronate I-5:16
- etiology I-16:12
- etodolac I-19:14
- etomidate I-19:14
- etoposide I-19:14
- European Dialysis and Transplant Association II-14:11
- evoked potentials, multimodality stimulus-related II-7:13
- ex vivo reconstruction I-22:10
- exchange volume II-1b:1
- exercise I-1:15, I-2:27, II-6:9
- exercise training II-10:3
- expiration/inspiration ratio II-4:3
- expiratory reserve volume II-5:45
- exsanguination I-9:4
- extracellular plasmin-binding protein I-6:42
- extracorporeal circulation volume II-1a:2
- extracorporeal immunoadsorption II-1d:34
- extracorporeal photopheresis II-1d:33
- extracorporeal shock wave lithotripsy I-1:36, I-11:3, I-15:1
- extravasation
 - pyelosinus e. I-1:42
 - urine e. I-1:31
- extremity, lower I-20:3
- Fabry disease I-11:16
- facial
 - f. dystonia II-4:21
 - f. palsy I-25:22
 - f. paralysis I-8:15
- factitious hyponatremia I-3:30
- factor B II-1a:11
- factor G II-4:32
- factor H II-1a:5
- factor V Leiden mutation I-10:24
- factors VII, IX, and X II-5:59
- factor VIII/von Willebrand factor complex II-4:19
- failure to thrive I-2:30, I-23:9
- famciclovir I-19:14
- familial hypocalciuric hypercalcemia I-5:3, 11
- familial juvenile nephronophthisis I-11:8, 9
- familial Mediterranean fever I-8:25, I-10:19
- familial X-linked hypophosphatemic rickets I-5:26
- family history I-2:24, I-15:19, I-20:1, I-20:4
- famotidine I-19:14
- Fanconi syndrome I-3:16, I-5:27
- fas ligand III-1:9
- fast breath-hold gradient echo techniques I-1:36
- fast sodium channel II-13:27
- fat malabsorption I-15:14
- fat metabolism I-3:4
- fatigue I-9:27, I-25:15, II-10:2, II-13:22
- fatty acids I-15:14
 - free f.a. I-6:8
 - long chain f.a. I-5:4
- fatty casts I-1:7
- Fazadinium I-19:14
- feeding I-25:15
- felodipine I-19:14, I-20:19
- female genitalia I-11:11
- femoral II-13:5
 - f. artery I-1:37
 - f. pulse I-24:3
 - f. vein II-1d:13
 - f. vein cannulation II-2:9
- fenoprofen I-19:16
- fentanyl I-19:16, III-3:3
- fentanyl citrate I-23:18
- Fenwal CS3000 II-1d:9
- ferritin I-18:8, II-7:5
- fetal
 - f. bradycardia I-9:11
 - f. death I-24:11
 - f. distress I-11:14
 - f. hydrops I-9:4

- f. lobulation I-16:3
- f. loss I-9:19
- fever I-8:19, I-12:1, II-4:9
- fexofenadine I-19:16
- fiber I-5:4
 - f. bundle volume II-1a:20
 - f. length II-1a:1
- fibric acid derivates I-6:9
- fibrillary glomerular diseases I-8:2
- fibrillin gene I-24:10
- fibrin I-8:12, II-3:14, II-14:8
 - f. cap I-7:4
 - f. sleeves II-2:11
- fibrinogen II-1d:32
 - f. receptor II-4:18
 - f. factors V, VII, VIII I-6:10
- fibrinolysis I-9:28
- fibrinolytic system II-4:18
- fibroadenomatosis I-11:8
- fibrodysplastic lesions I-22:9
- fibromas I-16:9
- fibroplasia
 - intimal f. I-1:37
 - medial f. I-22:4
 - periarterial f. I-1:37
 - perimedial f. I-1:37
- fibrosarcoma I-16:14
- fibrosis
 - confluent f. III-4:26
 - congenital hepatic f. I-11:8
 - interstitial f. I-8:4, 8, 15, I-21:7, III-4:15, 21
 - intra-alveolar f. I-8:15
 - marrow f. II-7:6
 - retrobulbar f. I-1:20
 - retroperitoneal f. I-1:31, I-14:1, I-17:9
 - striped f. III-4:26
- filariasis I-8:2
- filling defects I-1:42
- filtration
 - carbon f. II-1a:25
 - cascade f. II-1d:1
 - double cascade f. II-1d:22
 - glomerular f. I-13:10
 - glomerular f. rate I-21:9
 - semiselective double f. II-1d:31
 - zero net f. II-1c:9
- firoinal II-13:17
- first-order kinetics II-13:15
- first-pass hepatic metabolism I-19:4
- first-use syndrome II-1a:14, II-4:13
- fish oil II-2:19
- fist clenching I-2:11
- fistula
 - arteriovenous f. I-1:37
 - autologous arteriovenous f. II-2:1
 - biliary f. I-5:31
 - brachial-basilic vein f. II-2:13
 - cutaneo-peritoneal f. II-3:1
 - cutaneous f. III-3:10
 - f. formation I-1:38
 - snuff-box f. II-2:15
 - transposed elbow brachial-basilic f. II-2:15
 - vesicocolic f. I-1:42
 - wristadial-cephalic f. II-2:15
- fistulogram II-2:18
- fistulography II-2:2
- fixed reimbursement II-1a:18
- flank mass I-14:6
- flavanoids I-23:9
- Flavobacterium II-1a:23
- flecainide I-19:16
- fleroxacin I-19:16
- flexibility II-2:5
- flocculating agent II-1a:27
- fluconazole I-19:16, II-5:19, III-6:13
- flucytosine I-19:16
- fludarabine I-19:16
- fluid
 - cerebrospinal f. I-11:5
 - diarrheal f. I-3:20
 - distribution of f. I-4:1
 - extracellular f. I-4:1, II-4:2
 - f. and electrolyte balance I-18:1
 - hypertonic f.s I-3:32
 - interstitial f. I-4:1, II-4:2
 - intracellular f. I-4:1, II-4:2
 - isosmolar f. I-4:12
 - K⁺-rich colonic f.s I-2:20
 - perirenal f. I-1:30
 - plasma f. I-4:1
- fluid
 - f. flow II-1b:1
 - f. intake, low I-15:19
 - f. loss during dialysis II-6:20
 - f. overload II-1c:19
 - f. replacement, hyponcotic II-1d:18
- flumazenil I-19:16
- flunarizine I-19:16
- fluoride II-4:29
- fluoroquinolones I-12:1
- fluorouracil I-19:16
- fluoxetine I-19:16, I-23:19, II-13:27
- flurazepam I-19:16
- flurbiprofen I-19:16
- fluoroscopy II-2:7
- flush I-1:38
- flush aortography I-1:38
- flush before fill procedure II-1b:11
- flushing I-20:23, I-25:23, II-4:14, II-13:27
- flutamide I-19:16
- fluvastatin I-19:16, III-7:7
- flvoxamine I-19:16
- flux, high water II-1a:8
- focal segmental glomerulosclerosis (FSGS) I-8:36, II-1d:25
- focal seizure II-4:20
- folate II-7:4, II-9:11
- folate supplements III-7:6
- folinic acid I-17:31, I-20:14, III-6:17
- fomepizole II-13:12
- fomepizole Antizol I-3:41
- foot processes of the podocytes I-6:11
- formaldehyde I-3:40, II-4:14, II-4:28, II-7:4
- formic acid I-3:40, II-13:10, II-1a:21
- foscarnet I-19:16, III-6:10
- fosinopril I-19:16, I-20:18
- fracture rate III-7:7
- Framingham study I-24:1
- Franklin-Silverman needle I II-5:15
- fraxiparine II-1a:32
- free fatty acids I-6:8
- free hemoglobin II-4:17
- free magnesium concentrations I-5:28
- free pigmenturia I-1:3
- free radical III-5:4
- free (unbound fraction) drug level II-4:22
- freezing point I-1:3
- frequency I-11:3
- Fresenius AS104 II-1d:9
- friction rub II-4:9
- fructose I-5:26, II-1b:10
- fructose intolerance I-11:17
- fulminate hemorrhagic alveolar capillaritis I-8:15
- fundoscopic examination I-20:5, I-24:6
- fungus II-5:13

Subject Index

- fungus balls I-12:16, I-16:13,
III-6:14
furans II-6:2
furosemide I-9:19, I-17:15,
I-19:16, I-20:16
– f. renogram I-1:41
- G protein I-5:2
G protein-coupled receptors I-5:2
gabapentin I-19:16
gadolinium I-1:35, I-16:4
Gala, Gal-containing receptors
I-12:7
galactosemia I-11:17
galactosidase I-11:16
galamine I-19:16, III-3:3
gallium nitrate I-5:15, I-17:31
gallop rhythms I-20:5
Galloway syndrome I-11:15
gamma
– g. camera capture I-1:40
– g. irradiation II-2:19
– g. sterilized II-13:4
ganciclovir I-19:16, III-6:8
– g.-oral I-19:16
ganglioneuromatosis I-23:12
ganglionic blocker I-24:8
gas
– g. abscess I-12:11
– g. diffusion II-1b:3
– g. embolization I-1:38
gastric emptying, delayed II-14:12
– g. lavage II-13:10
– g. ulcer II-5:56
gastritis II-7:4
– erosive g. II-5:56
– hemorrhagic g. II-13:13
gastroesophageal reflux II-5:3,
II-14:12
gastrointestinal II-4:18
– g. bleeding I-1:14
– g. function I-18:1
– g. lesions, stenotic I-2:18
gastroparesis I-7:9, I-18:10,
I-19:4, II-5:3
gastrostomy II-14:12
gelatin II-1b:10
gemfibrozil I-19:16
gene I-2:27
gene deletion I-11:13
genetic
– g. counseling I-11:13
– g. testing I-2:25
genital abnormalities I-11:1
genital herpes simplex virus
I-12:17
gentamicin I-12:10, I-19:16
germicides II-1a:20
GH binding protein II-14:8
giant mitochondria III-5:13
Giemsa technique III-6:16
gingival bleeding II-4:18
Gitelman's syndrome I-2:16,
I-2:21, I-4:8
glacial acetic acid I-1:6
glibornuride I-19:16
gliclazide I-19:16
glipizide I-19:16
glomerular
– anti-GBM antibody disease
I-11:14
– g. thrombi I-8:12
– g. atrophy III-4:21
– g. basement membrane (GBM)
thickening I-7:4
– g. consolidation I-8:20
– g. filtration I-13:10
– g. filtration rate I-18:1, 6, I-21:9
– g. hyperfiltration I-7:5
– g. hypertrophy I-6:14
– g. negative charge I-6:12
– g. perfusion pressure I-17:11
– g. sclerosis I-8:4, I-21:7
– g. tufts I-6:45
glomerulonephritis
– acute postinfectious GN I-1:23
– acute post-streptococcal g.
I-8:32
– crescentic g. I-6:33, 44
– fibrillary g. I-8:22
– focal segmental necrotizing g.
I-8:27
– hepatitis C-related g. I-8:29
– immunotactoid g. I-8:2
– membrano proliferative g.
I-8:27, I-21:8
– membranous g. III-2:14
– mixed membranous and prolife-
rative g. I-6:32
– necrotizing g. I-8:14
– Pauci-immune rapidly progressi-
ve (necrotizing) g. II-1d:23
– rapidly progressive g. I-17:7
glomerulonephropathy, immuno-
tactoid I-8:22
glomerulopathy
– chronic t. g. III-5:22
– collapsing g. I-6:18
glomerulosclerosis I-22:1
– cirrhotic g. I-8:31
– focal segmental g. (FSGS)
I-8:36, II-1d:25
– intracapillary g. I-7:4
– nodular g. I-22:5
glucagon I-7:3
glucagon stimulation test I-23:14
glucocorticoid remediable aldos-
teronism I-2:24, I-20:7, I-24:5
glucocorticoid-suppressible hyper-
aldosteronism I-23:6
gluconeogenesis I-3:38
glucose I-5:26, I-9:2, I-21:8
– g. disappearance rate III-8:10
– g. intolerance I-20:1
– g. oxidase I-1:2
– g. polymers II-1b:10
– g. tolerance test III-2:4
– g.-free dialysate II-1a:32
glucosuria I-11:17
glucuronidation I-19:5
glutamine I-3:12
glutaraldehyde II-1a:21
glutethimide II-13:6
glyburide I-19:16
glycerol II-1b:10
glycine I-4:9, II-13:12
glycogen I-3:2
glycolic and oxalic acids II-13:12
glycolipids, myelin-associated
II-1d:28
glycolysis I-5:24
glycopeptides I-15:6
glycoprotein
– Tamm-Horsfall g. gel I-1:7
– myelin-associated g. II-1d:28
glycosaminoglycans I-15:6
glycosuria I-3:29, I-9:2
glycosuric I-5:31
– glycosylated hemoglobin II-5:5
glycosylation I-7:3
glycyrrhetic acid I-2:26, I-23:9
glycyrrhizic acid I-20:8, I-24:5
glyoxylate II-13:12
– g. aminotransferase I-15:15
– g. immunotransferase III-2:16
goiter II-13:13
gold I-6:24
gold sodium thiomalate I-19:16
gonorrhea I-12:17
Goodpasture antigen I-11:14
Goodpasture disease I-6:45
Goodpasture's syndrome I-8:3
Gordon syndrome I-2:7, I-25:14
gouty diathesis I-15:13

- GPIb II-5:59
 GPIIb/IIIa II-5:59
 GPIIb-IIIa molecules II-4:19
 graded exercise treadmill stress test II-10:6
 graft arteriopathy III-4:16, 37
 graft atherosclerosis III-5:21
 graft loss III-2:13, III-8:1
 grafts II-14:5
 gram stain I-12:8
 gram-negative II-5:13
 – g.-n. bacilli I-12:3
 – g.-n. bacteria II-1a:28
 – g.-n. microbial infections I-17:27
 gram-positive II-5:13
 granular activated carbon II-1a:27
 granular casts I-1:7, I-17:8
 granulocyte inclusions I-11:11
 granulocyte macrophage colony stimulating factor III-1:6
 granuloma I-10:3, 11
 granulomatous diseases I-21:6
 granzyme III-1:9, III-5:15
 grey and white matter II-1c:16
 griseofulvin I-19:16
 Grocott's rapid silver stains III-6:16
 growth I-5:3
 – g. abnormalities II-5:50
 – g. hormone I-5:20, I-7:3, I-17:18, I-18:7
 – g. hormone/insulin-like g. factor axis II-14:8
 – g. retardation I-18:7, I-25:15, II-14:9
 – linear g. II-14:8
 guanabenz I-19:16, I-20:20, I-24:2
 guanadrel I-19:16, I-24:2
 guanethidine I-19:16, I-20:20, I-24:2
 guanfacine I-19:16
 guanidines II-6:2
 guanidinoacetic acid II-6:2
 guanidinosuccinic acid II-6:2
 guanine nucleotide regulatory protein I-5:23
 guidewire II-1b:10
 Guillain-Barré Syndrome II-1d:25
 gynecomastia I-2:19, I-18:7

 H^+ -ATP synthase I-3:1
 H^+ -ATPase I-3:12
 H^+/K^+ ATPase I-3:12

 H2 receptor blocking agents I-8:11
 haemonetics model 30, model V50, PEX, and ultralite II-1d:9
 haemophilus influenzae I-15:16
 – h.f. type b III-6:2
 Hageman factor (factor XII) II-1a:12
 hair I-5:9
 half-life II-4:22
 hallucinations II-4:29, II-13:27
 haloperidol I-19:16, II-4:22
 halothane III-3:3
 hamartoma I-1:33, I-1:44
 Hansel's stain I-1:6
 haplotype III-1:2
 haptens II-1a:3
 hard-water syndrome II-4:29
 Harrison's grooves II-14:9
 Hassan technique II-5:8
 haversian II-8:2
 HCMA I-3:21
 HCO_3^- I-3:1
 – fractional excretion of HCO_3^- I-3:15
 – rate of excretion of HCO_3^- I-3:15
 HDL see high density lipoprotein
 head and neck I-8:27
 headache I-9:4, I-20:4, I-22:1, I-25:15, II-4:17
 header sepsis II-4:32
 health care finance administration II-10:3, II-12:6
 heart I-18:10, I-20:10
 heart murmur I-20:4
 heart rate II-4:2
 Heinz bodies II-4:31
 Helicobacter pylori II-5:56
 HELLP syndrome I-9:4
 HELP system II-1d:31
 helper T lymphocytes III-1:8
 hemangioblastoma I-11:7
 hemangioma I-16:9, I-16:13
 hemangiopericytoma I-16:13
 hematochezia I-8:19
 hematocrit I-9:4, I-18:8, II-7:1
 hematogenous renal candidiasis I-12:16
 hematological function I-18:1
 hematoma I-1:30, II-1c:9
 – retroperitoneal h. II-2:9
 – subdural h. II-4:20, II-9:9
 hematopoiesis III-4:31

 hematopoietic
 – h. cells II-1a:17
 – h. system I-5:24, I-18:8
 hematoxylin I-1:50
 hematuria I-1:1, I-8:6, I-12:14
 – loin pain h. syndrome I-1:46
 – macroscopic h. I-11:2
 – microh. I-1:10
 – terminal h. I-1:44
 heme pigment I-17:8
 HEMO Project II-6:29
 hemochromatosis I-5:22, III-8:12
 hemoconcentration II-1c:10
 hemodiafiltration II-1a:10
 – continuous arteriovenous h. II-1c:6
 – veno-venous h. II-1c:6
 hemodialysis I-17:18, I-21:4
 – AAMI standards for h. water quality II-1a:28
 – continuous arteriovenous h. II-1c:6
 – continuous veno-venous h. II-1a:6, II-1c:7
 – NKF/DOQI h. adequacy work group II-6:17
 hemofilter II-1c:11
 hemofiltration II-1a:9
 – continuous arteriovenous h. II-1c:2
 – continuous veno-venous h. II-1c:6
 – high volume h. II-1c:9
 hemoglobin
 – free h. II-4:17
 – glycosylated h. II-5:5
 – h. casts I-1:7
 – h. concentration I-18:8
 hemoglobinuria I-1:1
 – paroxysmal nocturnal h. I-1:36
 hemolysis I-2:11, II-4:17, 27, II-7:3
 – acute h. I-5:22
 – delayed h. II-4:22
 – intravascular h. I-10:29
 hemolytic uremic syndrome I-9:18
 hemopericardium II-4:10
 hemoperitoneum II-3:14, II-5:11, II-1b:25
 hemophane II-1a:4
 – heparin coating of h. II-1a:31
 hemoptysis I-6:46, I-10:29, I-17:7
 hemorrhage I-8:19, I-16:8, I-20:11, II-4:18
 – adrenal h. I-2:29
 – intracerebral h. II-4:20

Subject Index

- intracranial h. II-4:20
- perirenal h. I-1:32
- pulmonary h. I-8:17
- retinal h.s II-1d:29
- splinter h.s I-17:7
- subarachnoid h. I-2:2, I-24:11, III-6:15
- thalamic h.s I-3:40
- hemorrhagic to antithrombotic profile II-1a:31
- hemostasis I-18:9, II-2:17
- hemothorax II-2:3, 8
- Henoch-Schönlein purpura I-8:2
- heparin I-19:16, 19, II-4:24, II-7:5
- h. coating of hemophane II-1a:31
- h.-free dialysis II-1a:30
- h.-induced extracorporeal LDL precipit II-1d:31
- low-molecular-weight h. I-19:18, II-1a:31
- h. rebound” phenomenon II-1a:31
- “tight” h. II-1a:30
- unfractionated h. II-1a:31
- heparinization III-3:5
- regional h. II-1a:31
- systemic h. II-1a:29
- hepatic I-1:32, I-19:4
- fulminant h. failure II-13:19
- h. lipase I-3:42
- h. microsomal P450 oxidase activity I-5:8
- h. rupture I-9:4
- hepatitis III-6:8
- anti-HCV I-8:29
- chronic persistent h. III-2:11
- h. B I-1:23, I-8:28
- h. B core antibody III-6:2
- h. B surface antibody III-6:2
- h. B surface antigen III-6:2
- h. B, C I-8:2
- h. Be antibody I-8:28
- h. C virus (HCV) I-8:27
- h. G II-5:3, III-6:12
- hepatobiliary disease II-13:23
- hepatocellular carcinoma III-2:12
- hepatocyte growth factor I-17:14
- hepatocytes, microvesicular fatty infiltration of I-9:27
- hepatomegaly II-13:20
- hepatorenal syndrome I-17:20
- hepatosplenomegaly III-6:16
- hereditary hypophosphatemic rickets with hypercalciuria I-5:27
- hereditary ovalocytosis I-3:8
- hernias II-1b:13, 25
- hernioplasty II-1b:25
- herpes simplex virus (HSV) III-6:2
- genital HSV I-12:17
- hetastarch II-1d:17
- heterogeneous nucleation I-15:4
- hexobarbital I-19:16
- hiatus hernia I-11:15
- high-density lipoprotein (HDL) I-18:3
- HDL cholesterol I-7:12, I-20:1
- high-flux (high porosity) membranes II-6:2
- high-flux dialysis II-1a:1
- high-flux synthetic membranes II-1c:7
- high molecular weight kininogen II-1a:12
- high protein diet I-1:14
- high-turnover osteopenia III-7:8
- high volume hemofiltration II-1c:9
- highly-selective immunoabsorption II-1d:31
- hippuric acid I-3:10, II-1a:10
- His-Purkinje tissue II-13:27
- histamine II-4:16, III-9:10
- histidine I-3:1
- histoplasmosis I-5:12, I-12:17, III-6:1
- HLA antibodies II-7:12
- HLA class II-1d:25
- hollow II-1d:11
- hollow fiber devices II-1d:9
- homeostasis I-20:9
- homocysteine II-9:11, III-7:5
- homocystinuria I-15:21
- homogeneous nucleation I-15:4
- homogentisic acid I-1:2
- homozygous familial hypercholesterolemia II-1d:31
- hospitalization risks II-5:64
- housing material II-1a:1, 2
- human immunodeficiency virus I-8:2
- human leukocyte III-1:1
- human peritoneal mesothelial cells II-5:62
- human serum albumin II-1d:16
- humic acid II-1a:25
- humoral immunity III-1:6
- hyaline casts I-1:7
- hyaline thickening of arterioles III-5:13
- hyaline thrombi I-8:30
- hyalinosis II-1d:25
- hydatidiform mole I-9:4
- hydralazine I-19:16, I-20:21, I-24:9, I-25:21
- hydrocalicosis I-1:25
- hydrocarbons I-6:45
- hydrochlorothiazide I-25:19
- hydrocortisone I-19:16
- hydrogen
- h. ions (H⁺) I-3:1
- h. ion excretion I-1:17
- h. peroxide II-1a:12, II-3:13, II-4:17
- hydronephrosis I-1:27, 32, I-9:1, I-12:17, I-14:1
- hydrophilic II-1a:4
- hydrostatic II-1b:2
- hydrostatic pressure I-4:4, II-1a:27
- hydrothorax II-1b:25, II-5:2, 44
- hydroxyapatite I-5:15
- hydroxyl II-1a:11
- hydroxyl radical scavenging I-17:24
- hydroxyurea I-19:16
- hydroxyzine I-19:16, 18
- hygrometer I-1:3
- hyperacetatemia II-4:4
- hyperactive reflexes II-13:27
- hyperadrenocorticism I-24:4
- hyperaldosteronism
- dexamethasone-suppressible h. I-23:6
- glucocorticoid-suppressible h. I-23:6
- primary h. I-2:24
- pseudoh. Type I I-2:30
- hyperalimentation I-17:18
- hyperaminoaciduria I-11:17
- hyperammonemia I-4:13, II-13:20
- hyperbaric oxygen therapy II-4:24
- hyperbilirubinemia I-5:24
- hypercalcemia I-18:7, I-21:6
- h. of malignancy I-17:31
- hypercalciuria I-2:21, I-11:3, I-15:6, I-25:19
- absorptive h. I-15:8
- idiopathic h. I-5:27
- hereditary hypophosphatemic rickets with h. I-5:27
- hypercatabolic state I-17:17
- hypercitratemia I-11:17
- hypercoagulability I-6:50, I-9:19

- hyperfiltration III-5:24
 – glomerular h. I-7:5
 hyperglycemia I-3:29
 hyperhomocysteinemia I-20:1, II-5:35
 hyperinsulinemia I-21:8
 – h. primary III-8:16
 hyperkalemic periodic paralysis I-2:33
 hyperlipidemia III-8:15
 hypermagnesemia I-5:29, I-17:17
 hypermethionemia I-1:2
 hypernatremia I-3:27, I-4:1, I-17:17
 hyperosmolality II-4:20
 hyperoxaluria, primary I-10:21
 hyperparathyroidism I-18:3, 6, II-1b:9, II-7:5
 – idiopathic h. I-5:6
 – primary h. I-15:17, I-23:15
 – secondary h. II-4:16
 hyperphosphatemia I-5:21, I-17:17, I-18:6
 hyperphosphaturia I-11:17
 hyperpigmentation I-2:29
 hyperplasia I-14:4
 – bilateral adrenal h. I-2:23, I-23:4, I-24:5
 – C-cell h. I-23:12
 – diffuse h. I-5:10
 – fibromuscular h. II-2:19
 – medial h. of the blood vessels I-22:1
 – micronodular h. I-24:6
 – myointimal h. II-2:22
 – parathyroid h. I-20:8
 – unilateral adrenal h. I-23:4
 hyperpolarizing factor I-20:11
 hyperreninemia I-2:13
 hypersensitivity, delayed-type I-10:1, III-1:9
 hypersplenism II-7:5
 hypertension I-20:1
 – accelerated h. I-24:6
 – autosomal dominant h. with brachydactyly I-20:8
 – benign intracranial h. II-14:9
 – borderline h. I-20:3
 – childhood h. I-25:4
 – chronic h. I-9:3
 – diuretic-associated hypokalemic h. I-23:8
 – essential (primary) h. I-20:6
 – essential h. II-9:5
 – gestational h. I-9:3
 – hyperkinetic h. I-23:12
 – h. genes I-20:6
 – h. detection and follow-up program I-20:15
 – low-renin primary h. I-20:7
 – malignant h. I-24:6, III-2:15
 – malignant h. I-20:11
 – portal h. I-11:5
 – prevalence of h. I-21:7
 – pseudo-h. I-20:3
 – renovascular h. I-20:4, I-22:1, I-25:11
 – Scandinavian STOP h. study I-20:15
 – secondary h. I-20:4
 – systemic h. I-18:9
 – systolic h. I-20:3
 – systolic h. in elderly patients (SHEP) study I-20:15
 – systolic h. in the elderly program I-24:1
 – white coat h. I-20:4
 hypertensive
 – h. crisis I-24:6
 – h. emergencies I-20:19
 – h. encephalopathy I-20:5
 hyperthermia I-17:33, II-1c:19, II-13:27
 hyperthyroidism I-5:12, I-20:5, I-23:12, I-23:15
 hypertonic fluids I-3:32
 hypertonic saline solutions II-4:7
 hypertrichosis I-9:12
 hypertriglyceridemia I-3:30, I-20:1
 hypertrophic cardiomyopathy II-9:8
 hypertrophy I-14:4
 – benign prostatic h. I-14:1
 – compensatory h. I-13:14, III-4:23
 – glomerular h. I-6:14
 – left ventricular h. (LVH) I-20:1, II-5:2, II-7:15
 hyperuricemia I-17:17, I-20:1
 hyperuricosuria I-15:9
 hyperuricuria I-11:3
 hyperventilation I-5:25, II-1d:14
 hyperviscosity II-1d:23
 – h. syndrome II-1d:29
 hypervolemia II-7:14, II-1b:19
 hypoalbuminemia I-9:18, I-18:2
 hypoadosteronism I-3:47
 – hyporeninemic h. I-2:31, I-18:2
 – syndrome of hyporeninemic h. I-2:30
 hypocalcemia I-17:17, I-18:6
 hypocalvaria I-9:9
 hypocapnia I-3:31, II-4:11
 hypochlorite II-4:17
 hypocitraturia I-15:10, 12
 hypocomplementemic urticarial vasculitis I-8:14
 hypodipsia, primary I-4:23
 hypogammaglobulinemia II-5:63
 hypoglycemic agents II-4:22
 hypoglycemic reactions I-23:12
 hypogonadism I-23:7
 hypokalemia I-17:17, I-20:4
 hypokalemic periodic paralysis I-2:27
 hypomagnesemia I-2:21, I-5:6, I-5:30
 hypomagnesiuria I-15:15
 hyponatremia I-4:1, I-17:17
 hypoosmolality II-4:20
 hypophosphatemia I-11:17
 hypoplasia I-5:9
 – segmental h. I-25:11
 – segmental renal h. I-13:1
 hypoplastic lungs I-9:9
 hyposthenuria I-1:17
 hypotension I-9:8, I-25:23, II-5:38
 – orthostatic h. I-20:20, I-23:10
 – intradialytic h. II-4:1
 – postural h. I-3:30, I-24:1
 hypothermia I-5:26, II-1c:19
 hypothyroidism I-11:14, I-20:5, I-23:15
 hypouricemia I-11:17
 hypoventilation I-2:39, I-3:8, II-4:11
 hypovolemia I-20:4, II-1b:19
 hypoxemia II-4:10
 hypoxia I-2:39, I-3:24
 hypoxic vasodilatation II-7:13
 hysterectomy I-9:26

¹³¹I meta-iodobenzylguanidine I-24:5
 iatrogenic I-17:2
 ibandronate I-5:16
 ibuprofen I-19:18, I-22:2
 ICAM-1 I-17:34
 icodextrin II-1b:2
 idarubicin I-19:18
 iodohippurate sodium ¹³¹I I-22:7
 idiopathic
 – i. epilepsy II-4:20
 – i. hypercalciuria I-5:27

Subject Index

- i. thrombocytopenic purpura II-1d:29
- idiotypic/antiidiotypic antibody balance II-1d:2
- ifosfamide I-17:31, I-19:18
- IgA deficiency II-1d:16
- IgA nephropathy I-21:7, II-1d:24
- IgE antibodies II-4:14
- IGF binding proteins II-14:8
- IgG antibodies II-4:14
- IgG anti-ganglioside antibodies II-1d:25
- IgG, portion of III-1:10
- ileal conduit III-3:7
- ileal disease I-15:14
- ileus III-3:8
- iliac horns, bilateral I-11:16
- iliorenal bypass I-22:10
- iloprost I-19:18
- imipenem I-12:10, I-17:29, I-19:18
- Imipramine I-19:18
- immobilization I-17:7, II-10:2
- immune defects II-1a:17
- immune deviation III-1:14
- immune response III-1:1
- immunization III-6:2
- immunoabsorption III-5:17
- immunocompromised patients I-17:20
- immunoelectrophoresis I-1:16, I-10:18
- immunofixation I-1:23, II-1d:24
- immunofluorescence microscopy I-8:30
- immunohistochemistry I-11:12
- immunosuppression III-1:15, III-6:1
- immunoturbidimetry I-1:16
- impaired neutrophil function II-1a:17
- implantation II-3:6, III-3:6
 - i. method II-3:7
- impotence I-2:19, I-18:7, II-9:12
- imulus amebocyte lysate-reactive material II-4:32
- inactivity II-10:2
- incontinence I-11:22
 - diurnal i. I-13:6
- indapamide I-19:18
- indicator dilution principle II-2:26
- indinavir I-19:18
- indobufen I-19:18
- indoles II-6:2
- indomethacin I-19:18
- indoxyl sulfate II-1a:10
- induction therapy III-4:2
- infantile nephrotic syndrome I-11:14
- infarction I-8:19, II-5:2
 - digital i. I-17:7
- infarcts I-1:33
- infection III-6:1
 - gram-negative microbial i.s I-17:27
 - bronchopulmonary i.s II-5:2
 - chronic exit site i.s II-5:23
 - disseminated fungal i. I-2:29
 - enterococcal i.s I-17:28
 - exit site i.s II-14:8
 - fungal i.s I-17:28, III-6:13
 - graft i.s II-9:13
 - gram-negative i.s I-17:28
 - gram-positive i.s I-17:28
 - nosocomial i. risk III-6:3
 - opportunistic i.s III-6:4
 - parasitic i.s I-8:34
 - surgical wound i. II-1b:24
 - tunnel i.s II-5:24, II-14:8
 - urinary tract i. (UTI) I-9:1, II-9:13
 - viral i. I-18:9
 - wound i. III-6:3
- infective endocarditis I-8:3,34
- infertility II-6:3
- inflammation I-8:10
 - chronic i. II-5:2
 - pancreatic i. I-8:15
 - tracheal i. I-8:15
- inflow II-6:10
- inflow arm II-3:4
- influenza III-6:2, 13
- influenza virus III-6:7
- infrared spectroscopy I-15:2
- infrascapular murmur I-20:5
- infundibular stenosis I-1:25
- INH III-6:17
- inlet and outlet end caps II-1a:2
- inner medullar collecting ducts I-4:6
- inorganic elements II-6:2
- inorganic phosphate I-1:36
- inositol phosphate I-24:12
- inotropes I-3:38
- insoflurane III-3:3
- insulin I-3:4, 28, 33, I-5:20, I-18:3, I-19:18, I-21:8
 - i. pump I-7:12
- i. resistance I-17:17, I-21:8, I-23:16
- i.-like growth factors I-5:20, I-17:14
- intraperitoneal administration of i. II-1b:13
- Lispro i. I-19:18
- plasma i. levels II-1a:32
- intercompartment mass transfer area coefficient II-6:18
- interferon III-1:3, III-6:12
 - i. γ and β II-1a:16
- interleukin (IL)
 - anti-IL-2R III-4:8
 - IL-1 II-1a:12
 - IL-1b II-1c:17
 - IL-2 I-17:31
 - IL-2 receptors II-1a:13
 - ILs 1 and 6 (IL-1, IL-6) II-7:3
 - IL-8 II-1c:17
- intermittent centrifugation II-1d:9
- intermittent claudication I-20:4, II-9:10
- intermittent peritoneal dialysis II-1b:13
- internal diameter II-1a:1, II-3:4
- intersalt I-20:2
- interstitial
 - i. colloid osmotic pressure II-4:2
 - i. fibrosis I-8:4, 8, 15, I-21:7, III-4:15, 4:21
- intestinal
 - i. absorption I-5:3
 - i. hyperabsorption I-15:13
 - i. ileus II-13:27
 - i. mucosa I-15:14
 - i. resection I-15:14
- intra-access pressures, static II-2:27
- intra-alveolar fibrosis I-8:15
- intraaortic balloon pump I-3:38, II-13:25
- intracapsular bleeding III-3:7
- intracellular
 - i. anions I-2:4
 - i. acidosis I-3:43
 - i. fluid I-4:1, II-4:2
 - paradoxical acidification of the i. fluid I-3:26
 - i. half-life I-17:27
- intracerebral hemorrhage II-4:20
- intracranial II-4:18
 - i. hemorrhage II-4:20
 - i. pressure I-25:8
 - primary or metastatic i. neoplasms II-4:20

- intradialytic symptoms II-1a:22
 intraglomerular pressures I-7:3
 intrapelvic filling defects I-1:24
 intraperitoneal administration of insulin II-1b:13
 intraperitoneal pressure II-1b:13
 intrarenal
 – i. reflux I-1:25, I-12:7, I-13:1
 – i. abscesses I-12:10
 – i. structural ARF I-17:1
 intrauterine growth retardation I-23:9
 intravascular volume I-17:14
 – i.v. contraction, I-9:4
 intravenous II-7:7
 – i. contrast media I-1:31
 – i. digital subtraction I-22:7
 – i. digital subtraction angiography I-1:39
 – i. gammaglobulin I-8:17
 – i. pyelogram I-12:10
 intravesical pressure I-13:6
 inulin I-1:11
 iodine
 – povidone i. II-1b:11, II-3:13
 – radioactive i. I-5:22
 iodocholesterol
 – i. nuclear scanning I-23:5
 – i. scan I-2:23
 – i. scintigraphy I-24:6
 iohexol I-1:12, I-1:23
 ion exchange resins II-13:4
 ionization II-13:6
 ionized calcium I-5:2
 – i. Ca²⁺ I-2:10
 iopamidol I-1:23
 iothalamate I-1:11, I-9:1
 ioversol I-1:23
 ioxaglate-dimer I-1:23
 ipratropium I-19:18
 iritis I-8:16
 iron I-5:6, II-7:3, II-13:1
 iron deficiency II-7:4
 irritability I-25:15
 ischemia I-3:24, II-2:20
 ischemia/reperfusion injury I-17:34, III-3:4
 ischemic
 – i. and reperfusion injuries III-4:16
 – i. cerebrovascular accident I-11:16
 – i. colitis II-5:11
 – i. injury I-8:28
 – i. involution III-4:15
 – i. myocardium I-3:26
 – i. optic atrophy II-5:2
 – i./necrotizing colitis II-5:3
 islet
 – i. cell antibodies III-2:4
 – i. cell tumors I-20:8
 – i. transplantation III-8:17
 isoagglutinins, anti-A and anti-B II-1d:16
 isocyanates II-1a:3
 isoniazide I-19:18, II-4:22, III-6:17
 isopropanol II-13:3, 13
 isopropyl alcohol I-3:11
 isoproterenol II-13:25
 isosmolar fluid I-4:12
 isosorbide I-19:18
 isotopic renography I-1:41, III-5:3
 isovaleric acidemia I-1:2
 isradipine I-19:18, I-20:19, I-24:2, III-5:14
 isthmus I-11:21
 itai-itai disease I-10:20
 itraconazole I-19:18, III-6:15

 Jaffé reaction I-1:12
 Janeway lesions I-17:7
 jaundice I-9:27
 JC virus III-6:13
 jet flow II-1b:24
 Joint National Committee (JNC) I-18:9, I-20:15
 judgment defects II-4:29
 juvenile I-2:26
 juxtaglomerular apparatus I-2:30, I-18:2, I-20:9, I-23:8

 K⁺ ion channels I-2:2
 K⁺ ion-specific channels I-2:1
 K-Mag I-15:26
 kallikrein I-20:10
 kallikrein excretion I-25:6
 kallikrein-kinin system I-20:10
 kanamycin I-19:18
 Kaposi's sarcoma (KS) III-7:9
 kayexalate III-3:8
 KC II-6:18
 kernicterus I-9:15, I-12:10
 ketamine I-19:18
 – k. hydrochloride I-23:18
 ketanserin I-19:18, I-21:5, I-24:2
 ketoacid I-3:4, I-3:28
 ketoacidosis I-5:25
 – alcoholic k. I-3:39
 – diabetic k. I-5:27
 – rate of net k. production I-3:33
 ketoconazole I-15:8, I-19:18, I-23:18
 ketogenesis I-3:29, I-7:3
 ketonemia I-3:29
 ketoprofen I-19:18
 ketorolac I-19:18
 ketosis I-3:42
 ketotifen II-4:16
 kidney
 – aplastic/hypoplastic/dysplastic k.s II-14:1
 – horseshoe k. I-11:21
 – horseshoe or pancake k. I-1:36
 – medullary sponge k. I-15:6
 – pelvic k. I-11:21
 kidney capsule I-16:2, 3
 kidney stones I-11:1, 3
 Kimmelstiel-Wilson lesions III-2:16
 kinase II-1a:14, II-4:15
 kininogen I-20:10
 kinking of the catheter's intramural segment II-1b:25
 Klebsiella I-8:2, I-9:15, I-12:4, I-16:14
 Kodak type of analyzer I-3:32
 KR II-6:20
 Kt II-6:6
 Kussmaul
 – K. breathing II-4:27
 – K. respiration I-3:30

 L-arginine I-21:4
 L-carnitine II-4:12
 L-lactic acids I-3:1
 L-NAME I-21:3
 Labetalol I-20:17, I-24:3, I-25:21, I-25:23
 Labetolol I-9:12, I-19:18
 labia II-3:15
 lactate II-1b:2, II-1b:9
 lactate and pyruvate levels I I-1a:32
 lactic acid I-5:22
 lactoferrin I-1:20
 lactose I-5:4
 "ladder" or rotational approach II-2:18
 lamina densa I-11:16
 lamivudine I-19:18, III-6:12
 lamotrigine I-19:18
 lansoprazole I-19:18

Subject Index

- laparoscopic donor nephrectomy III-2:2
- laparoscopic fenestration I-11:5
- larger solutes II-1a:5
- laryngeal stridor II-4:14
- laryngospasm II-1d:14
- laser lysis II-5:6
- laser nephelometry I-1:16
- lassitude II-4:24
- lateralization I-20:7
- laxative I-1:24
- laxative abuse I-2:17, I-2:22
- LDL (see low-density lipoprotein)
- lead I-23:20
- lead intoxication I-10:19, II-7:5
- Leber's congenital amaurosis I-11:9
- lecithin-cholesterol acyltransferase I-6:8
- lectin III-9:17
- Ledbetter-Politano method III-3:6
- leflunomide III-9:17
- left atrial diameter II-7:12
- left ventricular
 - LV diastolic volume II-1c:14
 - LV end-diastolic diameter II-7:12
 - LV filling II-1c:14
 - LV filling pressure I-24:13
 - LV hypertrophy I-20:1, II-5:2, II-7:15
 - LV mass II-7:12
 - LV mass-to-height ratios I-24:1
- leg cramps II-4:27
- leg, elevating the II-4:7
- legionella I-8:2, III-6:5
- legionella pneumophila III-6:5
- leiomyomas I-16:9
- leiomyosarcoma I-16:14
- lens I-7:3
- leprosy I-5:12, I-8:2
- lethargy I-3:29
- leukapheresis II-1d:17
- leukemia
 - acute lymphocytic I. I-17:33
 - acute myelogenous I. I-8:25
 - chronic lymphocytic I. I-8:27
 - human T cell I. virus-1 III-6:2
- leukoagglutinins II-1d:15
- leukocyte function-associated antigen-3 III-1:7
- leukocytes I-1:4
- leukocytoclastic angiitis I-8:13
 - I. vasculitis I-8:19
- leukocytosis I-3:30, I-6:49, II-5:21, II-13:14
- leukoencephalopathy, progressive multifocal III-6:13
- leukopenia I-5:16, III-4:32
 - acute intradialytic I. II-1a:3
- leukoplakia III-7:9
- leukotrienes II-1a:12
- levamisole I-6:16
- levarterenol II-13:29
- levromakalim I-20:21
- levodopa I-19:18
- levofloxacin I-19:18
- libido, decreased I-2:19, I-18:7
- Lich-Gregoire technique III-3:6
- licorice I-20:4, I-23:9, I-24:5
- Liddle's syndrome I-2:26, I-20:7, I-25:14
- lidocaine I-19:18, II-13:28
- life span II-7:3
- light chain deposition disease I-8:2
- limb contractures I-9:9
- lincomycin I-19:18
- linkage analysis I-11:6
- lipase I-8:15
- lipid solubility II-13:6
- lipiduria I-1:10
- lipodystrophy I-1:21, I-8:3
- lipolysis I-3:35
- lipomas I-16:9
- lipopolysaccharide I-12:7
- lipoprotein B (Lp(b)) I-7:12
- lipoprotein lipase I-6:8, II-9:10
- liposarcoma I-16:14
- lisinopril I-19:18
- Lispro insulin I-19:18
- Listeria monocytogenes III-6:4
- lithium I-3:10, I-4:20, I-10:20, I-23:20, II-4:28
 - I. carbonate I-19:18
- lithotripsy
 - extracorporeal shock wave I. I-1:36, I-11:3, I-15:1
 - upper tract endoscopy and I. I-1:42
- livido reticularis I-10:26, I-17:7
- liver I-20:10
 - acute fatty I. of pregnancy I-9:27
 - I. abscess II-5:3
 - I. cysts I-11:4
 - I. disease I-20:11, II-1d:15
 - I. disorders I-8:1
 - I. failure I-3:38
 - I. infarction I-8:15
- I. transplantation I-11:5
 - polycystic I. I-11:5
- livido reticularis I-8:14
- living related donor transplants I-7:7
- living related kidney recipients III-2:1
- living wills II-11:2
- locus coeruleus I-21:3
- lomefloxacin I-19:18
- lomustine I-17:31
- long-acting barbiturates II-13:1
- long chain fatty acids I-5:4
- longitudinal splitting of the GBM I-11:12
- loop of Henle I-4:7
 - ascending limb of the loop of Henle I-4:5, I-17:11
- lorazepam I-19:18
- losartan I-19:18
- lovastatin I-9:19, I-19:18, III-7:7
- low birth weight I-9:23, I-20:2
- low-density lipoprotein (LDL) I-18:3
 - heparin-induced extracorporeal LDL precipit II-1d:31
 - LDL affinity apheresis II-1d:10
 - LDL cholesterol I-7:12, I-20:5
 - LDL hemoperfusor II-1d:31
- low dialysate flow areas II-1a:2
- low salt diet I-2:14
- low-molecular-weight heparin I-19:18, II-1a:31
- low-osmolality contrast media I-17:26
- low-protein diet I-6:7
- Lowe syndrome I-11:17
- Lp a column II-1d:31
- glue sniffing I-3:7
- Luer-Lock method II-1b:10, II-1b:11
- lugol I-1:39
- lumbar lordosis II-5:43
- lumbar puncture I-11:5
- luminal K⁺ channel I-2:22
- luminal membrane I-2:5, I-4:5, 6
- luminal potential I-5:5
- lung, hypoplastic I-9:9
- lung disease
 - chronic I.d. I-20:4
 - chronic obstructive I.d. II-4:21
- lung parenchyma I-3:48
- lupus anticoagulant syndrome I-1:22, II-1d:24

- lupus tolerogens I-8:12
 lying/standing ratio II-4:3
 lymph II-1b:3
 lymphatics I-4:4
 lymphocele I-1:30, III-3:14
 lymphocyte
 – cytotoxic T l.s III-1:8
 – cytotoxic T l. antigen-4 III-1:11
 – acute l. depletion III-4:3
 – helper T l.s III-1:8
 – mixed l. culture III-4:5
 – naive T l.s III-1:8
 – precursor l. III-1:14
 – T l. mitogen III-1:8
 lymphoid tissue III-4:6
 lymphokine I-6:13, I-17:31
 lymphoma I-1:33, I-8:11, I-16:14, III-7:9
 lymphoproliferative disorder II-1d:30
 lymphotoxin III-1:8
 lysine hydrochloride II-13:3
 lysosomal storage disease I-11:17
 – lysosomes I-17:27

 M component I-10:18
 M protein I-6:40
 macrocytosis II-7:11
 macroglossia I-6:3
 macroporous resins II-13:4
 macroscopic hematuria I-11:2
 macrothrombocytopenia I-11:11
 maculopapular rash I-10:6
 magnesium I-15:15, I-20:15
 – m. ammonium phosphate I-15:5
 – m. sulfate I-9:8
 – m. supplements I-15:28
 magnesuria I-5:31
 magnetic resonance I-1:35
 – MR angiography I-1:30, I-1:35, I-11:5
 – MR imaging I-20:7
 – MR spectroscopy I-1:36
 maintenance therapy III-4:2
 major histocompatibility complex III-1:1
 major motor seizures II-4:20
 malabsorption I-15:17
 malaise I-3:29, I-8:19, II-4:17
 malakoplakia I-16:15
 malar rash III-2:15
 malaria I-6:24, I-8:2
 malathion II-13:1
 malignant fibrous histiocytomas
 (fibrosarcomas) I-16:13
 malnutrition I-17:17, I-18:3, II-1a:16, II-5:49
 malnutrition, protein catabolism and II-1a:16
 Maltese cross spherulites I-1:10
 managed care II-12:2
 Managed Care Organization (MCO) II-10:5, II-12:9
 management I-3:25
 mannitol I-17:15, II-13:12, III-3:3
 mannitol infusions II-4:7
 manual exchanges II-3:14
 manual formaldehyde reprocessing II-1a:18
 manual reprocessing II-1a:18
 maple syrup urine disease I-1:2
 maprotiline I-19:18
 Marfan syndrome I-24:10
 marfanoid habitus I-23:12
 marginal donors III-5:8
 marrow fibrosis II-7:6
 marrow inhibition II-7:3
 masculinization I-23:7
 mass removed II-1a:4
 mass transfer area coefficient II-6:10
 mass transfer coefficient II-5:4
 Masson's trichrome I-1:50
 mast cells II-4:16
 matrix I-15:2
 matrix calculi I-15:3
 May-Hegglin I-11:11
 McKenzie rehabilitation program II-5:43
 MCP-3 III-9:15
 mean arterial pressure II-4:2
 mean effective II-6:11
 mean patient clearance II-6:15
 measles I-12:17, III-6:2
 meat I-15:20
 meat consumption I-1:3
 mechanical assist II-1b:11
 mechanical ventilation I-3:26
 meclofenamic acid I-19:18
 meconium ileus I-24:11
 medicaid II-12:2
 Medical Research Council study I-20:15
 Medicare health maintenance organizations (HMOs) II-12:2
 medium-chain fatty acid I-15:28
 medullary collecting duct I-4:8

 medullary
 – m. cysts I-11:9
 – m. hypertonicity concentration gradient I-17:8
 – m. hypertonicity gradient I-17:11
 – m. interstitium I-3:15
 mefenamic acid I-19:18
 mefloquine I-19:20
 megacolon I-23:12
 megakaryocytes I-2:11
 megalin I-6:26
 megaureter I-11:22
 – primary m. I-14:8
 melanogen I-1:2
 melanoma I-1:2, III-2:18
 melanosis II-5:56
 melena I-8:19
 melphalan I-8:24, I-19:20
 membrane
 – bioincompatible m.s II-1a:13
 – cell m.s I-4:1
 – celluloid acetate and polyamide m.s II-1a:27
 – cuprophane m.s I-17:20, II-1a:11, II-4:10
 – high flux (high porosity) m.s II-1a:8, II-6:2
 – high-flux synthetic m.s II-1c:7
 – m. attack complex II-1a:11
 – m. biocompatibility I-17:13
 – m. failure II-5:1
 – m. limited II-1a:7
 – m. materials II-1a:3
 – m. plasma separation II-1d:9, 11
 – m. surface area II-1a:1
 – m. type II-4:6
 – thin film composite m.s II-1a:27
 memory loss II-4:29
 meningitis II-4:20
 meningococemia II-1d:31
 menopause I-20:1, I-23:12
 mental status I-20:5, II-13:1
 meperidine I-19:20, II-4:22
 meprobamate I-19:20
 mercaptoacetyltriglycine I-1:40
 mercapurate II-13:20
 mercury I-10:20, I-17:30
 meropenem I-19:20
 mesangial
 – m. expansion I-7:4, I-7:9
 – m. proliferation III-2:13, III-5:17
 mesenteric insufficiency II-5:11
 mesna I-17:31

Subject Index

- metabolic process type of analysis
I-3:3
- meta-iodobenzylguanidine scans
I-24:4
- metabolic
– m. abnormalities III-4:31
– m. disorders II-4:20
– m. encephalopathy I-5:24
– m. or toxic myoclonus II-4:20
- metabolism
– intermediate m. I-18:1
– lipid m. I-18:3
- metaiodobenzylguanidine
scanning I-25:13
- metanephrine/creatinine ratio
I-23:12
- metanephries I-20:5
- metaproterenol I-19:20
- metaramine II-4:7
- metformin I-7:9, I-19:20
- methadone I-19:20
- methamphetamine I-24:9
- methanol I-3:4, I-3:39, II-13:1,
II-1a:21
- methaqualone II-13:6
- methemoglobinemia II-4:30
- methenamine mandelate I-19:20
- methenamine silver I-1:50, III-6:16
- methicillin I-19:20
- methicillin-resistant *S. epider-*
midis II-5:19
- methimazole I-19:20
- methotrexate I-17:31, I-19:20
- methoxyflurane I-15:15
- methyl red I-1:3
- methyl salicylate II-13:16
- methyl dopa I-9:11, I-19:20,
I-20:20, II-4:22
- methylene blue II-4:31, II-5:44
- methylglucamine I-1:23
- methylguanidine II-6:2
- methylphenidate I-23:22
- methylprednisolone I-8:8, I-19:20
- metoclopramide I-19:20, I-23:19
- metocurine I-19:20
- metolazone I-19:20
- metoprolol I-19:20, I-20:17,
I-25:21
- metronidazole I-19:20
- mexiletine I-19:20
- mezlocillin I-19:20
- mibefradil I-20:19
- miconazole I-19:20
- micro-emulsion III-4:15
- microalbumin I-13:23
- microalbuminuria I-7:1, I-20:5
- microangiopathy II-1d:24, III-8:15
- microbial enzymes II-1a:17
- microcephaly I-11:15
- microchimerism III-1:15
- microencapsulated I-2:18
- microhematuria I-1:10
- microscopy
– immunofluorescence m. I-8:30
– phase-contrast m. I-1:4
- microsomal oxidation I-19:5
- microvesicular fatty infiltration of
hepatocytes I-9:27
- microvilli I-17:27
- micturating cystogram I-1:41
- micturition, dysfunctional I-13:6
- midazolam I-19:20
- middle aortic syndrome I-25:12
- “middle molecules” II-6:4
- midline catheter implantations
II-1b:24
- midodrine I-19:20, II-4:7
- midscapular murmur I-24:3
- miglitol I-19:20
- milk II-4:28
- milk-alkali syndrome I-5:13
- milrinone I-19:20
- mineralocorticoid I-3:47, I-9:2,
I-24:3
– m. receptor I-20:7
– primary excess of m. I-2:37
- mini-cycler II-1b:14
- minimal inhibitory concentration
I-17:28, II-5:21
- minimal inner fiber diameter
II-1a:2
- Minnesota antilymphocyte
globulin III-4:7
- minocycline I-11:5, I-19:20
- minoglycosides I-9:16
- minor histocompatibility antigens
III-1:3
- minoxidil I-9:12, I-19:20, I-20:21,
I-25:21
- mithramycin I-5:15, I-17:31
- mitochondrial
– m. cytopathies I-11:17
– m. dysfunction II-5:43
– m. membrane I-3:1
- mitogen-activated protein kinase
I-24:12
- mitomycin C I-17:31, I-19:20
- mitoxantrone I-19:20
- mitral regurgitation I-11:5
- mitral valve prolapse I-11:5
- mivacurium I-19:20
- mixed lymphocyte culture III-4:5
- molecular mimicry I-10:2
- molecular weight
– m.w. of the solute II-1b:3
– high m.w. kininogen II-1a:12
- Molluscum fibrosum pendulum*
I-11:8
- monoamine oxidase inhibitors
I-23:12, I-24:2
- monoclonal
– m. gammopathies I-1:16
– m. gammopathy of undeter-
mined significance II-1d:28
– m. immunoglobulin light chains
I-6:4
– m. immunoglobulins I-8:3
– m. protein II-1d:28
- monocyte I-10:1, II-4:16
- mononeuritis multiplex I-8:15,
I-8:28
- mononuclear cell I-5:6, III-1:1
- monophasic IgM II-1d:25
- Montcrief-Popovic II-5:9
- moricizine I-19:20
- morphine I-19:20, I-24:10, II-4:22
- mortality II-1a:15
- mortality probability monitoring
II-1c:19
- moth-eaten papilla I-1:24
- motor deficits I-8:16
- moxalactam I-9:15, I-19:20
- moxonidine I-20:20, I-24:1
- MPO I-8:3
- mRNA I-21:4
- mucor III-6:15
- mucormycosis III-6:15
- mucosal neuromas I-5:11
- multi-compartment models
II-6:18
- Multimat B-ICU II-1c:7
- multiorgan failure I-12:11
- multiple endocrine adenomatosis
I-5:11, I-20:8
- multiple myeloma I-1:23, I-21:6,
II-7:5
- multiple organ dysfunction syn-
drome II-1c:1
- multiple sclerosis II-1d:28
- multivitamin supplements II-7:4
- mumps I-12:17
- municipal water supplies

- II-1a:25, 27
 mupuricine II-3:13
 muscle
 – m. contraction I-2:11
 – m. cramps I-20:4, II-4:11
 – m. dystrophy I-11:15
 – m. mass II-6:4
 – m. twitching II-4:24
 – m. weakness II-1d:27, II-14:9
 mushrooms II-1d:4
 mutation identification I-11:6
 mutations I-2:26
 myasthenia gravis II-1d:27
 myasthenic crisis II-1d:27
 mycobacterium II-1a:23, II-5:12,
 III-6:4
 – *M. chelonae* III-6:18
 – *M. hemophilum* III-6:18
 – *M. kansasii* III-6:18
 – *M. marinum* III-6:18
 – *M. tuberculosis* I-12:17, III-6:17
 mycophenolate mofetil I-8:11,
 III-6:4
 mycoplasma I-8:2, I-12:15
 myeloblastin I-1:20
 myeloid bodies I-17:27
 myeloma light chains II-1d:23
 myeloperoxidase I-1:20, I-8:16
 myocardial
 – m. blood flow I-24:7
 – m. contractility II-1b:9, 10,
 I-3:25, II-4:2
 – m. depressant II-1a:32
 – m. depressant substances, circu-
 lating II-1c:15
 – infarction, acute I-24:7
 – acute phase proteins III-5:15
 myocardium II-13:27
 myoclonic jerks II-13:27
 myoclonus II-1a:27, II-4:21
 – nocturnal m. II-5:2
 – toxic m. II-4:20
 myoglobin I-17:22, II-1b:3
 myoglobinuria I-1:2
 myoinositol I-4:14
 myopathy II-4:12, II-5:2
 – uremic m. II-10:3
 myosin ATPase activity
 III-8:16
 myosin isoenzyme III-8:16

 N-3 fatty acids II-5:35
 N-acetyl-beta-D-glucosaminidase
 I-13:23
 N-acetyl-procainamide I-19:20,
 II-13:24
 N-acetylcysteine I-19:20,
 II-13:1, 19
 N-acetylimidoquinone II-13:20
 Na⁺, K⁺, 2 Cl⁻ cotransporter I-3:12
 Na⁺, or K⁺ exchange resins I-3:47
 Na⁺/H⁺ exchanger I-3:8, 12, I-4:7
 Na-K-ATPase I-17:12
 nabumetone I-19:20
 NaCl co-transporter I-2:22
 nadolol I-19:20, I-20:17
 nadroparin calcium II-1a:32
 nafcillin I-19:20
 nail
 – brittle n. I-5:9
 – n. abnormalities I-11:16
 – n.-patella syndrome I-11:16
 naive T lymphocytes III-1:8
 nalidixic acid I-19:20
 naloxone I-19:20, II-13:1
 naloxone hydrochloride I-23:18
 naproxen I-19:20
 nasal
 – n. carriage of *S. aureus* II-5:18
 – n. erosions I-8:15
 – n. oxygen II-4:7
 Nashville Rabbit Antithymocyte
 Serum III-4:7
 nasogastric I-5:31
 National Institute of Diabetes and
 Digestive and Kidney Disease
 II-6:29
 native kidney clearance II-6:20
 native kidney nephrectomy
 III-2:19
 natural killer II-1d:34
 nausea I-7:9, II-4:17
 – chronic n. I-4:14
 neck resections, radical I-5:22
 necrosis I-16:8
 – acute cortical n. I-1:33
 – acute hepatic n. I-3:38
 – avascular n. III-7:8
 – avascular n. of the femoral head
 II-14:9
 – bilateral cortical n. I-9:26
 – cortical n. I-9:5
 – fibrinoid n. I-1:19
 – fibrinoid n. of arterioles I-8:20
 – focal n. I-8:14
 – hemorrhagic n. I-23:15
 – n. of the nasal septum I-8:15
 – papillary n. I-12:11, II-13:20
 – renal papillary n. I-10:13
 – sorbitol-induced colonic n.
 I-2:34
 – steato n. II-5:3
 – tissue n. I-3:24
 – tubular cell n. III-5:13
 necrotizing arteritis III-5:6, 11
 Nedd 4 protein I-2:27
 needle-stick injury II-2:19
 nefazodone I-19:20
 nelfinavir I-19:20
 neonatal I-9:3
 neonatal severe hypocalcemia I-5:3
 neoplasia I-6:50, II-5:3
 neoplasms
 – primary or metastatic
 intracranial n. II-4:20
 neostigmine I-19:20
 nephrectomy I-21:10
 – laparoscopic donor n. III-2:2
 – native kidney n. III-2:19
 nephritic syndrome I-8:1
 nephritis
 – acute allergic interstitial n.
 I-17:30
 – acute allergic tubulointerstitial
 n. I-1:6
 – acute tubulointerstitial n. I-10:2
 – allergic interstitial n. I-10:5
 – Balkan n. I-10:10
 – chronic tubulointerstitial n.
 I-10:9
 – classes of lupus n. I-8:4
 – Fanconi's syndrome or tubular
 interstitial n. I-8:22
 – Heymann n. model I-6:26
 – IgA n. (IgAN) I-6:35
 – interstitial n. II-13:13
 – lupus n. II-1d:24
 – radiation n. I-10:22
 – resistant lupus n. I-8:11
 – shunt n. I-1:23, I-8:34
 – tubulointerstitial n. I-10:1
 nephrocalcin I-15:6
 nephrocalcinosis I-3:46, I-5:13,
 I-10:21, I-15:15
 nephrogenic adenoma I-1:44
 nephrogenic diabetes insipidus
 II-13:13
 nephrogram I-1:24
 nephrolithiasis I-15:1
 – hypomagnesiuric calcium n.
 I-15:15
 – X-linked recessive n. with renal
 failure I-5:27
 nephron dosing III-5:25
 – n. number, functioning III-5:24
 nephropathy

Subject Index

- acute urate n. I-1:10
- acute uric acid n. I-17:6
- analgesic abuse n. I-16:12
- analgesic n. I-10:12
- cadmium n. I-10:20
- calcium n. I-5:13
- cast n. I-8:22, I-10:16
- chronic allograft n. III-5:21
- contrast n. I-17:24
- crystalline n. I-14:2
- diabetic n. III-8:13
- endemic n. I-10:10
- heavy metal n. I-6:3
- human immunodeficiency virus associated n. I-8:35
- IgA n. I-21:7, II-1d:24
- light chain n. I-8:22
- membranous n. I-8:28
- postobstructive n. I-3:47
- reflux n. I-13:1, II-14:1
- nephrosclerosis, malignant I-13:23
- nephrosclerosis, hypertensive I-18:8
- nephrostomy
 - external n. tubes III-3:13
 - percutaneous n. I-11:3, I-14:11
 - percutaneous n. tube III-3:10
- nephrotic syndrome I-8:1, I-18:2
 - infantile n.s. I-11:14
- nephrotomography I-16:8
- nephrotoxic I-21:6
- nerve conduction II-1d:26
- net anionic charge I-3:9
- net ultrafiltration rate II-1b:4
- netilmicin I-19:22
- neuraminidase I-6:42
- neuroblastomas I-23:14
- neuroectodermal cancer I-5:11
- neurofibromas I-20:8
- neurofibromatosis I-20:5, I-25:11
- neuroleptics II-13:27
- neurologic symptoms I-1:22
- neurological disease I-8:15
- neurological function I-18:1
- neuromas I-23:12
- neuromuscular blocking agents II-4:22, III-3:3
- neuromuscular irritability II-13:13
- neuropathy II-5:2
 - autonomic n. III-8:13
 - diabetic n. I-7:9, II-5:2
 - peripheral n. I-18:10, II-1d:28
 - uremic n. II-5:2
 - xantomathous n. II-1d:31
- neuropsychological tests II-7:13
- neutropenia I-12:4
- neutrophil activation III-5:4
- nevirapine I-19:22
- nicardipine I-19:22, I-20:19, I-25:21
- nickel I-10:20
- nicotine I-20:13, I-23:17
- nicotinic acid I-6:9, I-19:22, III-7:7
- nifedipine I-9:13, I-19:22, I-20:19, I-25:21
- nimodipine I-19:22, I-24:11
- nisoldipine I-19:22
- nitrate I-1:4, II-4:28, II-4:31
- nitrazepam I-19:22
- nitrendipine I-25:21
- nitric oxide I-9:6, I-20:11, II-13:20
- nitrite I-13:25, II-4:31
- nitrofurantoin I-9:15, I-19:22, II-4:22
- nitrogen balance I-17:18
- nitroglycerine I-19:22, I-24:7
 - parenteral n. I-24:7
- nitroprusside I-9:13, I-19:22
 - n. reaction I-1:2
 - sodium n. I-24:2, I-24:7, I-25:23
- nitrosores I-17:31, I-19:22
- nizatidine I-19:22
- Nocardia III-6:4, III-6:6
- nocturia I-10:14
- nocturnal
 - n. enuresis I-13:6
 - n. intermittent peritoneal dialysis II-1b:7
 - n. myoclonus II-5:2
- nodular
 - n. glomerulosclerosis I-22:5
 - n. hyalinosis III-4:21
 - n. lesions I-8:28
- nomogram II-1d:8, II-6:12
- non-Hodgkin's lymphoma I-8:27, I-17:33
- non-human primate III-9:5
- non-tuberculous mycobacteria II-1a:28, II-4:32
- non-xanthomonas II-5:13
- non-compliance II-5:2
- non-obstructive mesenteric infarction II-5:3
- non-salt-sensitive I-20:14
- non-selective enlarged pores I-7:6
- noradrenaline I-25:20
- norepinephrine I-21:3, II-4:7
- norfloxacin I-19:22
- nortriptyline I-19:22
- nosocomial infection risk III-6:3
 - n. UTIs I-12:15
- NPH1 I-11:9
- nucleation I-15:4
- nuclei I-21:3
- nutrition I-8:10
- nutritional recovery syndrome I-5:26
- nutritional supplementation I-17:18
- nystatin II-5:19, III-6:13
- O rings II-4:32
- O-set II-1b:11
- oat cell carcinoma I-2:25
- obesity I-20:1, I-25:7, II-5:2
- obliterative microangiopathic changes III-4:15
- obstruction I-9:1
 - bladder outlet o. I-1:43, I-14:11
 - catheter o. II-3:14
 - congenital o. I-1:36
 - functional (aperistaltic) o. I-14:7
 - intraluminal o. I-17:27
 - intratubular o. I-14:2
 - mechanical (anatomic) o. I-14:7
 - o. of the renal calix or pelvis I-14:2
 - one-way o. II-1b:24
 - outflow o. II-3:4
 - outlet o. I-1:43
 - two-way or complete o. II-1b:25
 - ureteral o. I-12:7, I-14:3, III-3:13
 - ureteropelvic junction o. I-13:3
 - urethral o. I-1:43
 - urinary tract o. I-14:1f.
- obstructive uropathy II-14:1
- occipital ischemia I-9:5
- occluded fibers II-1a:20
- occlusion
 - acute arterial o. I-22:9
 - omental o. II-14:8
 - positional o. II-2:11
 - renal artery o. I-22:4
 - segmental o. I-1:38
- ocult
 - o. malignancy I-8:26
 - o. vomiter I-2:17
 - o. vomiting I-2:22
- occupational III-6:1
- octreotide I-7:13, I-24:5
- ocular abnormalities I-6:6
- ofloxacin I-19:22
- OKT3 III-4:5, III-4:7, III-6:4

- oligohydramnios I-9:9
 oligomenorrhea I-18:7
 oliguria I-17:6
 omental occlusion II-14:8
 omentum
 – o. wrapping II-3:16, II-1b:25
 – incarcerated o. II-5:11
 omeprazole I-19:22
 Onchocerca volvulus I-12:17
 oncocytoma I-1:33, I-16:9
 oncotic pressure II-1a:7, II-1b:2
 ondansetron I-19:22
 operative risk I-22:10
 ophthalmologic function I-18:1
 opiate intoxication II-13:1
 optic fundi I-20:5
 oral
 – o. and intravenous contrast I-16:4
 – o. hypoglycemic agents I-7:9
 – o. iron II-7:10
 – o. phenazopyridine I-12:4
 – o. supplementation I-3:34, 35
 Oreopoulos-Zellerman II-5:9
 organ
 – o. of Zuckerkindl I-9:13, I-23:10
 – o. perfusion III-8:7
 – o. preservation III-8:1
 – o. procurement III-8:7
 – o. system failure II-1c:19
 organic
 – o. anions I-3:13, II-1b:9
 – o. osmolytes I-4:14
 – o. phosphates I-2:4, I-3:34
 – o. solvents I-6:45
 organogenesis I-9:21
 organomegaly II-1d:28
 ormaplatin I-17:30
 orphenadrine I-19:22
 orthohippurate I-1:40
 orthophosphate I-10:22
 oscillometry I-25:1
 Osler's nodes I-17:7
 Osler's sign I-20:3
 Oslo study I-20:15
 osmol-free water I-4:12
 osmolal gap I-17:32
 osmolality I-4:2, I-17:8
 osmoreceptor I-4:24
 osmostat I-9:2
 osmotic II-1b:2
 – o. demyelination syndrome I-4:8
 – o. lysis III-1:9
 – o. ultrafiltration II-1b:3
 osteitis fibrosa I-5:23, II-14:9
 osteitis fibrosa cystica I-5:7, 11
 osteo-onychodysplasia I-11:16
 osteoblast II-14:10
 osteoclast I-5:6, II-8:3, II-14:10
 osteocyte I-5:6
 osteodystrophy II-14:1
 – mixed uremic o. II-8:17
 – renal o. I-18:6, II-8:1
 – uremic o. II-8:17
 osteoid II-8:6
 osteolysis I-5:11
 osteomalacia I-5:13, II-8:17, II-14:10
 osteomyelitis II-2:10, III-6:14
 osteon II-8:3
 osteopenia I-5:11, II-5:2
 osteoporosis I-8:10, I-20:14
 osteosclerosis I-5:11
 ostial stenosis I-1:37
 ostium I-22:4
 ouabain I-19:22
 ouabain-like factor I-21:6
 outflow
 – o. arm II-3:4
 – o. obstruction II-1b:24, II-3:4
 – o. time II-3:4
 oval-fat bodies I-1:7
 ovarian cancer I-5:11
 over-the-counter I-10:12
 overall resistance II-1a:8
 ovulation II-1b:25
 oxalate I-5:4, I-15:13, II-5:2
 oxaluria, primary III-2:16
 oxaproxin I-19:22
 oxatomide I-19:22
 oxazepam I-19:22
 oxcarbazepine I-19:22
 oxidation I-3:4
 oxidative damage II-4:17
 oxoplasmosis I-8:2
 oxycodone II-13:17
 oxygen I-17:12, II-4:10
 – alveolar-arterial o. gradient II-5:45
 – hyperbaric o. therapy II-4:24
 – nasal o. II-4:7
 – patient o. uptake II-10:3
 – reactive o. species II-1a:12
 – supplemental o. II-4:21
 oxygen-hemoglobin dissociation curve I-3:49
 oxygenation I-17:14, III-8:7
 oxymetazoline hydrochloride I-23:19
 P-450 I-2:25
 p-arsanilic acid I-1:4
 p-diethylaminobenzaldehyde I-1:3
 P-fimbriae I-10:7
 P-fimbriated E. coli I-13:5
 P-selectin III-9:10
 P29 I-1:20
 P-fimbriated E. coli I-12:3
 Paclitaxel I-19:22
 "Page" kidney I-20:4
 Paget's disease I-5:12, I-5:23
 pain II-3:7
 – abdominal p. I-8:19
 – back p. II-1b:13, II-5:2
 – bone p. II-14:9
 – epigastric p. I-11:11
 – flank p. I-12:8
 – joint p. I-9:18
 – localized outflow p. II-1b:24
 – loin p. hematuria syndrome I-1:46
 – p. on inflow II-1b:24
 – perineal p. I-12:14
 – pleuritic p. I-10:29
 – precordial p. II-4:9
 – retrosternal p. II-4:13
 – right upper quadrant p. I-9:4
 – severe abdominal p. II-4:17
 Pallor I-23:10
 palpable purpura I-1:22, III-6:14
 palpable purpuric rashes I-8:19
 palpitation I-20:4, I-22:1
 pamidronate I-5:16, II-4:29
 pancreas-kidney transplantation III-8:1
 pancreatectomy III-8:12
 pancreatic I-1:32
 – p. carcinomas I-8:27
 – p. cysts I-23:12
 – p. inflammation I-8:15
 – p. insufficiency I-15:14
 pancreatitis I-5:11, II-5:3, III-2:19, III-6:8, III-8:7
 pancuronium I-19:22
 pancytopenia I-8:25, I-15:27
 panic attacks I-23:12
 PapG I-12:7
 papillary collecting ducts I-13:7
 papilloma I-1:44
 para-aminohippurate (PAH) I-1:40
 paracentesis I-17:21
 paracetamol I-10:13

Subject Index

- paraganglia chromaffin cells I-23:10
- paraldehyde II-4:22
- paralysis II-4:27
- paramedian insertion II-1b:24
- paraneoplastic syndrome I-5:11, I-8:1
- parapelvic cysts I-1:32
- paraproteinemias I-8:22, II-7:5
- paraquat II-13:6, II-1d:4
- parasympathetic pathway II-4:3
- parathion II-1d:4
- parathyroid
 - p. adenomas I-5:7
 - p. carcinomas I-5:10
 - p. hormone I-15:8, I-18:5
 - p. hormone-related protein I-5:11
 - p. hyperplasia I-20:8
- parathyroidectomy I-5:22, I-15:28, II-7:6
 - subtotal p. II-4:16
- parenchymal thickness I-13:13
- paresthesias
 - acral p. II-1d:14
 - perioral p. II-1d:14
- paroxetine I-19:22
- partial
 - p. lipodystrophy I-6:30
 - p. omentectomy II-3:16
 - p. thromboplastin time I-9:4
- particulate matter II-1a:19
- PAS I-8:30, I-19:22
- patency rate I-22:9
- patent ductus arteriosus I-9:9
- patient
 - p. clearance II-6:15
 - p. education II-10:4
 - p. size II-6:26
- peak
 - p. concentration hypothesis II-1b:17
 - p. level I-19:6
 - p. oxygen uptake II-10:3
 - p. plasma levels II-1b:17
 - p. voiding pressure I-13:7
- pelvic
 - p. cancer I-14:1
 - p. mass I-17:7
- pelvicaiectasis I-17:9
- pelvis I-11:22
 - extrarenal p. I-1:32
 - obstruction of the p. I-14:2
- pelvocalyceal I-13:9
- perbutolol I-19:22
- penicillamine I-6:24, I-15:27, I-19:22
- penicillin I-17:29, II-4:20
 - p. G I-8:33, I-19:22
 - penicillinase-resistant p. II-5:27
 - p. VK I-19:22
- pentagastrin test I-20:8, I-23:12
- pentamidine I-2:32, I-8:35, I-19:22, III-6:17
- pentastarch II-1d:17
- pentazocine I-19:22
- pentobarbital I-19:22
- pentopril I-19:22
- pentosidine II-6:2
- pentoxifylline I-7:13, I-19:22, III-5:14
- peracetic acid II-1a:12, 21
- percodan II-13:17
- percutaneous
 - p. cannulation II-13:5
 - p. nephrostomy I-11:3, I-14:11
 - p. nephrostomy tube III-3:10
 - p. renal biopsy I-1:47
 - p. transluminal angioplasty I-1:38, I-22:8, I-25:23
 - p. transluminal balloon catheter angioplasty II-2:21
- perfloracin I-19:22
- perforans I-10:1
- perforation I-1:38
- perforins III-1:9
- performance testing II-1a:20
- perfusion I-17:10
- perfusion-pressure flow studies I-14:8
- periarterial lesions I-22:4
- periarthritis nodosa I-1:23
- pericardial II-4:18
 - p. effusion II-4:9
 - p. tamponade I-3:38
- pericarditis I-8:16, I-9:18, I-18:10, II-4:8
 - dialysis p. II-4:9
 - uremic p. II-4:9
- pericardium I-23:10, III-6:15
- pericatheter II-3:13
 - early p. leakage II-1b:24
 - p. leaks II-1b:13
- perimedial I-22:4
- perindopril I-19:22
- perinephric abscesses I-12:10
- periodic acid Schiff I-1:50
- perioperative antibiotic prophylaxis III-6:3
- periorbital II-4:14
- peripheral
 - p. arterioles I-20:10
 - p. artery disease I-18:1
 - p. chemoreceptors I-3:48
 - p. neural lesions I-8:15
 - p. neuropathy II-1d:28
 - p. smear I-9:4
 - p. tolerance III-1:13
 - p. vascular disease I-20:4, II-9:10
 - p. vascular resistance I-20:8, 11, II-4:2, II-7:12
- perirenal
 - p. fat I-16:8
 - p. hemorrhage I-1:32
- peristalsis I-14:3
 - u. peristalsis I-12:7
- peritoneal
 - p. adhesions II-1b:24
 - p. catheters II-1b:10
 - p. cavity II-1b:2
 - p. membrane II-6:1
 - p. membrane resistance II-1b:3
 - p. solute clearances II-1b:7
 - p. space II-3:7
 - p.-pleural scintigraphy II-5:44
- peritoneal dialysis
 - automated PD II-1b:21, II-14:7
 - chronic PD II-1b:20
 - complications of acute PD II-1b:19
 - continuous ambulatory PD (CAPD) II-1b:1
 - continuous cyclic PD II-1b:1
 - daytime ambulatory PD II-1b:13
 - intermittent PD II-1b:13
 - nocturnal intermittent PD II-1b:7
 - tidal PD II-1b:14
- peritoneoscopy II-1b:10
- peritonitis I-9:25, II-1b:1, II-5:1, II-9:13
 - bacterial p. I-8:15
 - eosinophilic p. II-5:15
 - incidence of p. II-1b:13
 - relapsing p. II-5:22
 - sclerosing encapsulating p. (SEP) II-5:7, II-5:8
- permanent catheter II-1b:10
- permeability I-4:1
- pernicious anemia I-2:4
- peroxide mixture II-1a:21
- peroxidase I-1:2
- personality changes II-1a:27
- perspiration I-20:4
- pet III-6:1
- petechiae II-4:30

- PEX gene I-5:26
 PGH2 I-21:4
 pH I-3:1
 phagocytic stimuli II-1a:17
 phagocytosis I-5:24, II-7:13
 phase-contrast microscopy I-1:4
 phenacetin I-1:42, I-10:12
 phenacyclidine II-13:3
 phenelzine I-19:22
 phenobarbital I-5:8, I-19:22,
 II-1d:20, II-4:22, II-13:1, 6
 phenol II-6:2
 phenolic acids II-6:2
 phenothiazines II-4:22
 phenoxybenzamine I-24:5, I-25:21
 phenotolamine I-24:5, I-25:21
 phenylbutazone I-19:22
 phenylephrine hydrochloride
 I-23:19
 phenylepinephrine II-4:7
 phenylethanolamines I-20:4
 phenylketonuria I-1:2
 phenylpropranolamine I-23:12, 19
 phenytoin I-9:8, I-19:22, II-1d:20,
 II-7:11
 pheochromocytoma I-9:13, I-20:4,
 I-24:4
 – extra-adrenal p. I-9:13
 – pseudo-p. I-24:1
 phlebitis I-2:18
 phlebotomy I-2:10
 phlegmon I-1:30
 phosphate I-5:4, 18
 phosphate binders I-17:17
 phosphate-binding antacids I-5:25
 phosphatidic acid I-1:22
 phosphatidylcholine I-1:22
 phosphatonin I-5:20
 phospholipase I-5:20, I-24:12,
 III-1:5
 phospholipids I-17:27
 phosphomonoester (MP)/Pi ratio I-
 1:36
 physical rehabilitation II-10:1
 physical training II-10:2
 physiological responses I-3:16
 physostigmine II-13:29, I-23:19
 phytates II-7:10
 picrate I-1:12
 picric acid method I-3:32
 pigments I-1:2
 Pima indians I-21:8
 picnacidil I-20:21
 pindolol I-19:22, I-20:17
 pipecuronium I-19:22
 piperacillin I-19:24
 piretanide I-19:24
 piroxicam I-19:24
 pKa I-15:10
 placental cells I-9:3
 planimetric surface area I-13:14
 plaquenil I-8:10
 plasma
 – p. clearance I-17:27
 – p. concentrations I-19:5
 – p. exchange I-6:47, I-9:28
 – p. half-life I-17:27
 – p. insulin levels II-1a:32
 – p. magnesium I-5:29
 – p. membrane I-2:1
 – p. oncotic pressure II-4:2
 – p. osmolal gap I-3:10
 – p. osmolality II-4:2
 – p. phosphorus I-5:17
 – p. renin activity I-20:5, I-21:2
 – p. trough levels I-17:28
 – p. volume II-1d:8, II-4:2
 plasma exchange
 – therapeutic p.e. II-1d:1
 – unselective p.e. II-1d:31
 plasmaflow II-1d:11
 plasmapheresis II-1d:1f, I-8:11,
 I-9:27, II-13:16,
 plasminogen activation inhibitor
 I-6:10, I-9:28
 plasminogen activator I-9:28
 plasticizers II-1a:19
 platelet I-6:10
 – p. activating factor II-1a:12
 – p. aggregation II-1a:31, II-7:13
 – p. count II-7:13
 – p.-derived growth factor B
 I-6:20
 – p. dysfunction II-4:18
 – p. hyperaggregability I-6:10
 plates II-8:5
 platinum I-17:30
 pleural effusion I-4:1
 pleuro-peritoneal communication
 II-1b:25
 pleurodesis II-1b:25
 plicamycin I-19:24
 pneumococcus I-8:2
 pneumocystosis III-6:16
 pneumonia
 – bacterial p. III-6:3
 – pneumocystis carinii p. III-6:4
 pneumothorax II-2:3
 PO₄³⁻ II-6:2
 POEMS syndrome II-1d:28
 point mutation I-11:13
 poison II-1d:4
 poisoning II-13:1 f.
 – acute fluoride p. II-4:30
 – barium p. I-2:2
 – ethylene glycol p. I-1:10, I-3:41,
 I-10:21
 – methanol or ethylene glycol p.
 I-3:36
 – methanol p. I-3:39
 polarized light I-1:4
 polyacrylonitrile II-1a:4, II-4:10
 polyamines II-6:2
 polyangiitis, microscopic I-8:3
 polyarteritis nodosa I-8:19
 polycarbonates II-1a:2
 polycations II-1b:10
 polyclonal antilymphocyte agents
 III-6:4
 polycystic kidney disease (PKD)
 I-18:8
 – PKD1 locus I-11:2
 – PKD2 locus I-11:2
 – PKD3 I-11:2
 polycystin I-11:2
 polycythemia I-14:6, III-5:28
 polydipsia I-3:29, I-11:9, I-25:15
 – primary p. I-4:13
 polyetherpolycarbonate II-1a:4
 polyethylene glycol-electrolyte so-
 lution II-13:1
 polymerase chain reaction I-1:53
 polymers II-1a:2
 polymethylacrylate II-1a:4
 polymorphonuclear cells I-1:6
 polyneuritis I-10:22
 polyneuropathy II-1d:28, II-5:2
 – paraprotein-associated p.
 II-1d:28
 – chronic inflammatory demyeli-
 nating p. II-1d:26
 – rapidly evolving p. II-5:2
 polyol pathway I-7:3
 polyoma virus III-6:7, 13
 polyp, fibrous I-1:44
 polypeptides II-1b:10
 polysaccharide capsules I-12:7
 polystyrene II-1a:2
 polysulfone-PS II-1a:4
 polytetrafluorethylene II-1d:13,
 II-7:14, III-6:2
 polyurethane II-1a:3

Subject Index

- polyurethane potting material
II-4:14
- polyuria I-2:23, I-3:29, I-11:9, 17,
I-17:6, I-20:4
- pons I-24:11
- poor detrusor function I-1:43
- pore size II-1a:5
- porphobilinogen I-1:2
- porphyria I-1:2
- portal circulation I-19:3
- portal system II-1b:3
- post-therapy cultures I-12:6
- postdialysis
– final equilibrated p. concentration (CE) II-6:15
- posterior
– p. fossa I-23:16
– p. hypothalamic I-21:3
– p. pituitary gland I-4:6
– p. urethral valves I-11:22, I-12:7
- posttransplantation hypercalcemia
I-5:12
- p. lymphoproliferative disorder
III-7:9
- posture I-1:15
- potassium I-20:2
– p. balance I-18:2
– p. citrate I-15:25
– p. exchange resin III-3:8
– p.-magnesium citrate I-15:26
– p. phosphate, neutral I-15:26
– p.-sparing diuretics I-25:19
- Potter syndrome I-11:8
- potting II-1a:3
– polyurethane p. material
II-4:14
– p. material II-1a:1
- povidone iodine II-1b:11, II-3:13
- pravastatin I-19:24, III-5:27,
III-7:6
- prazepam I-19:24
- prazosin I-19:24, I-20:17, I-25:21
- pre-kallikrein II-1a:12
- pre-zidovudine I-8:35
- preabsorbing antigen I-6:42
- precursor lymphocyte III-1:14
- predialysis BUN
– CE II-6:20
– p. concentration II-6:15
– p. serum creatinine levels
I-17:19
- prednisolone I-19:24
- prednisone I-19:24, I-20:7,
II-1d:20
- preclampsia I-9:2, 3, I-20:14
- preglomerular vasodilatation
I-14:5
- pregnancy I-9:1, I-18:7, I-20:2
- prekallikrein activating factor
II-1d:19
- preload II-4:4, II-1c:14
- premature glomerular obsolescence
I-20:8
- premature ventricular contractions
II-4:27
- prematurity I-9:19
- prerenal azotemia I-1:14, I-14:13,
I-17:1
- preservation III-8:7
- pressor I-17:16
- pressor agents II-13:8
- pressure
– p. alarms II-1c:7
– p. drop II-1a:1, II-1c:7
– p. natriuresis I-22:2
– p.-flow profiles II-2:24
– p.-leak testing II-1a:19
– p.-natriuresis curve I-22:1
– p.-natriuresis relationship
I-20:12
- presynaptic nerve terminal
II-1d:27
- prevalence of stone risk factors
I-15:2
- prevalence in ESRD II-9:2
- prevention of reflux nephropathy
I-13:25
- prevention of recurrent stone formation
I-15:17
- primaquine I-19:24, III-6:17
- primary aldosteronism I-20:4,
I-24:5
- primary excess of mineralocorticoid
I-2:37
- primary hyperaldosteronism I-2:24
- primary hyperoxaluria I-10:21
- primary hypodipsia I-4:23
- primary megaureter I-14:8
- primary or metastatic intracranial
neoplasms II-4:20
- primary oxaluria III-2:16
- primary polydipsia I-4:13
- primary renal sarcomas I-16:13
- primidone I-19:24
- primigravida I-9:4
- priming solutions II-4:14
- principal cells I-2:5
- prisma II-1c:7
- pro-ischemic factors II-5:34
- probenecid I-1:13, I-19:24
- probucoI I-19:24
- procainamide I-19:24, II-9:9,
II-13:3
- prochlorperazine I-23:19
- progesterone I-9:1, I-23:18
- progressive multifocal leukoencephalopathy
III-6:13
- progressive systemic sclerosis
I-8:4
- promethazine I-19:24
- propafenone I-19:24
- properdin I-6:31
- propofol I-19:24
- propionyl II-5:43
- propoxyphene I-19:24, II-13:17
- propranolol I-19:24, I-20:17,
I-25:20, II-1a:32, II-13:15
- propylthiouracil I-19:24
- prorenin I-23:8
- ProSORba columns II-1d:34
- prostacycline I-9:3, I-20:11
– p. analogs I-10:27
- prostadynia I-12:14
- prostaglandin I-9:1, I-20:11, I-22:2
– p. synthesis I-5:16
– p. -12 biosynthesis II-5:35
- prostate I-17:7
– transurethral resection of the p.
I-4:9
- prostatic
– p. calculi I-12:15
– p. cancer I-14:1
– p. hypertrophy, benign I-14:1
– p. massage I-12:14
- prostatitis I-1:6, I-12:14
– acute bacterial p. I-12:14
– chronic bacterial p. I-12:14
– nonbacterial p. I-12:14
- protamine sulfate II-1a:31
- proteases II-1a:16
- protein A column II-1d:22
- protein binding I-19:4, II-13:3, 6
- protein C II-5:59
- protein C, antithrombin III I-6:10
- protein catabolic rate (PCR)
I-17:17, II-1b:18, II-6:4, 22
– normalized PCR I-17:18
- protein catabolism II-1a:16, II-6:17
- protein coating II-1a:20
- protein electrophoresis I-17:8
- protein equivalent of nitrogen appearance (PNA)
II-1b:18
- protein intake I-18:3

- average p.i. I-18:2
- excessive p.i. I-18:2
- protein kinase C activation I-24:12
- protein kinase C pathway I-5:20
- protein metabolism I-18:2
- protein S I-6:10, II-5:59
- protein sieving II-1a:23
- protein tyrosine kinases III-1:5
- proteinase I-1:20, I-8:16, II-1a:12
 - streptococcal cationic p. I-6:42
- proteinuria I-7:1, I-18:2
 - Bence-Jones p. I-6:4, I-17:8
 - nephrotic-range p. I-22:4
- Proteus species I-9:15, I-12:4
- prothrombin time I-9:4, II-13:20
- proton pump inhibitors I-10:6
- protozoal I-8:34
- protryptiline I-19:24
- proximal
 - p. convoluted tubule I-3:11
 - p. muscle wasting I-24:3
 - p. tubule concentrating defects III-3:7
- prozac II-13:27
- Prune-Belly syndrome I-11:22
- pruritus I-18:6, II-4:14, 15, II-5:3, 57
- pseudoaneurysm II-2:19
- pseudoephedrine hydrochloride I-23:19
- pseudohermaphroditism I-23:7
- pseudohyperkalemia I-2:11
- pseudohypoadosteronism type I I-2:30
- pseudohypoparathyroidism I-5:7
- pseudomonas I-12:4, II-1a:23, II-4:32, II-5:13
- pseudonaneurysms I-1:37
- psoralen and ultraviolet A II-1d:33
- psoriasis I-5:9
- psychiatric disorder III-2:20
- psychological rehabilitation II-5:2, II-10:1
- psychosis III-2:20
- psychosocial
 - p. well being of children with ESRD II-14:12
 - p. issues of the transplant recipient III-2:20
- PTH/PTHrP receptor I-5:20
- pulmonary I-24:7
 - p. arterial catheter III-3:2
 - p. arterial pressure II-13:25
 - p. arterial wedge pressure II-13:25
 - p. artery pressure II-4:3
 - p. capillary wedge pressure I-3:37, I-9:5, I-24:13
 - p. cysts I-1:32
 - p. disease, chronic obstructive (COPD) I-3:50
 - p. embolism I-6:10, II-2:9
 - p. embolus I-3:49
 - p. hemorrhage I-8:17
 - p. lesions varies I-8:14
 - p. leukosequestration II-4:11
 - p. lymphangiomyomatosis I-11:8
 - p. medullary cystic kidney disease I-11:8
 - p. vasoconstriction II-4:23
- pulse
 - p. cyclophosphamide II-1d:24
 - p. pressure I-23:15
 - p. steroid therapy III-5:27
- pulsus paradoxus II-4:9
- pupils, dilated II-13:27
- purification of dialysate water II-7:4
- purified protein derivative III-6:2
- purine I-15:20
- purine-rich diet I-15:10
- puromycin aminonucleoside I-6:12
- purpura II-4:18
- purpuric I-8:14
- putamen I-24:11
- pyelocaliectasis I-1:30, I-14:1
- pyelocalyceal collecting system I-1:24
- pyelogram, bulb I-1:42
- pyelographic phase I-1:24
- pyelography
 - antegrade p. III-3:14
 - intravenous p. I-12:10
 - retrograde p. I-1:42
- pyelolithotomy I-14:8
- pyelonephritis I-9:16, I-11:3, I-12:4, 6, I-13:1
 - chronic atrophic p. I-13:1
 - emphysematous p. I-1:33, I-12:11
 - xanthogranulomatous p. I-1:30, 33, I-16:14
- pyeloplasty I-11:22, I-14:8
- pyelorenal backflow I-13:22
- pyelosinus extravasation I-1:42
- pyelotubular back flow I-1:42
- pyonephrosis I-1:33
- pyrazinamide I-19:24, III-6:17
- pyridostigmine I-19:24
- pyridoxine I-10:22, I-15:13, II-9:11, II-13:12, III-2:17
- pyrimethamine I-19:24
- pyrimidines II-6:2
- pyrophosphate I-15:6
- pyruvate I-3:38
 - p. dehydrogenase I-3:38, 39
- pyruvic I-3:1
- pyuria I-12:14
- QRS I-5:31
- QRS prolongation II-13:27
- QT
 - QT interval II-1d:14
 - long QT syndrome II-5:32
- qualitative cystine test I-15:21
- quality
 - q. assurance II-1a:21
 - q. of care II-12:1
 - q. standards of care II-12:2
 - q. of life II-5:2, II-10:1
- quazepam I-19:24
- quinapril I-19:24, I-20:18
- quinidine I-19:24, II-13:22, II-13:25
- quinine I-19:24, II-4:13
- quinolone I-9:16, I-10:6
- quinupristin/dalfopristin II-5:19
- rachitic rosary II-14:9
- racial differences I-7:2
- radical neck resections I-5:22
- radioactive iodine I-5:22
- radiograph of the kidneys, ureter, and bladder I-15:21
- radioimmunoassay I-1:16, II-13:23
- radioisotope renography I-14:7
- radionuclide cystogram I-13:12
- radiotherapy I-23:15
- Raf-1 kinase I-24:12
- ramipril I-19:24, I-20:18, I-25:22
- ranitidine I-19:24
- RANTES III-9:15
- Rapa III-4:38
- rapid sequence IVP I-1:40
- rapidly evolving polyneuropathy II-5:2
- rate equation II-6:26
- rate method II-6:16
- raw elimination rate II-6:10
- Raynaud's phenomenon I-1:22, I-8:21, III-2:15

Subject Index

- reactive oxygen species II-1a:12
real time digital images I-1:25
real time sonography III-8:10
receptor-associated protein I-6:26
reciprocal creatinine concentrations III-4:15
recirculation II-2:26
recurrence rate of renal stones I-15:1, 2, 27
recurrent disease III-2:13
red blood cell membrane fragmentation II-1a:13
red blood cell rigidity and fragility II-4:17
red cell
– r.c. casts I-8:6
– r.c. lysis I-17:33
– r.c. transfusions II-7:5
– shearing of r.c. II-7:4
reentry arrhythmias II-13:27
reflex hypoventilation II-1a:32
reflex ileus II-1b:24
reflex tachycardia I-24:9
reflux I-12:13, II-5:3, III-3:6
– congenital vesicoureteral r. I-12:7
– gastroesophageal r. II-5:3, II-14:12
– intrarenal r. I-1:25, I-12:7, I-13:1
– r. nephropathy I-13:1
– vesicoureteral r. I-1:24, 25, I-13:1, I-14:8, I-25:10, II-14:1
refractometer I-1:3
regulators of complement activation III-9:11
regulatory volume control I-4:3
rehabilitation
– physical r. II-10:1
– intellectual r. II-10:1
– McKenzie r. program II-5:43
– psychological r. II-10:1
– social r. II-10:1
Reiter's syndrome I-8:22
rejection III-1:1
– acute r. I-1:30
– acute vascular allograft r. III-2:15
– chronic r. III-8:4
– chronic r. arteriosclerosis III-6:9
– delayed xenograft r. (DXR) III-9:13
– hyperacute r. III-9:4
– pancreas r. III-8:10
– rebound r. III-5:12
– refractory acute r. III-5:12
relapsers I-6:14
remikiren I-20:21
removal rate II-6:20
– fractional r.r. II-6:10
renal
– r. acidification defects II-13:13
– r. ammoniogenesis I-3:15
– r. candidiasis I-12:16
– r. cell carcinoma I-1:29, I-11:4
– r. clearance I-1:11
– r. colic I-1:24, I-10:14, I-15:1
– r. concentrating ability I-3:16, I-10:5
– r. cortical adenomas I-16:7
– r. cysts I-16:4
– r. distal tubule I-20:8
– r. duplex ultrasound I-22:4
– r. excretion I-19:4
– r. fascia I-1:31
– r. function curve I-20:12
– r. glycosuria I-3:30
– r. hypoperfusion I-22:1
– r. infarction I-17:27
– r. ischemia I-22:1
– r. insufficiency I-18:1
– r. K⁺ wasting I-2:23
– r. length I-9:1
– r. masses I-1:28
– r. medulla I-13:22
– r. osteodystrophy II-8:1
– r. ostia I-1:37
– r. parenchyma I-1:31
– r. parenchymal abscesses I-12:17
– r. plasma flow I-9:1
– r. prostaglandins I-14:9
– r. reabsorption I-3:5
– r. replacement therapy I-18:1
– r. salt wasting I-2:21, I-10:5
– r. sarcomas, primary I-16:13
– r. scan I-20:5
– r. scarring I-13:4
– r. scintigraphy I-22:7
– r. tuberculosis I-1:24, I-1:33
– r. tubular cells I-1:6
– r. tubular dysplasia I-9:9
– r. tubular epithelial cell casts I-1:10
– r. urea-nitrogen kinetics II-1b:18
– r. vein I-1:33
– r. vein renin determinations I-22:7
renal artery
– r.a. aneurysms I-1:38
– r.a. atheromatous plaque I-22:3
– r.a. disease, bilateral I-22:2
– r.a. occlusion I-22:4
– r.a. stenosis I-1:34, 37, I-22:3, I-25:11, 22, III-4:22
– r.a. stent placement I-22:9
renal biopsy I-1:1, 44
– percutaneous r.b. I-1:47
renal failure I-18:2
dye-related r.f. I-22:9
– r.f., acute (ARF) II-1a:14
renal-pulmonary syndrome I-8:1
renal-sparing surgery I-11:7
renalin II-1a:14
renin I-20:9, I-22:1
renin
– r. inhibitors I-24:2
– r. levels I-2:13
renin-angiotensin
– r.-a. aldosterone I-18:2
– r.-a. axis I-20:8
– r.-a. system I-20:9
renogram I-1:40
renomegaly I-1:30
repeated bleach reprocessing II-1a:23
reproductive system I-18:7
reprocessing method II-4:15
resection I-11:5
reserpine I-19:24, I-20:20
residronate I-5:16
residual clearance II-1b:16, II-6:17
resistivity index I-17:10, I-1:30
respiratory
– r. alkalosis I-3:35, 41, I-5:25, II-13:18
– r. depression II-4:26
– r. disease II-1b:19
– r. disorders, sleep-related II-5:2
– r. distress I-25:15
– r. failure I-5:24
– r. function II-5:2
– r. function abnormalities II-5:45
– r. muscle weakness I-3:8
– r. muscles I-3:48
– r. quotient I-3:49
– r. syncytial virus III-6:7, 13
restenosis I-1:38
resting membrane potential I-2:1
restless legs II-5:2
restriction fragment length polymorphism III-1:3
retention
– acute urinary r. I-12:14
– CO₂ r. I-2:10
– r. enema I-2:34
– sodium r. III-7:2, 3
– urinary r. II-13:27
– volume r. I-22:2
reticuloendothelial system II-1d:2
retina I-11:7, I-25:15

- retinal
 – r. detachment I-9:5
 – r. hamartoma I-11:8
 – r. hemorrhages II-1d:29
 – r. lesions I-10:22
 retinol dehydrogenase I-3:40
 retinol-binding protein I-13:23
 retinopathy II-1d:29
 – diabetic r. III-8:15
 retrograde
 – r. ejaculation I-20:17
 – r. menses II-1b:25
 – r. pyelography I-1:44
 – r. ureterography I-1:44
 – r. urethrography I-1:24
 retroperitoneal II-4:18
 – r. fibrosis I-1:31, I-14:1, I-17:9
 – r. hematoma II-2:9
 – r. involvement I-16:4
 – r. lymph node I-1:32
 – r. masses I-16:14
 retroviruses III-9:3
 revascularization III-3:3
 – r. techniques I-22:10
 reverse
 – r. isolation III-6:3
 – r. osmosis II-1a:26
 – r. osmosis membrane technology II-1a:25
 – r. ultrafiltration II-1a:28
 – r. urea effect theory II-4:25
 Rh disease II-1d:30
 rhabdomyolysis I-3:31, I-5:22, I-17:7, 22
 rhabdomyoma I-11:8
 rheumatoid factor I-1:23
 rhinorrhea II-13:22
 rhizopus III-6:15
 rHu-EPO resistance II-7:11
 ribavirin I-8:31, I-19:24, III-6:13
 rickets I-11:17
 – familial X-linked hypophosphatemic r. I-5:26
 – hereditary hypophosphatemic r. with hypercalciuria I-5:27
 – hypophosphatemic r. I-17:31
 – vitamin D deficient r. II-14:9
 – vitamin D-dependent r. I-5:26
 – vitamin D-resistant r. I-5:26
 rifabutin I-19:24
 rifampin I-1:2, I-10:9, I-19:24, II-13:22, III-6:17
 right atrial thrombus II-2:12
 right to life II-11:2
 rigid peritoneal catheter II-1b:10
 ringers lactate II-1d:16
 risk factors I-15:1
 risk of clotting II-1a:30
 ritodrine hydrochloride I-23:19
 ritonavir I-19:24
 RNA polymerase II I-11:7
 rocuronium III-3:3
 roseola III-6:11
 rostral ventrolateral medulla I-20:20
 Roth spots I-17:7
 Roux-en-Y reconstruction III-8:8
 RSV III-6:13
 RTA
 – classical RTA I-3:46
 – distal RTA I-3:46
 – incomplete RTA I-3:47
 Rubella I-8:2
 rugger jersey I-5:11, II-8:23
 Rumack-Matthew nomogram II-13:20
 rupture III-3:9
 ruptured
 – r. aneurysm II-4:20
 – r. diverticuli II-5:11
 S2-serotonin receptor blocker I-24:2
 S4 gallop I-24:13
 S6 kinase I-24:12
 salicylate I-3:13, II-1d:20, II-13:1
 salicylate intoxication I-3:41, II-13:16
 salicylic acid II-4:22, II-13:16, 17
 saline I-17:21, 26
 – s. solutions, hypertonic II-4:7
 – normal s. II-1d:16
 – s. rinsing II-4:24
 salt craving I-2:29
 salt-resistant I-20:14
 salt-sensitive I-20:14
 saquinavir I-19:24
 sarcoidosis I-8:22, I-10:11
 schistocytes I-9:4, III-5:13
 Schistosoma haematobium I-12:17
 Schistosoma mansoni I-12:17
 schistosomiasis I-6:12, 24, I-8:2
 Schwartzman reaction I-9:26
 scintigraphy II-5:6
 – iodocholesterol s. I-24:6
 – peritoneal-pleural s. II-5:44
 – renal s. I-22:7
 – thallium s. III-2:21
 scleritis I-6:42
 scleroderma II-7:5
 sclerosis I-11:5
 – capillary s. I-10:13
 – diffuse mesangial s. I-11:14
 – glomerular s. I-8:4, I-21:7
 – progressive systemic s. I-8:4
 – systemic s. III-2:15
 – tuberosus s. I-11:7, I-23:12
 scopolamine I-23:18
 screening I-11:6
 Scribner-Quinton II-2:7
 scrotum II-3:15
 secobarbital I-19:24
 secondary hypoadrenalism I-6:16
 sediment filters II-1a:26
 segmental
 – s. hypoplasia I-25:11
 – s. occlusion I-1:38
 – s. renal atrophy I-13:1
 – s. renal hypoplasia I-13:1
 – s. scars I-13:6
 – s. vasculitis I-1:19
 seizure I-3:31, I-8:16, II-4:20, II-7:14
 Seldinger technique, modified II-1c:18
 selectin III-1:7
 self-esteem II-14:12
 seminal vesicles I-11:22
 semipermeable membrane II-1a:27, II-6:2
 semustine I-17:31
 Senior-Loken syndrome I-11:9
 sepharose column II-1d:31
 sepsis II-2:3, II-1a:32
 septae I-1:29
 septic shock I-12:10, II-1c:9, 15
 septicemia II-4:24
 serologic tissue typing III-1:3
 serositis I-8:25
 serotonin I-21:5, III-9:10
 Serratia I-12:4, II-1a:23
 sertraline I-19:24
 serum
 – s. albumin I-9:1, II-1b:18
 – s. bicarbonate I-9:3
 – s. C3a desarginine II-1a:14
 – s. calcitriol I-15:8
 – s. creatinine I-9:1, I-20:5
 – s. iron II-7:5
 – s. ketones I-3:30
 – s. osmolality II-14:6
 – s. protein electrophoresis I-1:23
 – s. resistance proteins I-12:7
 – s. sickness I-8:28
 – s. solute concentration II-6:10

Subject Index

- s. urea/creatinine ratio II-6:5
- s. uric acid I-9:2
- sex I-20:3
- sexual infantilism I-23:7
- sexual intercourse I-12:11
- shagreen patch I-11:8
- shear rate II-1a:1
- Sheffield risk tables I-20:13
- shell vial III-6:9
- shingle III-6:8
- shock I-20:11, I-23:12, I-24:5
- short bowel syndrome I-10:21
- shunt II-2:7
 - external s. II-1a:30
 - peripheral arteriovenous s. II-6:8
 - ventriculo atrial s. I-8:34
 - ventriculoperitoneal s. I-8:34
- shunting, arteriovenous I-17:21
- siblings I-13:26
- sickle
 - s. cell anemia II-1d:30
 - s. cell disease I-1:36, III-2:17
 - s. hemoglobinopathies II-7:5
- sieving coefficient II-1a:5, II-1d:11
- sigmoid colon II-1b:25
- silastic catheters II-2:1, 5
- silica I-15:3
- silver I-17:30
- simplified acute physiological score II-1c:19
- simvastatin I-19:24, I-20:13, III-7:7
- single and double compartment models I-1:39
- single compartment model II-6:14, II-6:15
- single photon emission CT I-12:8
- sinoxipidan I-20:21
- sinus bradycardia II-13:14
- sinus tachycardia II-13:25
- sinusitis I-8:15, I-17:7
- sirolimus III-4:38
- Sjögren's syndrome I-8:3, I-8:22
- skeletal deformities II-14:9
- skeletal muscles I-2:28
- skin hyperpigmentation II-1d:28
- skin ulceration I-1:22
- sleep apnea syndrome I-20:5, I-23:17
- sleep-related respiratory disorders II-5:2
- slipped capital femoral epiphysis II-14:9
- small cell carcinomas of the lung I-23:14
- small solute clearance II-6:6
- small solutes II-1a:5
- smooth-muscle relaxants I-24:7
- SO₄²⁻ II-6:2
- social rehabilitation II-10:1
- socioeconomic status I-8:7, II-14:12
- sodium I-1:23, I-4:1, I-20:14
 - s. balance I-18:1
 - s. caprylate II-1d:16
 - s. chloride intake I-18:10
 - s. citrate II-1d:13, II-4:26
 - s. hypochlorite II-1a:19, II-4:28, II-7:4
 - s. intake II-4:4
 - s. modeling II-4:2
 - s. nitroprusside I-24:2, 7, I-25:23
 - s. polystyrene sulfonate I-3:47
 - s. salicylate II-13:16
 - s. valproate I-19:24
 - s.-phosphate cotransporter I-5:19
- solute II-6:5
 - s. carrier family 3, member 1 (SLC3A1) I-15:17
 - s. disequilibrium II-6:8, 14
 - s. drag II-1a:5
 - s. removal II-1c:3
 - s. removal index II-6:17
 - s. size II-1a:5
- solution compartment II-1b:2
- somatostatin I-7:13
- somnolence I-23:17
- sorbent II-13:8
- sorbitol I-4:9, I-7:3, II-1b:10
- sotalol I-19:24
- sparfloxacin I-19:24
- spasm
 - carpopedal s. II-1d:14
 - laryngos. II-1d:14
 - urethral s. I-12:18
 - vasos. III-3:4
- specific gravity I-1:2
- specific immunoglobulin adsorption II-1d:1
- Spectinomycin I-19:26
- Spectra II-1d:9
- spectroscopy
 - infrared s. I-15:2
 - magnetic resonance s. I-1:36
- speech abnormalities II-1a:27
 - s. disturbances II-4:21
- spermidine II-7:3
- sphincter dyssynergy I-1:43
- spike and port connection II-1b:11
- spinal
 - s. epidural abscess II-2:10
 - s. lordosis II-1b:26
 - s. regional anesthesia III-3:3
- spine II-8:23
- spiral CT I-12:9
- spironolactone I-19:26, I-20:7, I-24:4, I-25:19
- splanchnic vascular bed II-1b:3
- spleen III-6:15
- splenectomy I-9:28, II-7:6
- splenic I-1:32
 - s. trapping II-4:23
- splinter hemorrhages I-17:7
- spores II-1a:21
- spring-loaded "gun" device III-5:15
- squamous cell carcinoma I-1:33, 44, I-16:3, II-1d:24, III-7:9
- squamous epithelial cells I-1:7
- square wave' response to the Valsalva maneuver II-4:4
- stages I-6:25
- staging I-1:36
- standardized mortality rate II-9:4
- staphylococcal protein II-1d:19
- Staphylococcus I-8:2
 - S. aureus I-15:16, II-5:13
 - S. aureus nasal carriage II-5:28
 - S. epidermidis II-5:13, II-5:18
 - S. saprophyticus I-12:3
- starch replacement II-1d:17
- starry sky I-6:42
- starvation I-5:26
- static intra-access pressures II-2:27
- Stauffer's syndrome I-16:11
- stavudine I-19:26
- steady state I-4:4
- steal II-2:15
- steal phenomenon I-24:9
- stenotic gastrointestinal lesions I-2:18
- Stenotrophomonas II-5:19
- stent II-2:22
 - s. implantation I-24:3
 - s. placement I-22:8
- stenting I-1:38, I-14:11
- sterilant II-4:14
- sterile II-5:13
- sterile pyuria I-1:24, I-12:17
- sterilization II-1a:2
- steroid 11-β-hydroxylase (CYP11B1) I-23:6

- steroid dependency I-6:16
steroids I-20:4
Stevens-Johnson syndrome I-15:28
stillbirth I-9:3
stimulus, defective I-3:49
stoichiometry I-3:3
stone risk profile I-15:22
“strain” pattern I-24:13
streptococcal
– s. cationic proteinase I-6:42
– s. serologies I-1:22
– s. species II-5:13
Streptococcus faecalis I-9:15
– s., group B I-9:15
streptokinase I-19:26, II-1b:25
streptomycin I-19:26, III-6:17
streptozotocin I-17:31, I-19:26
streptozotocin-induced DM I-7:13
stress I-4:15, I-17:20, I-23:17
striated sphincter contraction
I-1:43
stridor I-8:15, I-11:11
string of beads I-1:37
striped fibrosis III-4:26
stroke I-20:1, II-5:37, II-9:9,
III-6:15
stroke volume II-4:2
struvite I-15:3
subacute bacterial endocarditis
I-1:23
subarachnoid hemorrhage I-2:2,
I-24:11, III-6:15
subclavian II-14:5
– s. or internal jugular vein
II-1d:13
– s. veins II-13:5
subcortical white matter I-24:11
subcutaneous II-7:7
– s. tunnelling II-1c:10
subdiaphragmatic peritoneum
II-1b:3
subdural hematoma II-4:20, II-9:9
subendothelial expansion I-8:20
subendothelial MPGN I-6:31
– s. nodules I-11:8
subglottic I-8:15
succinylcholine I-19:26
sufentanil I-19:26
sulbactam I-19:26
Sulfa I-9:15
sulfamethoxazole I-9:15, I-19:26
sulfate I-3:2, I-15:20
– dextran s. II-1d:31
– indoxyl s. II-1a:10
– magnesium s. I-9:8
– protamine s. II-1a:31
– s. clearance II-5:49
– s. conjugation I-19:5
sulfapyrazone I-19:26
sulfisoxazole I-19:26
sulfonamides I-10:6
sulfosalicylic acid I-1:3, I-10:18
sulfur granules III-6:6
sulindac I-19:26
sulotroban I-19:26
sun exposure II-4:17
superior mesenteric artery
I-22:10
suprahepatic veins I-11:5
supraoptic nucleus I-4:5
suprapubic aspiration I-1:1
supraventricular II-4:8
– s. tachyarrhythmia II-13:22
surface antigen III-6:2
surface porosity II-13:4
surgery I-24:2
surgical reimplantation I-11:22
surgical technique of renal
transplantation III-3:4
survival I-8:7, II-5:1, II-1b:15
– s. rate I-17:19, II-1a:14
swallowtail deformity I-13:14
swan neck II-5:9
sweating I-11:16
sympathetic
– s. amines I-17:11
– s. nerve activity II-4:3
– s. tone I-20:9
sympathomimetic I-20:17
syncope II-4:30
syndrome
– s. of cortisol resistance I-23:7
– s. of hyporeninemic hypoal-
dosteronism I-2:30
– s. of inappropriate secretion of
AVP I-4:16
synthetic II-1a:3
– s. androgens II-7:6
– s. fibers II-1a:2
syphilis I-1:23, I-8:2, III-6:2
syrup of ipecac II-13:28
systemic
– s. diseases I-8:1
– s. inflammatory response syn-
drome II-1c:1
– s. lupus erythematosus (SLE)
II-7:5, I-8:1
– s. oxalosis I-15:15
– s. sclerosis III-6:2
– s. vascular resistance II-13:25
– s. vasculitis I-1:23
systolic I-20:3
– s. dysfunction II-5:2
– s. function III-8:16
T cell activation III-1:7
T cell crossmatch, positive III-5:6
T cell receptor for antigen III-1:3
T lymphocyte mitogen III-1:8
T waves I-5:31
T-cells I-17:31
T1-weighted I-16:12
T2-weighted I-16:12
tablets I-2:18
tachyarrhythmias I-2:10, I-17:15
tachycardia I-3:30, I-20:4, I-25:23
tacrolimus I-8:21, I-9:24, I-17:32,
III-1:5
Takayasu arteritis I-8:19, I-24:3
Takayasu disease I-25:12
talc II-1b:25
Tamm-Horsfall glycoprotein gel
I-1:7
Tamm-Horsfall protein I-13:23,
I-17:12
tamoxifen I-19:26
tannates II-7:10
tapeto-retinal degeneration I-11:9
tazobactam I-19:26
technetium-99m-dimercaptosuc-
cinic acid renal scans I-13:4
technetium-99m-macroaggregated
albumin II-1b:25
teflon II-5:45
teicoplanin I-19:26
temazepam I-19:26
Tenckhoff catheter II-3:4, II-1b:10
Tenckhoff single and double cuff
catheters II-5:9
tenderness
– abdominal I-3:30
– rebound I-3:30
tendon rupture II-5:2
tendonitis II-5:2
teniposide I-19:26
tensile strength II-1a:4
terazosin I-19:26, I-20:17
terbutaline I-19:26
terfenadine I-19:26
Tesio catheters II-2:5
testosterone enanthate II-7:6
tetanus III-6:2

Subject Index

- tetany II-1d:14
- tetrogenicity I-9:16
- tetrabromophenol blue buffered I-1:3
- tetracycline I-12:10, I-17:29, I-19:26, II-1b:25, II-8:6, II-13:15
- tetrahydrozoline hydrochloride I-23:19
- tetradotoxin-sensitive I-2:33
- thalamic hemorrhages I-3:40
- thalamus I-24:11
- thallium I-10:20
 - t. scintigraphy III-2:21
- theophylline I-19:26, II-13:1
- therapeutic drug monitoring III-4:38
- therapeutic plasma exchange (TPE) II-1d:1
- thermofiltration II-1d:1, 33
- thermostat II-4:22
- thiabendazole II-13:15
- thiamine I-3:36, II-13:1
 - t. deficiency I-3:39
- thiazide I-19:26
 - t. diuretics I-20:7
- thickening
 - glomerular basement membrane t. I-7:4
 - hyaline t. of arterioles III-5:13
 - intimal t. I-8:20
 - medial t. I-22:4
- thin basement membrane disease I-6:6
- thin film composite membranes II-1a:27
- thiocyanate I-24:8
- thiopental I-19:26
- thioridazine hydrochloride I-23:19
- thirst I-3:29, II-4:27
 - t. center I-4:5
 - t. mechanism I-4:21
- thoracic location of ectopic kidney I-11:21
- threshold for reabsorption I-9:2
- thrill II-2:15
- thrombectomy II-2:12
- thrombocytopenia I-8:12, III-2:16
- thrombocytosis I-6:49
- thromboembolic complication of CNF I-11:14
- thrombogenicity II-2:5
- thrombolysis II-2:2, III-5:9
- thrombomodulin II-2:22
- thrombosis I-1:22, I-8:12, II-14:8
 - access t. II-7:14
 - acute vascular t. III-5:9
 - capillary t. I-8:20
 - deep vein t. I-6:10
 - iliofemoral t. II-2:9
 - intracatheter t. II-2:11
 - mural t. II-2:11
 - renal artery t. I-10:23, 24
 - renal vein t. I-1:33, I-6:10, I-10:23
 - vein t. I-10:27
- thrombotic
 - t. or embolic stroke I-24:11
 - t. microangiopathy I-8:1, 3, 12, III-5:13
 - t. thrombocytopenic purpura I-9:27, II-1d:2, 21
- thromboxane I-7:13, I-20:11, II-5:35, III-7:2
- thymus III-1:13
- thyroid I-20:5, III-6:15
 - medullary carcinoma t. I-5:11, I-20:8, I-23:12, 14
 - t. hormone I-18:7, I-20:4
 - t. surgery I-5:22
- thyrotoxicosis I-2:27, I-23:15
- ticarcillin I-19:26
- ticlopidine I-19:26
- tidal peritoneal dialysis II-1b:14
- tidal volume II-1b:14
- “tight” heparin II-1a:30
- tilt/recumbent norepinephrine levels II-4:12
- tiludronate I-5:16
- time of flight techniques I-1:36
- time-averaged concentration II-6:25
- timed collections I-1:4
- timolol I-19:26, I-20:17
- tinnitus I-3:42, I-20:23
- tissue
 - His-Purkinje t. II-13:27
 - increased t. breakdown I-1:14
 - lymphoid t. III-4:6
 - mixed connective t. disease I-8:3,20
 - monocyte-derived t. thromboplastin II-1d:31
 - serologic t. typing III-1:3
 - t. acidosis I-3:28
 - t. binding II-13:3
 - t. debris II-1b:25
 - T. factor pathway inhibitor III-9:22
 - t. ingrowth II-3:7
 - t. macrophages III-1:4
 - t. necrosis I-3:24
 - t. oxygenation II-1c:15
 - t. plasminogen activator II-4:10
 - t. volume ratios II-6:9
- titration I-3:2
- transmembrane pressure II-1d:11
- TNF- α I-18:5, II-1c:17
- tobramycin I-19:26, II-1d:20
- tocainide I-19:26
- tocolysis I-9:12
- tolazamide I-19:26
- tolbutamide I-19:26
- tolmetin I-19:26
- toluene I-3:4, I-3:42
- tonicity I-4:2
- tonicity receptors I-4:5
- topical emollients II-4:17
- topiramate I-19:26
- topotecan I-19:26
- torsades de pointes II-5:32
- torsemide I-19:26
- total body water I-4:1
- total cell volume II-1a:20
- total lymphoid irradiation I-8:12
- toxicity I-5:30, I-19:1, II-13:12
 - antibiotic t. II-5:29
 - cardiac t. I-2:10
 - cardiotoxic. II-13:24
 - drug t., cisapride II-5:3
 - ethylene glycol t. I-17:6
 - myelotoxic. I-6:50
 - neurotoxic. I-1:38
 - ototoxic. I-25:19
 - procainamide t. II-13:24
 - theophylline t. II-13:15
 - urotoxic. I-17:31
 - vestibular t. II-9:14
- toxoplasmosis gondii III-6:2
- TPE Cobe Centry plasma separator II-1d:11
- tracheal inflammation I-8:15
- tracheobronchial tree I-11:11
- tracheotomy I-8:15
- “tram-track” I-6:31
- tranexamic acid I-19:26
- tranquilizers I-23:14
- transcaltachia I-5:4
- transcapillary colloid osmotic gradient II-4:2
- transcription factors III-1:5
- transesophageal echocardiography I-24:7
- transferrin I-6:10
 - t. saturation I-18:8, II-7:8

- transforming growth factor beta
I-6:20, III-1:14, III-7:3
- transgenic pigs expressing human
RCA III-9:12
- transient ischemic attack (TIA)
II-9:9
- transitional cell carcinoma
I-1:33, 44
- transitional epithelial cells I-1:7
- transplant
– bone marrow t. I-12:17
– cadaveric kidney t. III-2:1
– cadaveric renal t. I-7:7
– chronic t. glomerulopathy
III-5:22
– living related donor t.s I-7:7
– post-t. II-1d:25
– post-t. ascites II-5:62
- transplantation
– contraindications to t. III-8:6
– bone marrow t. I-17:32
– bone marrow t., autologous
I-8:25
– islet t. III-8:17
– liver t. I-11:5
– pancreas-kidney t. III-8:1
– t. tolerance III-1:7
- transport
– t. mechanisms II-1a:5
– t. surface II-1a:1
- transporters I-4:1
- transtubular gradient I-2:11
- transurethral
– t. resection of the prostate I-4:9
– t. sphincterotomy and external
drainage I-12:13
- tranylcypromine I-19:26
- trauma
– bladder and/or perineal t. I-1:24
– endothelial t. III-5:4
- traumatized exit sites II-5:26
- travel III-6:16
- trazodone I-19:28
- tremor I-6:49
- Trendelenburg position II-4:23
- triacetate II-1a:3
- triamcinolone I-19:28
- triamterene I-1:7, I-15:3, I-19:28,
I-20:7
- triazolam I-19:26
- trichomonas vaginalis I-12:15
- tricyclic antidepressants I-23:22,
I-25:15, II-13:26
- tricyclic antidepressant
intoxication II-13:26
- triglyceride I-3:5, I-18:3, I-20:5
- trigone I-11:22
- trihalomethanes II-1a:25
- trihexyphenidyl I-19:26
- trimethadione I-19:26, II-4:22
- trimethaphan I-24:8
- trimethoprim I-9:15, I-19:26
- trimethoprim-induced
hyperkalemia I-2:32
- trimethoprim-sulfamethoxazole
I-8:18, I-9:15, I-12:1, II-5:19
- trimetrexate I-19:26
- trimipramine I-19:26
- tripelennamine I-19:28
- triple phosphate I-1:10
- triprolidine I-19:28
- trisomy 7 and 17 I-16:7
- trocar – cannula II-3:8
- thrombophlebitis, suppurative
II-2:10
- trophoblastic I-9:5
- trough level I-19:6
- Trousseau signs I-5:31
- Tru-Cut III-5:15
- tryptophan I-3:38, I-15:13
- TSC1 I-11:7
- TSC2 I-11:8
- tube feeding II-14:12
- tuberculosis I-1:23, I-5:12,
I-10:11, III-6:2, 17
- tuberous sclerosis I-11:7, I-23:12
- tubocurarine I-19:28
- tubular
– primary t. dysfunction I-3:47
– t. atrophy I-8:8, I-8:14
– t. dysfunction, primary I-3:47
– t. function I-9:2
– t. nephrogram I-16:6
- tubulitis III-5:10
- tubulointerstitial disease I-8:1,
I-21:10
- tubulointerstitial disorders I-8:1
- tubulointerstitial nephritis/uveitis
TINU I-10:8
- tumor I-20:7
– ACTH-producing t. I-2:25
– adrenocortical t. I-25:23
– adult Wilms t. I-16:13
– Cincinnati Transplant T. Regi-
stry III-2:17
– ectopic aldosterone-producing t.
I-23:4
– juxtaglomerular cell t. I-16:9
– Koenen t. I-11:8
- renal pelvis t. I-1:42
– retroperitoneal t. I-16:14
– t. lysis syndrome I-2:4, I-5:22,
I-14:2, I-17:33
– t. necrosis factor II-1a:12, II-7:3
– t. stage I-1:36
– t. suppressor gene I-11:7
– t.-associated secondary eryth-
rocytosis I-16:7
– Wilms t. I-11:15
- tunneling maneuver II-3:7
- Turner syndrome I-24:3
- twin gestation I-9:4
- twin or double bag systems
II-1b:11
- twin studies I-20:6
- type I I-15:11
- Type I endothelial activation
III-9:10
- type I pseudohypoparathyroidism
I-5:22
- type I ultrafiltration failure
II-1b:26
- Type II CGN I-6:48
- type II pseudohypoparathyroidism
I-5:23
- type II ultrafiltration failure
II-1b:26
- type III CGN I-6:49
- type IV collagen I-11:10,12
- tyrosinemia I-11:17
- ulceration I-8:14
- ulcerative I-2:18
– u. colitis I-1:20, I-15:14
– u. lesions I-2:18
- ultrafiltrate I-4:3
- ultrafiltration II-4:2, II-1a:1
– centrifugal u. II-13:23
– linear or modeled u. II-4:4
– net u. rate II-1b:4
– osmotic u. II-1b:3
– reverse u. II-1a:28
– type I u. failure II-1b:26
– type II u. failure II-1b:26
– u. coefficient II-1a:7
– u. failure II-5:5
- ultrapure water II-4:32
- ultrasonography I-1:25
- ultraviolet light device II-1b:11
- ultraviolet B phototherapy II-4:17
- uncomplicated stone disease
I-15:24
- unfractionated heparin II-1a:31
- ungual fibroma I-11:8

Subject Index

- United States Food and Drug Administration I-20:19
- United States National Cooperative Dialysis Study II-6:1
- University of Wisconsin preservation solution III-5:7
- University of Wisconsin solution III-8:7
- unselective plasma exchange II-1d:31
- upper tract cytology I-1:44
- upper tract endoscopy and lithotripsy I-1:42
- upright posture test I-23:4
- uranium I-17:30
- urapidil I-20:17, I-24:9
- urate I-1:10
- urea II-1b:16
 - u. and creatinine kinetics II-1b:15
 - u. clearance II-6:6
 - u. generation II-6:25, 27
 - u. gradients II-6:12
 - u. kinetic modeling II-4:16
 - u. kinetics II-6:12
 - u. rebound II-6:9, 16
 - u. reduction ratio II-6:17
 - u.-ammonia cycle I-19:3
 - u.-splitting bacteria I-1:3
 - u.-splitting organisms I-15:3
- ureaplasma urealyticum I-12:15, I-15:16
- urease inhibitor I-15:27
- uremia I-7:8, I-17:17, I-18:1, 10
- uremic anemia II-7:5
 - u. concentration II-1a:16
 - u. encephalopathy II-4:20
 - u. myopathy II-10:3
 - u. neuropathy II-5:2
 - u. osteodystrophy II-8:17
 - u. pericarditis II-4:9
 - u. platelet dysfunction II-7:5
 - u. state II-7:3
 - u. syndrome I-18:1
- ureter III-3:6
 - duplicate u. I-1:25
- ureteral dilatation I-9:1
- ureteral
 - u. obstruction I-12:7, III-3:13
 - u. peristalsis I-12:7
 - u. strictures I-12:17
- ureteric
 - u. duplication I-11:22
 - u. ectopia I-11:22
 - u. obstruction I-14:3
 - u. reimplantation I-14:8
- u. strictures I-14:3
- ureterolithotomy I-14:8
- ureteropelvic urolithiasis I-13:4
- urethra I-11:22
- urethral
 - u. hypotonia I-12:7
 - u. obstruction I-1:43
 - u. spasm I-12:18
 - u. syndrome I-12:17
- urgency I-10:14
- uric acid I-10:19, I-11:3, I-20:5, II-6:2
- uricosuria I-11:17
- urinalysis I-1:1, I-12:8, I-20:5
- urinary
 - u. acidification II-13:1
 - u. albumin excretion I-7:7
 - u. alkalization I-10:18, II-13:18
 - u. ascites III-3:12
 - u. calcium excretion I-20:16
 - u. electrolytes I-1:17
 - u. excretion of K^+ I-2:4
 - u. free cortisol level I-24:4
 - u. pH I-11:3, I-15:12, 15, II-13:1
 - u. sediment I-1:1, I-6:5
 - u. stasis I-9:1, I-15:6
- urinary tract infection (UTI) I-9:1, 13
 - candida UTI I-12:15
 - parasitic UTI I-12:17
 - tuberculous UTI I-12:17
 - viral UTI I-12:16
- urinary tract obstruction I-14:1f
- urine
 - alkalizing the u. I-3:42
 - oxalate crystals in the u. I-3:41
 - ratio of u. osmolality to plasma osmolality I-2:11
 - stasis of u. I-9:1
 - u. and plasma norepinephrine and epinephrine I-9:13
 - u. culture I-12:8
 - u. extravasation I-1:31
 - u. ferric chloride test II-13:18
 - u. leaks III-5:17
 - u. net charge I-3:13
 - u. osmolal gap I-3:13
- urinomas I-1:30, I-1:35
- Urocit-K I-15:25
- urodynamic studies I-1:43
- uroflowmetry I-1:43
- urokinase I-19:28, II-1b:25
- urolithiasis I-12:7
 - ureteropelvic u. I-13:4
- urological procedures I-1:42
- uromodulin I-1:15
- urosepsis I-12:1
- urothelial cancer – transitional cell carcinoma I-16:12
- urticaria I-8:14, II-1d:15, II-4:14
- utero, drug in I-9:11
- uterus I-11:22
 - carcinomas of u. III-2:18
- UTI see urinary tract infection
- UVAR II-1d:33
- uveitis I-8:16, I-10:8

- V2 receptor I-4:6
- vaccines II-7:13, III-6:2
- vacuolization III-5:13
- vagina I-11:22
- vaginal colonization I-12:2
- vaginitis I-11:22
- vagus and glossopharyngeal nerves I-20:10
- valacyclovir I-19:28
- valproate sodium II-13:19
- valproic acid II-1d:20, II-4:22, II-13:18
- Valsalva ratio II-4:3
- valvular heart disease II-9:8
- vancomycin I-17:29, I-19:28, III-6:5
- vancomycin-resistant enterococci II-5:1, III-6:3
- variable sodium profiles II-1a:33
- variation programs II-1a:33
- Varicella III-6:2
- Varicella virus I-12:17
- Varicella Zoster virus III-6:2, III-6:8
- Varicella Zoster immune globulin III-6:8
- varicocele I-10:29
- vas deferents I-11:22
- vascular
 - v. access II-1d:12
 - v. anastomosis III-8:11
 - v. cell adhesion molecule-1 III-1:7
 - v. endothelial disease II-2:22
 - v. permeability II-1a:31
 - v. permeability factors I-6:13
 - v. smooth muscle cells II-2:22
 - v. thrombi I-8:12
 - v. vascular tone II-4:3
- vasculitis II-4:20
 - small vessel v. I-8:2
 - CNS v. I-8:16

- cerebral v. I-6:42
- Churg-Strauss v. I-1:23
- cryoglobulinemic v. I-8:30
- cutaneous necrotizing v. II-1a:19
- hypocomplementemic urticarial v. I-8:14
- leukocytoclastic v. I-8:19
- segmental v. I-1:19
- systemic v. I-1:23
- vasoactive intestinal peptide (VIP) I-23:12
- vasoconstrictor mechanisms II-4:6
- vasoconstrictors II-4:7
- vasodepressor reaction II-4:3
- vasodepressor syncope II-4:3
- vasodilatation II-4:3, 7
 - hypoxic v. II-7:13
 - preglomerular v. I-14:5
- vasodilators I-20:12
- vasomotor III-4:37
- vasomotor tone I-20:11
- vasopressin II-4:7
- vasopressin-regulated urea transporter I-4:6
- vasospasm III-3:4
- vasovagal episodes II-1d:18
- vecuronium I-19:28
- vegetarian diet I-1:3
- vein-to-vein dialysis II-6:8
- vena cava I-11:5
 - inferior v.c. I-1:33, II-1b:2, II-2:7
 - superior v.c. II-2:7
- venlafaxine I-19:28
- veno-occlusive disease I-17:33
- veno-venous hemodiafiltration II-1c:6
- venodilatation, inappropriate peripheral II-4:3
- venous air embolism II-4:23
- venous outlet stenosis II-2:20
- venous pressure
 - central v.p. II-4:23
 - jugular and central v.p. I-3:30
- venous renin samples I-1:37
- venous tone II-7:12
- ventilation-perfusion mismatch I-3:49
- ventricular
 - v. arrhythmias I-5:31, II-4:8
 - v. ectopy II-1d:18
 - v. fibrillation II-5:32
 - v. filling pressures II-1c:14
 - v. septal defect I-24:3
 - v. tachyarrhythmias II-13:25
 - v. tachycardia II-5:32
- venules I-8:12
- verapamil I-19:28, I-20:19, I-25:21, II-13:22
- Verres needle technique II-5:8
- vesicoureteral
 - v. junction I-1:25
 - v. reflux (VUR) I-1:24, I-1:25, I-13:1, I-14:8, I-25:10, II-14:1
 - primary v. reflux I-13:2
- vesicoureterogram (VCUG) I-13:2
- vessel perforation II-1c:18
- vestibule I-11:22
- vidarabine I-19:28
- vigabatrin I-19:28
- vinblastine I-19:28
- vinca alkaloids II-1d:29
- vincristine I-9:28, I-19:28, I-24:5
- vinorelbine I-19:28
- viral
 - v. hepatitis II-7:5
 - v. replication I-8:28
 - v. UTI I-12:16
- visceral afferent nerves II-4:4
 - v. perforations II-1b:24
 - v. sepsis I-8:34
- viscosity II-1c:10
- visual
 - v. blurring II-7:14
 - v. disturbances I-9:4
- vitamin B12 II-1a:15, II-7:4
- vitamin C I-15:15, II-4:31
- vitamin D I-5:20, I-6:10, I-15:8, I-21:6
- vitamin D deficient rickets II-14:9
- vitamin D receptor I-5:4, I-15:9
- vitamin D response elements II-8:14
- vitamin D-dependent rickets I-5:7, 26
- vitamin D-resistant rickets I-5:26
- vitamin D3 I-5:20
- vitamin E II-4:13
- vitamin K II-2:19
- voiding I-1:1
 - v. abnormalities I-1:24
 - v. cystography I-1:42
 - v. cystourethrogram I-1:24, I-12:13
 - v. cystourethrography I-13:11
- Volkman canals II-8:2
- voltage I-2:2
- voltage-gated Na⁺ channel I-2:27, I-2:33
- volume I-17:8
 - v. controllers II-4:5
 - v. excess I-3:27
 - v. expansion I-17:14, II-4:7
 - v. of distribution II-4:21
 - v. of urea distribution II-6:6, 12
 - v. regulation I-4:14
- vomiting I-7:9, I-11:11
- von Hippel-Lindau disease I-11:7, I-20:8
- von Willebrand factor I-9:28, I-17:20, II-4:18
- waist-hip ratio I-20:5
- Waldenström's macroglobulinemia I-8:22
- warfarin I-19:28
- warm agglutinins II-1d:30
- warm ischemia III-3:3
- water I-4:1, 12
 - osmol-free w. I-4:12
 - w. and electrolyte balance I-18:1
 - w. intoxication II-4:27
 - w. purification system II-1a:25
 - w. quality II-1a:19
 - w. softener II-1a:26
 - w. treatment II-1a:25
- wax matrix I-2:18
- waxy casts I-1:7
- weakness I-3:29, I-20:4
- Wegener's granulomatosis I-8:3
- weight
 - ideal body w. I-19:2
 - lean body w. II-1b:15
 - low birth w. I-9:23, I-20:2
 - w. gain II-4:4
 - w. loss I-2:30, I-25:15
- Werner's syndrome (MEA type I) I-5:11
- Wernicke's encephalopathy II-13:1
- Whitaker test I-14:8
- white cell casts I-17:8
- widened pulse pressures I-20:3
- Wilson's disease I-11:17
- windkessel function I-20:12
- World Health Organization I-8:4
- Wright's technique III-6:16
- toluidine blue O III-6:16
- wrist radial-cephalic fistula II-2:15
- wrist ulnar-basilic fistula II-2:15
- WT1 I-11:15
- X-ray diffraction crystallography I-15:2
- xanthine I-15:3

Subject Index

- xanthomas II-1d:31
- xanthomonas II-1a:23, II-4:32
- xantomathous neuropathy II-1d:31
- xenoreactive natural antibodies
III-9:5
- xenoses III-9:4
- xenotransplantation III-9:1
- xerosis II-4:15
- xylytol II-1b:10

- Y chromosome I-16:7

- Y-shaped transfer II-1b:11
- yarn weave II-1a:2
- yeast I-1:6
- Yersinia enterocolitica I-15:16
- yohimbine hydrochloride I-23:19

- zafirlukast I-19:28
- zalcitabine I-19:28
- zankiren I-20:21
- zero-calcium dialysate bath
II-1a:30

- zero-order kinetics II-13:15
- zidovudine I-19:28
- zileuton I-19:28
- zinc I-6:10, II-7:4, II-8:7
- zona fasciculata I-2:25, I-20:7,
I-23:6
- zona glomerulosa I-2:25, I-20:10,
I-23:2
- zoonoses III-9:3
- zymosan II-1a:17